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Preface 
Allergic rhinitis is a conunon disease resulting in a high morbidity. It is defined as an 
inflammation of the nasal mucosa and is characterised by symptoms such as itchy nose, 
sneezing, rhinorrhoea and nasal blockage. Repetitive allergen exposure gives rise to 
increased sensitivity to allergens (priming) and nonspecific stimuli. This nonspecific nasal 
hyperreactivily can be measured by history and by nasal challenge tests with methacholine 
or histamine. However, the pathogenesis of nasal hyperreactivity is still not clear. 
In asthmatic patients bronchial hyperreactivity seems to be associated with the latc phase 
response and allergic inflammation, suggesting that inflammation is involved in the 
pathogenesis of hyperreactivity. In analogy with the bronchial situation these associations 
were also studied in the nose. Until now, most studies investigating the relationship 
between nasal response to allergen and nasal hyperreactivity have been performed in 
patients with pollinosis. In these studies no relationship could be found between nasal 
hyperreactivity, nasal priming, the late phase response and nasal inflammation, 
Only a few studies have been performed in patients allcrgic to house dust mites (BDM). In 
this subgroup it has becn demonstrated that pre-existent nasal hyperreactivity can predict 
nasal response to allergen challenge, a finding more in agreement with the lower airways. 
In this thesis we further want to investigate the relationship between nasal hyperreactivity, 
nasal response to allergen and nasal inflammation in perennial rhinitis. 
Hereto, we evaluated the effects of therapeutic intervention on nasal response to allergen 
and hyperreactivity and data obtained during the placebo treatment. Nasal response to 
HDM challenge was monitored by symptoms and mediators in nasal lavage fluid. 
Allergen-induced nasal hyperreactivity was determined 24 hours later by nasal challenge 
with histamine or methacholine. 
It is expected that non-specific nasal hyperreactivity is particularly important in patients 
with perennial allergic rhinitis, since they are continuously exposed to allergen. However, 
the importance of routine histamine challenges in daily practice is not clear. Hereto, we 
studied nasal response to histamine and daily nasal symptoms. Inflammatory mediators in 
lavage fluid and eosinophils in cytospins were also determined in order to evaluate the 
involvement of inflammation in the ongoing allergic reaction. 
In addition, we investigated the impact of rhinitis symptoms on day-to-day life. By means 
of a rhinitis quality of life (QOL) questiOlUlaire, the relationship between nasal response to 
histamine, QOL and daily nasal symptoms was estimated in patients allergic to HDM. 
Part one presents the definitions and clinical aspects of allergic rhinitis (chapter one), the 
cells and mediators involved in the allergic reaction (chapter two) and the aims of the 
study (chapter 3). 
In part two the relationship between nasal hyperreactivity and inflammation is studied. 
Chapter 4 describes a nasal challenge study in patients with perennial rhinitis. 
Inflammatory mediators and nasal hyperreactivity were compared between patients with an 
early and late phase response and individuals expressing an isolated early response only. In 
chapter 5, inflammatory mediators in nasal lavage, eosinophils in nasal blUshes and 
responsiveness to histamine were studied in non-challenged patients with perennial rhinitis 
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and healthy subjects. 
Part three concerns the therapeutic intervention on nasal response to allergen challenge 
and hyperreactivity with a c0l1icosteroid (fluticasonc propionate) and an antihistamine 
(levocabastine). In chapter 7-10 the effect of two weeks topical fluticasone propionate on 
the immediate and late nasal symptoms, inflammatory mediators and nasal response to 
histamine is described. In chapter 11, the characteristics of the glucocorticoid receptor of 
the patients responsiveness or non-responsiveness to fluticasone propionate were compared. 
Chapter 13 describes the results of one week topical levocabastine on nasal response to 
allergen (symptoms and mediators), to histamine and to methacholine challenge. Chapter 
14 discusses the results of an in vitro study. The effect of pre-incubation with 
levocabastine on mediator release of human leucocytes and on the contractile response of 
guinea-pig trachea and lungparenchyma is described. 
Part four (chapter 15) discusses the relationship between nasal hyperreactivity, quality of 
life and daily nasal symptoms in 48 patients with perelUlial allergic rhinitis. 
Part five is the general discussion and summary. 
Nasal challenges were performed at the department of Allergology of the Academic 
Hospital Rotterdam and the ill vitro studies and the assessment of mediators and cells at 
the department of Pharmacology of the Erasmus University Rotterdam. 
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General introduction 

Chapter 1 
Allergic rhinitis 
C. de Graaf-in't Veld', l.M. Garrelds'·2 
lDepartmcnt of Allergology, University Hospital Hospital Rotterdalll"Dijkzigt, 2Department of Pharmacology. 
EraslIllls University Rotterdam, The Netherlands. 
1.1 Historical review of allergy 
The history of allergic diseases goes back to 1819, when Bostock described his own 
Itperiodical affection of the eyes and chest1\ which he called l!summer catarrh". Since they 
thought it was produced by the effluvium of new hay, this condition was also called hay 
[ever. Later, in 1873, Blackley6l established that pollen played an important role in the 
causation of hay 'fever. 
In 1902 Portier and Richet described the development of anaphylaxis in dogs a few 
minutes after reinjection with anemone toxine. By this experiment they demonstrated that, 
in this case, immunity was not protective but damaging to the individu. ArUms observed in 
1903 that after repeated injections with substances which had not caused any reaction the 
first time, the injected tissues became inflamed, Von Pirquet517 noted that under some 
conditions, patients, instead of developing immunity, had an increased reactivity to 
repeated exposure with foreign substances, By putting together the Greek words l1allosH 
meaning different or changed, and !lergosl1 meaning work or action, he introduced in 1906 
the term allergy, Both immunity and hypersensitivity were thought to have similar 
underlying immunologic mechanisms, Later, in 1923, Coca and Cookel14 proposed the 
term atopy for the clinical forms of allergy, manifested by hay fever and asthma, in which 
Uthe individuals as a group possess a peculiar capacity to become sensitive to certain 
proteins to which their environment and habits of life frequently expose theml1, Thus, an 
inherited predisposition to become sensitized is a characteristic feature of atopy, Prausnitz 
and Kiistner518 demonstrated in 1921 that the semm of allergic individuals contained a 
humoral factor that caused specific allergen sensitiveness in a non-allergic individuaL The 
factor responsible for the Prausnitz-KUstner reaction was named reagin by Coca and 
Cooke, These reagins were characterised by Ishizaka e/ al,314 and independently at the 
same time also by Johansson and BenuichJ22 as a new immunoglobulin class which they 
named immunoglobulin E (lgE). Gell and Coombs'" subdivided allergy into 4 types: 
immediate IgE~depelldent reaction (I), cytotoxic reaction (II), inmlUne complex reaction 
(III), delayed cellular immune reaction (IV). 
From a clinical view, Voorhorst650 defined aJIergy in 1962 as an altered sensitivity, 
deviating from the norm (i.e, normergy) in a quantitative sense, 
Nowadays, the definition of allergy as an lluntoward physiologic events mediated by a 
variety of different immunologic reactionsU described by Middleton, Reed and EIlis441 is 
used, Accepting this definition, one should also keep in mind the following three criteria: 
(l) identification of the allergen, (2) establishment of a causal relationship between 
exposure to the antigen and occurrence of the lesion and (3) identification of the 
immunologic mechanism involved in the illness, 
In this thesis, the term allergy will be restricted to the IgE-dependent reactions. The most 
important clinical manifestations of IgE~dependent reactions are allergic conjunctivitis, 
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allergic rhinitis, allergic asthma and atopic dermatitis. However, we will restrict in this 
thesis to the allergic rhinitis. 
1.2 Allergic rhinitis 
1.2.1 Epidemiology 
Allergic rhinitis is the most common manifestation of the IgE-mediated disorders, with a 
prevalence ranging from 2 to 20 percent. 161 The prevalence of allergic rhinitis seems to be 
increasing. In a study performed in Swedish army recmits, the prevalence of hay fever 
increased from 4.4% in 1971 to 8.4 % in 1981.1 The prevalence of allergic skin test 
reactivity, i.e. atopy, increased from 39% to 50% in a community sample in the USA of 
individuals of all ages for a mean of 8 years.34 Since skin reactivity and allergic disease 
are associated, this suggests that the prevalence of allergic rhinitis is also increasing. 
1.2.2 Clinical aspects of allergic I'hinitis 
According to the international consensus rhinitis is defined as an inflammation of the nasal 
mucosa characterised by one of the following symptoms: nasal itchyness, sneezing, 
rhinorrhoea and nasal congestion,3lI Other symptoms, such as 'popping' of the ears, 
headache, throat clearing and coughing, arc less common. In patients with allergic rhinitis 
these symptoms are due to the interaction between allergens and specific IgE antibodies. 
Allergic rhinitis can be subdivided in seasonal and perennial rhinitis. In seasonal rhinitis 
symptoms are triggered by exposure to tree, grass, and/or weed pollen. In non-tropical 
parts of the world, seasonal allergic rhinitis occurs during a defined period of the year, 
which implies that patients also have a symptom free period. In contrast, patients with 
perellllial rhinitis suffer from almost continuous nasal symptoms throughout the year. The 
most common perellllial allergens are indoor allergens like the house dust mite 
(Dermatophagoides pteronyssinus and D. farinae) and animal danders and in some areas 
also certain mould species and cockroaches. Although the house dust mite is regarded as a 
perennial allergen, an increased number of house dust mites are found in the autumn, 
which may result in an increase in symptoms in tlils period.216,518,652 
1.2.3 Impact on daily activities and quality of life 
However, patients with rhinitis are not only troubled by nasal symptoms. Nasal symptoms 
also interferes with their day-to~day lives and with their quality of life. Patients are limited 
in their daily activities, concentration and sleep are impaired. Associated symptoms as 
headache are troublesome, practical things such as the availability of a handkerchief and 
blowing the nose are a nuisance, social interaction is limited and there is an impact on 
emotional well-being,33S In school aged children with pollinosis, learning abilities during 
the poBen season were reduced and this effect could only be partially counteracted by non-
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sedating antihistamines.654 This impact on day-to~day life and QOL is a major cause of 
morbidity. Due to impaired concentration and reduced productivity rhinitis patients may 
even lose earnings. So in addition to the costs of medication, health services and sick 
absence, this loss in personal income attributes to the economic impact of rhinitis. To 
measure the influence of nasal symptoms on day-to~day life, rhinitis quality of life (QOL) 
questionnaires have been developed. 71 ,335,336 These questionnaires are useful to study the 
effect of allergen exposure and therapeutic intervention in clinical trials. Juniper e/ al. 335,336 
demonstrated that QOL deteriorated after allergen exposure (pollen season) and increased 
after symptomatic treatment. 
1.3 Reactions of nnsal mucosa 011 allergen exposure 
Most studies concerning the pathophysiology of allergic rhinitis have been performed in 
patients with seasonal rhinitis. The effect of pollen exposure on the nasal mucosa can be 
determined during natural pollen season or by nasal challenge models performed outside 
the pollen season. In nasal allergen challenges studies, well~known amounts of standardised 
allergen are administered into the nose. In most studies, nasal challenges are used to 
investigate the pathophysiology of allergic rhinitis. However, one should keep in mind that 
the mode of exposure is not natural and that in a short time high concentrations of 
allergens are administered to elicit a clear nasal response instead of continuous exposure to 
lower and variable amounts of allergens. The problem of monitoring nasal response during 
natural exposure is the variable and unknown level and spectrum of allergen content. 
Several methods have been used to perform nasal allergen challenges, Connell ll9 developed 
a quantitated challenge with ragweed pollen. Later, standardised liquid allergen extracts 
were developed, which can be insufflated into the nose or can be administered by filter 
paper~discs or by special equipment like the 'nasal pool device. '39,257,465,467 
Nasal response to allergen challenge can be determined by different methods. No 
standardised method is available. Usually, the symptomatic response is monitored by the 
number of sneezes, the amount of secretion, and nasal blockage. Sneezing and itchyness 
are the result of a central reflex elicited in the sensory nerve endings in the nasal mucosa, 
It is easy to grade the sneezing reflex by counting. Sneezing and itchyness can also be 
subjectively measured by symptom scoring. Nasal blockage is the result of pooling of 
blood in the capacitance vessels of the mucosa, and to some degree the result of tissue 
oedema. It can be assessed subjectively by means of symptom scoring. An objective 
estimation of nasal blockage crnl be made by methods such as rhinomanometryl12, nasal 
peak flow determination2J3,685, acoustic rhinometryI81.287,381 and rhinostereometry264. 
Nasalsecretion can be assessed by weighing the blown secretion or by measuring the 
volume of secretion collected in a funnel equipped tube or syringe while the subject is 
bending her/his head forwards68. Several scoring methods have been developed: visual 
~nalogue scales395, combined symptom scores taking nasal blockage, secretion and 
sneczes70 and a combination of all signs and symptoms373 • 
Nasal response can also be monitored by analysis of nasal biopsiesI9o,6-u, brushes516, 
smears432, 01' lavages465. These techniques can he used to make an estimation of nasal 
inflammation by determination of mediator levels and cell populations. The presence of 
inflanmlatory cells such as cosinophils, mast cells, T ~cells and Langerhans cells has been 
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demonstrated in the nasal mucosa,188,334,642 The inflammatory cells and mediators involved 
in allergic rhinitis are described in detaiJ in chapter 2, allergic inflammation, 
1.3.1 Immediate allergic reaction 
When the nasal mucosa of patients with anergic rhinitis is exposed to allergen, allergen 
activates mast cells and basophiJs by bridging two or more IgE molecules on their surface. 
After being activated these cells produce and release biochemical mediators such as 
histamine, platelet activating factor (PAF), tryptase, leukotrienes, prostaglandin D2 (PGD2 
only produced by mast cells), cytokines and chemotactic factors. 95,465 Gomez et al. 244 and 
Fokkens et al. 189 demonstrated in biopsy studies an increased percentage of degranulated 
mast cells at the surface of the nasal mucosa after nasal pollen challenge, The released 
substances act on the local celis, vessels and sensory nerve endings, leading to nasal 
itching, sneezing, rhinorrhoea and nasal blockage, In some patients after this immediate 
allergic reaction, a recurrence of symptoms can be demonstrated. 
1.3.2 Late allergic reaction 
Blackley61 in 1873 was the first -to describe the recurrence of symptoms several hours after 
the introduction of grass pollen in his nose. This recurrence of symptoms has been termed 
the late phase reaction. 116,505 
To define the late phase reaction in the nose is difficult. Mygind et al,460 could not detect 
late phase reactions by means of symptom scores. Since it is hard for patients to make an 
estimation of their nasal patency tUld late phase responses are mainly characterised by 
nasal blockage and in a lesser extent by mild rhinorrhoea, this might declare the problems 
detecting clinical late phase responses, \Vhen estimating nasal obstruction by 
rhinomanometry, a recurrence of nasal blockage could be demonstrated,176 In other studies 
late phase reactions were determined by measurement of nasal obstruction and analysis of 
nasal lavage fluid. Naclerio et al. 467 measured a second increase of histamine, but not of 
PGD2, This suggests that basophils are, since they release histamine but no PGD2, involved 
in the late phase. In nasal lavage fluid obtained during the late phase period an influx of 
eosinophils was demonstrated.42 Also eosinophil derived mediators have been demonstrated 
during the late phase response, confirming the involvement of eosinophils in this 
period.43,55 Immunohistology of the nasal mucosa demonstrated an increase of T-helper 
cells, eosinophils and neutrophils 24 hoUl's after pollen challenge,642 
1.3.3 Nasal priming 
Connell 120,121 described in the sixties a phenomenon known as nasal prll1l1ng: repetitive 
exposure to allergen causes an increased sensitivity to allergens. This has been 
demonstrated with repetitive exposures to pollenrich natural environment as weB as by 
repetitive nasal provocation with aiJergen, This effect was confirmed by others by nasal 
challenge studies. 28,261 \Vachs et al,655 demonstrated that after repetitive pollen challenge, 
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increased levels of mast cell mediators could be detected in nasal lavage fluid, which may 
implicate an increase in the number and/or the releasability of mast cells. However, in a 
biopsy study by Fokkens el al. 189, no correlation was found between nasal priming by 
pollen challenge and the number of mast cells or amount of degranulation. Bentley et al. 49 
demonstrated by immunohistology of the nasal mucosa an influx of inflanunatory cells 
after allergen challenge. Since both systemic and topical corticosteroids abolish the primed 
response to allergen, this might suggest that priming is related to antigen-induced nasal 
inflanunation.515.S16 However, the exact processes resulting in nasal priming remain unclear. 
In perelmial rhinitis the priming phenomenon has only been examined in one study.226 This 
Dutch study demonstrated an increased threshold sensitivity to house dust mite challenge 
in autumn, compared to spring months corresponding with the peak of house dust mite 
levels between August and October. 
1.4 Allergen-induced nosol hype .... eoctivity 
Hyperreactivity can be described as a clinical feature characterised by an exaggerated 
response of the nasal mucosa to everyday stimuli (perfume, tobacco smoke, change of 
temperature) as estimated by history (clinical hyperreactivity). In comparison to allergens, 
these stimuli are nonspecific, that is, they can affect the nasal mucosa of any individual, 
albeit to a different extent. In analogy with challenge studies in bronchial asthma, rhinitis 
patients were challenged with histamine260,410 and methacholine6S.4 IO to measure nonspecific 
nasal hyperreactivity. It is well known that histamine and methacholine have different 
effects on the nose. Histamine, acting by HI and H2 receptors, leads to vasodilatation and 
increased vasopermeability resulting in nasal congestion.83,IS8 Nasal discharge is also 
increased and is believed to be caused by both transudation and glandular secretion.532 The 
involvement of reflexes is demonstrated by the induction of sneezesl5S.488 (see 2.2). 
Methacholine acts by the M3 receptor and has a direct effect on glands only.68,531 
Determination of nasal hyperreactivity by nasal provocation tests with pharmacological or 
physical agents assumes a relationship between this form of nasal hyperreactivity and 
hyperreactivity as estimated by history. Gerth van \Vijk e/ alYs demonstrated that the 
amount of secretion and the number of sneezes in response to histamine challenge were 
associated with the clinical hyperreactivity assessed by a hyperreactivity score. It was also 
demonstrated that assessment of the number of sneezes and the anlOllllt of secretion is 
more appropriate in distinguishing patients from healthy subjects in terms of 
reproducibility and estimation of clinical hyperreactivity compared with assessment of 
nasal airway resistance after histamine challenge.225 
In patients with allergic rhinitis, part of the symptoms is due to exposure to nonspecific 
stimuli. Repetitive exposure to allergen not only increases sensitivity allergens, but also to 
nonspecific stimuli. Borum and Mygind69 demonstrated that in patients with seasonal 
allergic rhinitis during the pollen season nasal response to histamine and methacholine 
increased. Allergen challenge also increased nasal response to histamine 10,395 and 
methacholine346. In contrast, repeated challenges with histamine or methacholine did not 
increase nasal responsiveness to histamine. 261 
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The observation that the increase of nasal sensitivity to histamine was very well correlated 
with the increase of sensitivity to allergen suggested a common pathogenesis. 10 However, 
the presence of increased numbers of mast cells might explain nasal primingl64, but not the 
closely related nasal hyperreactivity to histamine. The occurrence of certain cell 
populations together with the induction of nasal hyperreactivity after allergen challenge 
implies a time relationship. Inflammatory cells stich as eosinophils could release mediators 
with toxic effects on the nasal mucosa, thereby causing nasal hyperreactivity. However, 
very few investigations have been designed to study the relationship between nasal 
hyperreactivity and the number of cells and or mediators. In one study only, a weak 
correlation between Ecr and allergen~induced hyperreactivity to histamine could be 
demonstrated. 395 In another study no relation between eosinophil influx into lavage fluid 
and hyperreactivity could be demonstrated. 346 In a few studies evaluating the effect of 
topical corticosteroids, an effective anti~inflal11matory drug, nasal hyperreactivity was 
reduced348,J56, which might indirectly give evidence of the involvement of inflammation in 
this process. 
The importance of routine histamine challenges to assess nasal hyperreactivity in daily 
practice is not clear. Recently, a correlation between daily symptoms and response to 
histamine challenge was demonstrated in patients suffering from non-allergic nasal 
hyperreactivity.265 It is expected that non-specific nasal hyperreactivity is particularly 
important in patients with perennial allergic rhinitis, since they are continuously exposed to 
allergen. Gerth van \Vijk e( al. 228 found in 12 selected patients with peremlial allergic 
rhinitis, that nasal reactivity to histamine was associated with clinical symptoms and the 
sensitivity to everyday stim.uli. However, such studies have not been performed routinely 
in daily practice. 
Mechanisms of hyperreaclivify 
The exact mechanism of nasal hyperactivity is unknown. Although it is widely believed 
that allergen~induced mucosal inflammation provides the background for this condition, no 
evidence to support the role of a specific element or event of the allergic inflammatory 
process exists. Several hypotheses with respect to the mechanisms underlying 
hyperreactivity have been advanced. (1) Increased epithelial permeability, which would 
lead to an increased accessibility for stimuli to sensory nerve endings, vessels and nasal 
glands. An indirect support to this hypothesis has been delivered by Buckle and Cohen18, 
who demonstrated that topically applicated 1251~albumin penetrated better into the nasal 
mucosa in allergic rhinitis compared with healthy subjects. However, in more recent 
studies there is little evidence that the nasal epithelium suffers much damage in acute or 
chronic allergic rhinitis.2S8,6u (2) Increased sensitivity of sensory nerve endings (irritant 
receptors) would induce an exaggerated response to normal stimuli. No firm data are 
available to confirm this theory, (3) Imbalance of the autonomic nerve regulation caused 
by changes of the neuroreceptors in the nasal mucosa. Megen el al. 430 demonstrated an 
increased sensitivity and a decreased number of muscarinic rcceptors in the nasal mucosa 
of allergic subjects. These findings Illay reflect the cholinergic-induced hypersecretion. In 
addition, a decreased number of p~adrenoreceptors was found which may be an indication 
of a p-adrenergic abnormality. Increased presence of the neuropeptide substance P or 
diminished levels of vasoactive intestinal peptide (VIP) might contribute to hyperrcactivity. 
8 
Allergic rhinitis 
Until now, evidence for this hypothesis has only been demonstrated in the lower 
airways.35.490,491 The role of neuropeptides in allergic rhinitis is unclear. 
1.5 Allergic rhinitis. A Illodel to study airway inflaulluation? 
Astluna and allergic rhinitis are common disorders, with a high socio-economic impact and 
causing a lot of morbidity. Many studies have been performed concerning the 
pathophysiological mechanisms. In the nose such studies are more easy to perform since 
the nose is readily accessible and biopsies and lavages are less accompanied by any risk 
and discomfort for the patient. It would therefore be easy if studies evaluating the 
pathophysiology and therapeutic intervention of asthma were to be replaced by studying 
the nasal mucosa. However, the upper and lower airways are not entirely similar since part 
of the symptoms in asthma are caused by smooth muscle tissue contraction, resulting in 
bronchoconstriction. 
Repetitive allergen challenge causes an increased sensitivity to allergen and nonspecific 
stimuli. This phenomenon was first described for the lower airways1l6 and could also be 
explored in the nasal situation1o,346,395. In the lower airways, the late phase response to 
allergen challenge was found to be associated with inflanunation and bronchial 
hyperreactivity92,1l5,162,445 suggesting that inflammation is involved in the pathogenesis of 
hyperreactivity. Several studies have been performed to find out whether similar 
associations could also be shown in allergic rhinitis patients. However, no relation was 
found between nasal hyperreactivity and late nasal response230, between nasal 
hyperreactivity and activation of eosinophils346 or between nasal priming and late nasal 
response31O in studies performed in pollinosis patients tested outside the pollen season. 
In contrast, in a study with rhinitis patients allergic to house dust mite, an association 
between nasal responsiveness to allergen and pre-existent nasal hyperreactivity was 
found229, a finding more in agreement with data from the lower airways. So this 
subpopulation might be more suitable to study the association between nasal 
hyperreactivity, nasal inflanullation and the latc phase response and might serve as a better 
model to study airway inflanullation. 
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Allergic inflammation 
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Hospital Hospital Rotterdam-Dijkzigt, The Netherlands. 
2.1 Introduction 
The histopathological features of allergic inflammation involve an increase in blood flow 
and in vascular permeability leading to plasma exudation and the formation of oedema. In 
addition, a cascade of events occur which involve a variety of inflammatory cells. These 
inflanunatory cells migrate under the influence of chemotactic agents to the site of injury 
and induce the process of repair. Several types of inflanunatory cells have been implicated 
in the pathogenesis of allergic rhinitis. \Vhat remains unclear is how the different cellular 
components interact with each other to induce the pathological symptoms of allergic 
rhinitis and the relationship between the inflanullatory infiltration, cellular activation and 
hyperreactivity still need to be established, After specific or non-specific stimuli, 
inflanunatory mediators are generated from cells normally found in the nose, such as mast 
cells, antigen-presenting cells and epithelial cells (primary effector cells) and from cells 
recruited into the nose, such as basophils, eosinophils, lymphocytes, platelets and 
neutrophils (secondary effector cells). 
For inflammatory cells the primaty function is phagocytosis and the secretion of 
inflammatory mediators, The phagocytic cells, by eliminating particles or organisms that 
have gained access to the host, act as a protective barrier between envirolUllent and the 
host. The secretory cells release inflammatory mediators, which increase vascular 
permeability and chemotactic factors, which results in recruitment of other inflammatory 
cells. 
This chapter will describe the identification of each of the inflanunatory cells and their 
mediators which play a role in the perelUlial allergic processes in the nose of rhinitis 
patients, 
2.2 Cells in allergic rhinitis 
2.2.1 Primal), effector cells 
Mast cells 
Mast cells are polymorphonuclear leukocytes that differentiate in the bone marrow with a 
lifespan of approximately 10 days and are ordinarily distributed tluoughout normal body 
tissues. The maturation of human mast cells is known to be dependent on cytokincs, such 
as Interleukin-3 (IL-3). granulocyte macrophage-colony stimulating factor (GM-CSF) and 
thus highly dependent on the local environment,232,423,600 
I-Iuman mast cells Can be characterised by the presence of tryptase on the one hand (MeT) 
or tryptase and chymase (MCd on the other. More than 95% of the epithelial mast cells 
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and 75% of the subepithelial mast cells in human ainvays are of the MCT_subtype,312,S6s 
Binding of allergen to specific IgE-molecules on mast cells leads to a series of events 
finally resulting in allergic symptoms, JgE is able to bind to the high affinity JgE-receptors 
(FcERr) on mast celis, which induces secretion of mediators,122,623 These mast cell-derived 
mediators can be divided into two main categories: pre-formed or granule-associated 
mediators and the newly-formed or membrane-derived mediators, Pre-formed mediators 
include histamine, proteoglycans such as heparin and chondroitin sulphate, neutral 
proteases tryptase and chymase and acid hydro lases. 563 The membrane-derived mediators 
are mainly metabolites of arachidonic acid, such as prostaglandin D2 (PGD2), leukotriene 
B4 (LTB4) and the cysteinyl leukotriencs C4, D4 and E4, and platelet activating factor 
(PAF),291,362,S62 Mast cells additionally generated, adenosine672, nitric oxideH ,57,422 and 
cytokines, such as IL-3, IL-4, IL-5, IL-6, GM-CSF and TNF_o:74,128,598,660,692, but not IL-2 
and IFNy, 107,519,689 
Rhinitis: Mast cells have been implicated in the pathogenesis of allergic diseases ever 
since histamine was localized to these cells,s39 The number of mast cells in the nasal 
mucosa is increased in allergic rhinitis.49,189,276,302,486.487,49s.648 Elevated levels of mast cell 
mediators are present in the nasal lavage fluid after experimental allergen challenge9S,465 
and challenge with cold dry air620, and experimental application of mast cell mediators to 
the nasal mucosa produces symptoms of rhinitis. 532.604 Several studies have demonstrated 
that the amount of mast cells in the epithelial layer is increased after allergen exposure, 
which can be interpreted as shift of cells from the lamina propria to the epithelium or 
proliferation of precursor cells in the epithelium. 164,401,486,487,496,647 Borres demonstrated that 
metachromatic cells can be found superficially in the nasal mucosa 5-24 hours after 
allergen challenge, with a correlation between the amount of cells and symptom score.66 
Mast cells are multifunctional cells which can play more than one role and can contribute 
to the chronic inflammation underlying allergic diseases by producing a number of 
imlUunomodulat01Y and proinflammatory cytokilles and mediators.108.2Is 
Antigell~presentillg cells 
Responses to most antigens require processing of the antigen by antigen-presenting cells 
(APC), because T -cells ordinarily recognize antigens only together with major histocom-
patibility complex (MHC; Human leukocyte antigen HLA-DR,-DQ,-DP) autigens on the 
surface of other cells. The first step in the immune response following entry of the antigen 
involves capture and processing of the antigen by APC and presentation of the processed 
form of the antigen to a subset of T-cells. These class II MHC proteins are expressed 011 
the surface cell membrane of macrophages, dendritic cells in lymphoid tissue, Langerhans 
cells in the skin and the nose, Kupffer cells in the liver, microglial cells in the central 
nervous system tissue, epithelial cells and B-cells, These cells phagocytose the antigen 
from which fragments become noncovalently associated with class II molecules, whereafter 
the complex is transported to the celJ surface, where it is then accessible to the T-cell, B-
cells are relatively poor activators of T-cells when presenting antigens, possible because 
such T-cells require activating factors such as interleukins which B-cells fail to provide. 
Therefore, it is believed that macrophages or Langerhans cells probably play the domimUlt 
role as APCs in the initial or primary immune response whereas B-cells may dominate in 
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the memory or secondary response.187.191.J91.JJI 
Macrophages are differentiated from blood monocytes which are derived from bone 
marrow. Macrophages play a central role in host defense, which includes ingesting and 
killing invading organisms/antigens and releasing a number of factors involved in host 
defense and inflammation. They also fUllction as antigen-presenting cells (APC) during the 
development of specific inul1unity.2s8.42J Macrophages possess low affinity IgE-receptors 
and after binding of IgE they will release mediators.J30,411 They produce thromboxane A2 
(TxA2), PGD2 407, PGF24, LTB4 419.420.53\ LTC4 178 and PAF.IS.SS0 They also release 13-
glucuronidase, neutral proteases, lysosomal enzymes212.624 and complement C3a.30.471 
Macrophages/monocytes produces cytokines, like TNPCl , IL_1I36S,166,S85, IL_6246, GM_CSp79,S6 
and IL_IO,413 They release 02'-radicals, which are inflammogen, bronchoconstrictor, and 
cause bronchial hyperresponsiveness. 34o Macrophages also are able to produce nitric 
oxideI82,527 and express iNOS in areas of acute and chronic inflammation.3S3 However, 
other investigators showed that monocytes and macrophages failed to produce NO after 
stimulation with different cytokines. 325 
Rhinitis: Although macrophages are the most common cell type residing in the lumen of 
the lower airways, little is known about the presence and pathogenic implications of 
macrophages in thc upper airways. Both local allergen challenge and natural exposure 
increase the number of macrophages on the mucosal surface during the immediate as well 
as late phase reactions, indicating that macrophages are involved in the inflammatory 
processes of allergic rhinitis.26,3Jl 
Langerhans cells are from dendritic morphology. The origin and relationship of dendritic 
cells to the monocytes/macrophages lineage are not established, it is likely that they 
originate from a common stem-cell precursor. 537 They contain IgE receptors (FctR) on 
their surface. \92 It is important to note that the undoubtedly effective antigen-presenting 
ability of pulmonary interstitial dendritic cells may be limited to the interstitial lung-
compartment296,47J; these cells might, therefore, not be expected to come into direct contact 
with inhaled antigens. This is in contrast with other investigators, who found that 
Langerhans cells were found in the epithelium and lamina propria of the nasal mucosa.l92 
Rhinitis: Higher amounts of Langerhans cells were detected in nasal biopsies of allergic 
patients compared with controls. 192 During the grass-pollen season, the nasal epithelium of 
patients with an isolated grass-pollen allergy demonstrated more Langerhans cells than 
before and after the season. 191 
Epithelial cells 
Epithelial cells play an important role in the defence of the airways and in inflammatory 
processes, it seems to be more than a protective barrier. 
Immunohistochemical studies of human lung tissue have reported that epithelial cells have 
the ability to express the HLA-DR antigens, suggesting that these cells play an important 
role in the antigen presentation and immunoregulation.355,544 
Epithelial cells produce mediators, like 15-hydroxy-5,8,ll,13-eicosatetraenoic acid (15-
HETE; which is chemotactic300,306,469,m,578,661), 12-HETE, PGE2 (which causes bronchodila-
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tation and decreases m.ast cell mediator release304,3M), small amounts of PGF2a 109,683 and 
PAF,409,5~9 Epithelial prostaglandin release can be stimulated by bradykinin37,J09,68J, calcium 
ionophore A23187 109,68J; PAF683, eosinophil major basic protein320 and ozone379,416, 
Epithelial POE, is also responsible for much of the transport of water and electrolytes by 
the airway epithelium.' Recent studies suggest that the release of IS-HETE is regulated by 
IL-4 (stimulation) and IFN-y (inhibition) of the IS-lipoxygenase. 123 It is possible that IL-4 
released by Tm lymphocytes causes increased expression of lS-lipoxygenase,54J The 
chemotactic substance LTD4 is produced by dog epithelial cells, but not by human,299 
Airway epithelial cells are able to produce chemotactic cytokines, like TNF_a351, IL_6416, 
IL_8 47o and GM_CSF JlO,4S5,497, which can be stimulated by TNF-a, IL-l and histamine. The 
epithelial layer in the airways is enriched with nerve endings which contain tachykinins, 
stich as substance P. This is chemotactic for neutrophils4J6 and m.onocytesS48, and 
potentiates phagocytosis and lysosomal enzyme release by neutrophils and macrophages3J. 
Substance P is mitogenic for T_lymphocytes502 and stimulates histamine release by mast 
cells197, It also stimulates airway epithelial ion transport5, causes airway smooth muscle 
contraction609 and stimulates submucosal-gland secretion67, Epithelial cells are able to 
produce constitutive and inducible nitric oxide synthase,I9 
Several studies have demonstrated that exposure of the airways to irritant substances, such 
as allergens and ozone, leads to inflammation and damage of the airways in astluna,366,687 
Epithelial damage may contribute to bronchial hyperresponsiveness in asthma,I31,145,290,323 
Rhinitis: Although damage of the epithelial layer causes an increased permeability to 
antigens, exposure of sensory nerve fibres and actuation of local reflex mechanisms, 
changes in osmolarity of the bronchial surface lining fluid and a decreased production of 
epithelial relaxant factors35,4I,18\ this has not been dernonstrated in the nose. Epithelial cells 
may play an important role in the local· rec11litment, differentiation, and survival of 
inflammatory migrating cellsJJ\, and contribute to the pathologic and clinical events which 
occur in allergic rhinitis, 
2.2.2 Secondary effector cells 
Basophils 
Basophils are circulating leukocytes with many of the functional properties of tissue mast 
cells. They share with mast cells high affinity IgE-receptors (Fc,RI) and cytoplasmic 
granules containing histamine, but differ from mast cells in that they differentiate and 
mature in the bone marrow, circulate in the blood, and are not normally found in 
connective tissue. IL-3 is a differentiation factor for human basophils.636 Basophils express 
a low-affinity receptors for IgO (FcrRII). 
Human basophils generate LTC4 but no prostaglandins and LTB4,3J2,562.668 Despite previous 
controversy about the synthesis of PAF by basophils, recent studies have demonstrated that 
these cells are capable of producing PAF and its analog, l-acyl-2-acetyl-sn-glycero-3-
phosphocholine (I-acyl PAF).''' It has been shown that basophils produce IL-4 and 
TNF(l598, but failed to produce IL-S, Whether basophils secrete other cytokines is 
unknown. 3 Tryptase is present in negligable quantities in basophils and does not exceed 
1 % of the level seen in mast cell grallules.94 
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IL-3, IL-5, IL-II, GM-CSF and IFN-y can prime basophils for enllanced histamine release 
in response to anti-IgE or C5a,53,426,44'J,551,669 In addition to histamine, LTC4 is released in 
response to triggers like C5a, Some of these priming cytokines also upregulate adhesion 
molecules on basophils,360 
Rhinitis: The blood basophil count increases during the pollen season, suggesting that 
basophilopoiesis may be influenced by environmental factors, such as allergens100,489, but 
this has not been confirmed by others,I6-1,165 Several studies have demonstrated that the 
amount of basophils in the mucus and in the nasal lavage fluid is increased 4-11 hours 
after allergen exposure, which can be interpreted as shift of cells to the superficial layers 
of the lllucosa,4-l,487 
It has been suggested that basophils play an important role in the late phase of the allergic 
process, based on their release of lipid mediators,3 However, whether basophils are 
associated with hyperresponsiveness is not known, 
Eos;nop!1i/s 
Eosinophils are bone marrow derived granulocytes, with a short life span, They are present 
in large numbers in the circulation and tissues, Although a precise model of human 
eosinophil proliferation and differentiation in vivo is not known, in vitro studies suggest 
that OM-CSP, IL-3 and IL-5 are important in the regulation of eosinophilopoiesis,2!O 
They have low-affinity receptors for 19B (Fc,Ru).'16 
The eosinophil possesses the capacity to produce and release several biological substances. 
In vitro expcriments have shown that eosinophil-derived enzymes are capable of degrading 
mast cell products, such as histamine and leukotrienes,67J,693 Eosinophils have cytoplasmic 
granules which contain cytotoxic proteins, like eosinophil peroxidase (EPG), major basic 
protein (MBP), eosinophil cationic protein (ECP) and eosinophil derived neurotoxin 
(EDN).267,644 MBP and ECP can stimulate upregulation of intercellular adhesion molecule-l 
(ICAM-l) on human nasal epithelial cells, which suggest a positive feedback mechanism, 
in which the products released from migrating eosinophils might promote additional 
human nasal epithelial cell-leukocyte adherence,9 Eosinophils also produce the superoxide 
(.0,'), the hydrogen peroxide (H,O,) and the hydroxyl radical (.OH), which contribute to 
eosinophil-mediated cytotoxicity, 406 
Although eosinophils arc able to function as phagocytes, they are less efficient than 
neutrophils both in the rate of phagocytosis and in the quantity of material ingested. 
Eosinophils can be activated by factors derived from T -lymphocytes, mast cells, vascular 
endothelium, and 1110nocytes, such as OM-CSF, IL-l, IL-3, IL-5 and TNF. 
The major product of the eosinophil is the arachidonic acid metabolite L TC4• 676,671 
Eosinophils also produce other products of arachidonic acid, like POE2 82.!86,23\, TxB2 186, 
15-HETEm , but no POD2 or POl2 186, However, these cells release quantitatively only a 
fraction of the cyclooxygenase products released by human macrophages 186, PAF is 
another product of the eosinophil.376 The eosinophil releases cytokines, like OM-CSP, IL-
3344, IL_5152, IL_6270, IL_8 76 and TNFa l29. Priming of eosinophils via exposure to chemo-
tactic stimuli, like LTB4, PAF, IL-3, IL-5 or OM-CSF increases the formation of L TC4.676 
The role of eosinophilic inflammation in allergy has been studied most thoroughly in the 
pathogenesis of the airway inflanunatory response in asthma. Cytotoxic proteins are 
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elevated in sputum and bronchoalveolar lavage fluid of asthmatics, which are cytotoxic 
towards respiratory epithelium and causes histamine release.204,205,235,366,481,665 Alveolar 
macrophages may be primed by EPO for more effective killing of micro~orgallisms, 533 
There is evidence for eosinophil participation in the induction of airway hyperrreactivity in 
asthma,268 
Rhinitis: A relationship between the influx of eosinophils into the nasal mucosa and 
allergic rhinitis was noted l69 and during asymptomatic periods, the eosinophils were absent 
from the nasal secretions,396 The mechanisms underlying the accumulation of eosinophils 
in rhinitis are poorly understood, There are numerous factors, like GM~CSF, PAF and 
lymphocyte chemotactic factor (LCF), which have been shown to be chernotactic for 
eosinophils, to prolong eosinophil~progenitor multiplication, maturation and differentiati-
on,149,535 The eosinophils are probably in part derived from progenitors at the site of 
inflanmmtion, which are in turn derived from the hone marrow via the circulation. The 
role of the eosinophil in perennial rhinitis has been rather less intensively studied than in 
seasonal rhinitis, It has been shown that the number of eosinophils is increased in the 
biopsies and secretions compared with controls.49 An eosinophil infiltration has been 
identified in nasal secretions as early as 30 min, after nasal antigen~challenge and has been 
shown to persist as long as 48 hours.42,5M The eosinophil influx of the Ilasal response to 
allergen has been shov-/ll to occur independently of the symptoms and hyperresponsiveness 
of the late reaction. 3~8 
Neutrophils 
Polymorphonuclear neutrophils are formed in the bone marrow and the predominant 
leukocytes in the circulation, The neutrophil is not normally found in tissues unless 
recruited from the circulation to sites of tissue inflammation, They are primarily responsi-
ble for maintaining normal host defence and have phagocytic and microbicidal activity in 
the tissue sites of inflammation, 
Their cytoplasmic granules contain a potent array of digestive enzymes, which may either 
remove tissue debris or kill and degrade micro~organisms, and myeloperoxidase, and 02--
radicals and related products which may disrupt the airway epithelium.31 ,570,667,675 Activated 
neutrophils have been shown to induce epithelial cell damage. 581 
Peripheral blood neutrophils have cell surface receptors for the Fe portion of IgO (Fc,R), 
but appear to lack Fc receptors for IgE, IgD and IgM. 
Neutrophils are able to produce metabolites of arachidonic acid, such as L TB4 which is the 
major metabolite, LTC4, 5-HETE, PGE2 and TxA2 160,532,646 and also PAF404 , Neutrophils 
produce cytokines, like IL-l, TNF-a, IL-8 and OM-CSF."·93 They are also capable of 
producing nitric oxide,182,527 
One of the earliest events in acute inflammation is increased adherence of circulating 
neutrophils to vascular endothelium,289 In response to bacterial lipopolysaccharides and 
cytokines, such as IL~l, TNF and IFN-y, endothelial cells become adhesive for 
neutrophils,274 There are a large number of chemotactic factors that can recruit neutrophils 
to sites of tissue inflammation, The best~characterized of these are f~Met-Leu~Phe (FMLP), 
LTB4 and C5a, Cellular sources of factors chemotactic for neutrophils include bacteria, 
macrophages, lymphocytes, platelets and mast cells. 
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Rhinitis: Due to their ability to produce these inflamma.tory mediators, neutrophils could 
play an important role in allergic rhinitis, although the role of neutrophils is still unclear. 7 
An increased influx of neutrophils is measured in nasal lavages of rhinitis patients after 
exposure to ozone.255 
A1OJlOcytes/macrophages 
In the bone marrow, over a period of approximately 6 days, a progenitor cell termed 
!Icolony forming unit granulocyte macrophage lt (CFU-GM) differentiate under the 
influence of locally produced colony-stimulating factors (CSF) into a monoblast. The 
monoblast differentiates into a promonocyte and, subsequently, is released into the 
circulation as a monocyte, which are large cells with an oval, folded nucleus and 
containing fine azurophilic granules. Human monocytes, circulating in the bloodstream, 
have a half-life of about 1-3 days. The tissue macrophages arises either by immigration of 
monocytcs from the blood (probably the predominant mechanism) or by proliferation of 
precursors in local sites. The monocyte cell surface membrane has less immunoglobulin 
and complement receptors than the macrophage. During differentiation of monocytes to 
macrophages, the azurophilic peroxidase-containing cytoplasmic granules are lost and 
lysosymes containing hydrolytic enzymes become prominent. Although Illonocytes produce 
myeloperoxidase, macrophages do not.2"~9,378 Other products released by monocytes and 
macrophages and their role in rhinitis are already presented in chapter 2, paragraph: 
antigen presenting cells. 
Lymphocytes 
On the basis of expression of cell surface markers called clusters of differentiation (CD) 
and by their antigen receptors, 3 distinct lineages of lymphocytes have been identified: 
Thymus-derived lymphocytes (T-cells), bone-marrow-derived lymphocytes (B-cells) and 
natural-killer (NK)-cells, Moreover the presence or absence of certain cell surface markers 
has been used to dclineate stages of differentiation, states of cellular activation and 
functionally distinct subsets of lymphocytes. T-ceHs maturation involves T-cell progenitors 
which arise in the bone marrow, but further differentiate and proliferate in the thymus to 
give mature T ~cells. B~cel1s complete their differentiation in the bone marrow, with Hnal 
maturation in the peripheral lymphoid tissue, such as the spleen and lymph nodes. After 
direct interaction with antigen, B-cells can differentiate into plasma cells, which can 
secrete large amount of all immunoglobulin subclasses, including IgE. After the same 
exposure to antigcn, some B-cells can differentiate to memory B-cells which are 
responsible for the rapid recall response observed after re-exposure to antigens previollsly 
recognized by the immune system. In addition to producing immunoglobulin, B-cells can 
secrete certain mediators, so called lymphokines, such as IL-6 that affect the growth and 
differentiation of B-cells and other lymphocytes. 
Lymphocytes possess low-affinity IgE (Fc,RII) receptors." 
APC's present the processed antigen to the helper/inducer T-cells (Tn), expressing the 
surface protein CD4. The T-cell receptor complex on the cell surface of the TH-cell binds 
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to the peptide/NIHC on the APC. This interaction generates an activation signal for the T-
cells leading to differentiation and proliferation with the formation of T -lymphoblasts and 
the secretion of soluble mediators, sllch as IL-4 and IL-5 which augment to help B-cells to 
respond and regulate the IgE production.606 
Figure 1: Response of the immune-system after antigen triggering 
Two functional subclasses of murine T -helper clones have been described and are 
commonly designated THI and TII2 •452 The murine THI-lymphocytes produce dominantly IL-
2, IFN-y and TNF-a, and they are thought to be involved in delayed-type hypersensitivity 
reactions and in the synthesis of IgM and some IgG subclasses. The murine T H2-
lymphocytes, on the other hand, have been shmvn to synthesize IL-3, IL-4, IL-5, IL-6, IL-
8, IL-lO, and also TNF -a and are thought to be important in allergic-type inflammatory 
reactions and defense against parasites. H6,453 J It humans, atopic allergic disorders seem to 
be related with the activation of T -helper lymphocytes with a type 2 cytokine secretion 
profile, including high levels of IL-4 ,IL-5, IL-6 , TNF-a and GM-CSF, minimal IFN-y 
and little IL-2, although this profile is not as pronounced as in mice. J21 ,J39,684 Non-atopic T 
lymphocytes resembled murine Till-cells by secreting IFN-y, IL-2, IL-6, TNF-u and GM-
CSF, little IL-5 and no IL-4. The atopies' T",-cells were excellent helper cells for IgE 
induction and the non-atopic THI-cells were cytolytic active towards autologous antigen 
presenting cells.6s4 
Cytotoxic/suppressor T-cells (Tds)' expressing the surface protein CD8, have the ability to 
kill other cells that are perceived as foreign, for example virus-infected cells, These T~ls 
cells recognize peptide antigens bound to class I MHC molecules on the cell surface of the 
target cell, whereafter the target cell is destroyed by the T~:s-cell. 
NK-cells are a subset of lymphocytes that arise from a precursor cell in the bone marrow. 
Mature NK-cells are present in blood, bone marrow and spleen, but are infrequent in the 
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lymph nodes or thymus. The exact development relationship of NK-cells to T - and B-
lymphocytes is unknown. Most mature NK~celis are large granular lymphocytes. NKacelis 
were originally defined by their ability to kill certain tumour cells, but the most important 
role of NK-cells is probably in defense against viral infection, by killing virus-infected 
host cells. NK-cells mediate a variety of immune factors other than cytotoxity. After 
appropriate stimulation (e.g. interaction with celiain tumors, iymphokines, immunoglobulin 
complexes) NK-cells secrete several cytokines, including interferon-gamma (IFN-y), 
Tumour necrosis factor (TNF) and OM-CSF. 
A few studies have shown that T-cell subsets changes in bronchoalveolar fluid and 
peripheral blood from asthmatic patients.124)45,436 The production of IPN-y, IL-4 and IL-5 is 
enhanced in asthmatics, showing an increased activity of TH~cel1s.201,399 IL-3, IL-5 and GM-
CSF promote the production of eosinophils by the bone marrow and modulate mast cell 
differentiation. 285 
Rhinitis: It was recently demonstrated in biopsies from allergic patients and nonallergic 
controls that there were no differences between the number of T -helper celJs and cytotoxic 
T ucells in the epithelium, but a higher number of activated T-cells expressing CD4 was 
found in the allergic group in the lamina propria,292 Following a local allergen challenge of 
the nose, an increased number of CD4+ T -helper cells were found in the nasal 
submucosa.319 Thus, it seems that allergen could promote TMcell activation and 
proliferation. 
Platelets 
Platelets arise in the bone marrow from megakaryocyte cytoplasm, which lack a nucleus, 
and circulate within the intravascular space during their 8MlOMdays life span, They have 
cytoplasmic granules which contain proteolytic enzymes and cationic substances. 
Platelet activation is characterized by aggregation, by production of arachidonic acid 
metabolites, like TxA2, PGD2 and 12RHETE (a chcmoattractant for neutrophils), and PAF, 
and by secretion of the contents from the granules, such as adenosine diphosphate (ADP), 
serotonin, platelet factor 4 (a chemoattractant for neutrophils, monocytes and eosinophils), 
l3-thromboglobulin and fibrinogen and lysosomal enzymes, such as J3Mglucuronidase and 
acid phosphatase.H,50,458,482,635 Platelets also have a membraneRbound enzymatic system able 
to generate and release hydrogen peroxide H20 2 after membrane stimulation. 179,.156 Platelets 
produce Nitric Oxide (NO) by a calciumR and nicotinamide adenine dinucleotide phosphate 
(NADPH)-dependent synthase. IS' 
The role of platelets in inflammatory reactions is not as weB defined as that of the 
neutrophil, eosinophil, macrophage or mast celt However, activated platelets can release 
clotting and growth factors, amines and lipids with vasoactivity as well as neutral and acid 
hydro lases. Platelets are able to interact with the immune system through platelet cell 
surface FcyR and Fc~RlI. 284,329,450 
An increased number of platelets have been observed at the sites of the reaction in asthma 
after allergen-challenge.46 Cooperation of platelets with basophils and/or mast cells was 
reported in the release of histamine during antigen challenge of astlunatics, which resulted 
in a potentiated sixfold increase of histamine release. 351 
Rhinitis: A significant increase in platelet volume and a shorter life-span (2-3 days) of 
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platelets was noticed in patients with allergic rhinitis compared with controls.22 A potential 
role of platelet-release compounds in the development of delayed responses in allergic 
patients has been proposed.147 These findings suggest that platelets participate in the 
pathogenesis in the allergic disease. 
2.3 Pl'oducts of allergic inflammation 
The role of each product itself is complex and their interactions are even more complex. 
The most important features of the products relevant for rhinitis are reviewed in the 
following paragraphs. 
Inflammatory products may have a large spectrum of effects on a variety of target cells in 
the airways, which arc relevant in rhinitis. Some of them directly lead to contraction of 
smooth muscle or enhance muscle tone and indirectly, via secondary mediators or neuronal 
substances. They may also lead to oedema of the airways and exudation of plasma into the 
lumen. These inflrumllatory products can attract and activate inflammatory cells which 
thereafter can release mediators itself, consequently leading to ongoing inflammation. 
Histamine 
Histamine is formed by decarboxylation of the amino acid histidine by the pyridoxal-
phosphate-dependent enzyme I-histidine decarboxylase. I-Iuman stores of histamine are 
predominantly contained within the cytoplasmic granules of basophils and mast cells,539 
Histamine may be released from mast cells316 and basophilsJJ4 by a number of 
inullunologic, such as IgE, antigen and cytokines, and nonimmunologic, such as 
anaphylatoxins, peptides, e,g. substance P, drugs, e.g. opiates, and physical stimuli, After 
release from the storage granules, histamine rapidly diffuses into the surrounding tissues, 
and changes in blood concentration may be detected within minutes,3J8 
Released histamine interacts with specific receptors on target cells, To date, three subtypes 
of histamine receptors have been characterized: HI) H2 and H3 receptors, The first 
physiologic action of histamine to be described was smooth muscle contraction,142 In vitro 
blockade of smooth muscle contraction by histamine HI receptor antagonists has clearly 
demonstrated that this effect is mediated predominantly· via the HI receptor subtype,20 In 
human airways smooth muscle contraction in response to histamine callses 
bronchoconstriction,136,186 Histamine increases vascular permeability to macromolecules by 
the formation of intercellular gaps in the postcapillary vcmules,'n In the nasal airways, the 
effect of histamine on vascular permeability is not clear, Changes are usually quantified by 
measurements of nasal airflow, which reflect mucosal oedema resulting from vascular 
leakage, Pretreatment with an oral or nasal HI receptor antagonist has been shown to 
attenuate the histamine-induced increase in nasal airway resistance (NAR), whereas H2 
receptor antagonists alone have no significrult treatment effec1.277,568 Despite the 
ineffectiveness of pure H2 receptor antagonism, when administered in combination with I-II 
receptor antagonists a significant reduction in histamine-induced nasal airflow obstruction 
is seen. This supports a minor role for H2 receptors, with most of the vascular permeability 
changes being rnediated via the HI receptor. On human vessels histamine has a dual effect 
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with constriction mediated by HI receptors and vasodilatation via H2 receptors.<u Histamine 
effects both the quantity and viscosity of mucus secretion, mediated via H2 60,576 and HI 417 
receptors, respectively. The HI receptor subtype is involved in the histamine~induced 
increase in action potentials in nerves.550 The most important action of H2 receptor 
antagonists is to reduce the secretion of acid in the stomach and relaxation of blood 
vessels. H2-antihistamines enhance histamine release from human basophil 
leukocytes.388,389,632 The H2 receptors mediate the feed~back inhibition of histamine release 
from human basophils.6H Histamine modulates the response of a number of subtypes of 
leukocytes. The chemotactic activity of eosinophilsl1l and neutrophils572 may be increased 
by histamine and the antigen~induced histamine release from basophils is controlled632• 
Histamine also modulates immunoglobulin synthesis, which includes interference with the 
maturation of antigen~stimulatcd B~cellsl7l, suppressing antibody secretion from plasma 
cells43 [, and modulating immunoglobulin production of mature mononuclear cells392. The 
H3 receptor has been identified using the H3 receptor agonist R( -)-a-methylhistamine and 
the antagonist thioperamide, but the role in airways rernains to be established. 18 H3 
receptors regulate the histamine synthesis and release from histaminergic nerve 
endings. [7,18.315 
Rhinitis: Nasal challenge of rhinitis patients with hist.:'1mine induced nasal blockage, 
measured by NAR and is accompanied by dose-dependent sneezing and rhinorrhoea. 158,410 
A greater change in NAR is found in rhinitis patients compared with controls, suggesting 
nonspecific hyperreactivity of the upper airwaysl2S, which is in contrast with other 
investigations, in which an equal effect of histamine provocation on NAR in patients and 
controls was found. 225 
Thus, histamine derived from mast cells and acting via HI and H2 receptors is responsible 
for much of the sneezing, nasal blockage and rhinorrhoea during the early response to 
nasal allergen challenge. Increased concentrations of histamine are found in nasal washings 
of rhinitis patients immediately after allergen-provocation.2JO Also during the late phase 
response histamine, released from basophils is found in increased concentrations in nasal 
washings.44 
Tlyplase 
Proteases may be subdivided into those which cleave peptide bonds distant from the end of 
polypeptide chains (endopeptidases) and those which cleave only those bonds near to the 
end (exopeptidases).40 Four groups of elldopeptidases have been differentiated according to 
the nature of their catalytic site: serine, cysteine, aspartic and metalloproteases. The serine 
proteases are named after a serine residue in the catalytic site, and includes neutrophil 
elastase, mast cell tryptase and chymase. These enzymes are "neutral proteases'" with pH 
optimal well suited to the neutral conditions of the extracellular environment ~f the 
respiratory tract. 
Proteases are the major constituents of the mast cell secretory granule on a weight basis. 
To date three proteases have been isolated from human mast cells, tryptase566,591, 
chymasem ,556, and carboxypeptidasew . Of these, tryptase is the most abundant with an 
estirnated 10 pg per lung mast cel1. 565 Tryptase appears to be present only in mast cells. 
Subsequent studies have demonstrated that there are major compositional differences 
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between mast cells from different species, and also between different tissues of the same 
species, such that proteases have become valuable markers of mast cell heterogeneity. 
Tryptase has been found to cleave vasoactive intestinal peptide (VIP)96,60s, peptide 
histidine-methionine (PHM)60S, and calcitonin gene-related peptide (CORP)60S,657, but does 
not hydrolyze substance P, neurokinin A or neurokinin B96,608. 
Dog mast cell tryptase has been rep0l1ed to increase the contractile response of canine 
bronchial smooth muscle strips to histamine and other agonists. This effect appeared to be 
dependent on the enzymatic activity and was prevented by HI receptor antagonists and 
voltage dependent Ca2+ channel blockers. This observation has not been confirmed with 
human tissues, but raises the possibility that tryptase could contribute to bronchial 
hyperreactivity.656 Tryptase has been found to increase vascular permeability, when injected 
into guinea-pig skin and stimulate neutrophil accumulation.656,6ss 
Rhinitis: In rhinitis, comparatively little attention has been paid to the contribution of 
vroteases in disease pathogenesis. However, the recent development of sensitive procedures 
for the detection of proteases from mast cells, and the discovery of their potent biologic 
effects has provoked interest in the potential of these enzymes to act as Imtior mediators of 
allergic disease.97,561 The mast cell is an important source of proteases in rhinitis. Increased 
levels of proteases have been detected in the nasal secretions of rhinitis patients. 
Provocation of acute rhinitis with allergen or cold dry air is associated with the rapid 
release of mast cell tryptase as well as histamine and other mast-cell-derived mediators 
into nasal fluid. 95,)32,524 
Tryptase may thus participate in many of thc processes of rhinitis and deserves attention 
beyond its rolc as a marker for mast cell activation in the airways. 
Eicosanoids 
Eicosanoids are biologically active lipids formed out of arachidonic acid. The principal 
sources of arachidonic acid are membrane bound phospholipids, primarily 
phosphatidylcholine, phophatidylethanolamine, and phosphatidylinositol. Arachidonic acid 
is released from the cell via hydrolysis of the phospholipids by phospholipase A" 
phospholipase C, and/or diglyceride lipase. 143,150,151,337 Activation of phospholipase A2 may 
involve elevated concentrations of intracellular calcium, phospholipase C may involve 
generation of inositol phosphate and diacylglycerol. 177,)]),579 
Free arachidonic acid may be enzymatically oxygenated by two major pathways: 
cyclooxygenase and lipoxygenase. The prostaglandins and thromboxane are generated 
through the cyclooxygenase pathway and the leukotrienes are derived via the lipoxygenase 
pathway. 
Cyclooxygenase metabolites 
Arachidonic acid is oxygenated by catalyzation via cyclooxygenase (prostaglandin 
endoperoxide synthetase) to the endoperoxide P002, which is subsequently reduced to 
POH2. POH2 is transformed to POD2, POE2 by specific isomerases or non-enzymatic 
degradation, POF2u by reductase, POI2 by prostacyclin synthase and TxA2 by thromhoxane 
synthase. POI2 and TxA2 are unstable biological active mediators which arc rapidly 
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hydrolysed to 6-keto-PGF,. and TxB, respectively,,,,,,,,,59' 
Cyclooxygenase (COX) has two isoforms: COX, and COX,,'" COX, is constitntively 
expressed ill the stomach, intestine, kidney and platelets, while COX2 expression is 
inducible in e.g. monocytes, macrophages, fibroblasts by stimuli, such as growth factors, 
cytokines and endotoxin. 153•638 COXI is involved in prostaglandin synthesis in cellular 
"housekeeping functions", while COXl is involved in inflammatory processes. 153 
Prostanoid receptors have been classified into five types, based on potencies of natural 
agonists and on identification of ligand-binding sites.217.266 These receptor types are: TP, 
TxAlIPGH2; IP, POI2; EPI_3, POEl , FP, POF2et ; and DP, PGD1• These receptors differ 
greatly between species and within the same species, receptors may also vary between 
tissues?66 All these receptors are O-protein coupled. 
Almost aU inflammatory cells are able to generate cyclooxygenase products. After 
stimulation with IgE, human mast cells produce POD2.291 ,386,559 Human alveolar 
macrophages and aitway epithelial cells generate PGEl, POF2a and thromboxane. 241,472,677 
Cyc100xygenase products have effects on bronchial smooth muscle and vessels. POF2a and 
PODl are potent bronchoconstrictors.59,273,541,590 PODl also has vasoactive properties, 
causing increase in pulmonary arterial pressurc.595 TxAl has bronchoconstrictor 
properties538, stimulate airway smooth muscle cell proJiferation638, and causes 
vasoconstriction and platelet aggregationm . POEl and POll are broncho and 
vasodiiators. 307,359,595 However, inhaled POI2 may have bronchoconstrictor properties in 
some mild allergic asthmatics272, this paradox has not been resolved. POD2• POE2 and POll 
inhibit platelet aggregation,553 POF2o.' POEz and POll are potent inducers of cough, perhaps 
through stimulation of irritant receptors and C_fibres,117,130,540 POE2 inhibits phagocytosis, 
mediator function and cytotoxicity of macrophages, chemotaxis of macrophages and 
neutrophils and several lymphocyte functions.610 
Increased concentrations of POD2 and TxA2 were found in bronchoalveolar lavage fluid 
after antigen-induced bronchoconstriction in atopic asthmatics.6SO In addition to 
constrictor/dilator properties, prostanoids have also been demonstrated to induce airway 
hyperreactivity in asthma.20S,lll.662 
Rhinitis: POD2 was released into nasal secretions during the immediate response to nasal 
challenge with pollen antigen, though not during the late phase response. 467,478 In another 
study with allergic rhinitis patients, increased concentrations of PODl were reported to 
occur within minutes of and allergen-induced early nasal response.l13 
Lipoxygcnase metabolites 
In the presence of active 5-lipoxygenase unstable epoxide L TA4 is formed via the 
intermediate 5-hydroperoxyeicosatetraenoic acid (5_HPETE).551,55l LTA4 is a intermediate 
in leukotriene synthesis for L TB4 and the cysteinyl lcukotrienes (LTC4• LTD.; and 
LTE,,).385,551 12- or 15-lipoxygenase catalyzes the oxygenation of arachidonic acid to 12- or 
l5-HPETE, which is further converted into 12- and 15-HETE,'98 
In the guinea-pig lung distinct receptors mediating constriction for LTC" and LTD4 were 
classified as LTR, and LTR.J respectively.Jl8 In human bronchi such differentiation in LTC4 
and LTD" receptors appears to be absent,S'1 LTD" receptors are found in human lung tissue, 
but the L TC4 binding sites appear not to be receptors. LTC.~ binds to the ubiquitolls human 
enzyme glutathione-S-transferase with characteristics that mimic receptor bindings. 159.494,61)2 
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Thus, this suggest that there are specific receptors for LTD4, but not for LTC4 in human 
airways. LTE4 appears to act as a partial agonist at the LTD4 receptor, which can 
desensitize this receptor and displace radiolabeled LTD4, but only can induce a fraction of 
the biological activity. The mechanism is unknown.554 Specific binding sites for LTB4 are 
identified on human neutrophils. Also these receptors are G-protein coupled, 
Mainly, LTB,; is produced by neutrophils, airway epithelial cells and alveolar macrophages, 
whereas the other leukotrienes and HETE's only are released in small quantities. 17S,2.;o,299,546 
LTC,;, LTD4 and LTE4 are formed by eosinophils, basophils and mast cells:~99,5S9 
LTC4, LTD.; and LTE,; have potent bronchoconstrictor properties, increase microvascular 
permeability in the airways and decrease blood pressure. 19s,m L TB.; is a potent 
chemoattractant for neutrophils and monocytes, but is less effective for eosinophils, (9) 
L TB.; also stimulates the release of lysosomal enzymes from macrophages and 
neutrophils 174, increases vascular permeability and releases oxygen radicals from 
neutrophilsS7J, 5- and 15-HETE modestly contracted human bronchial muscle l2.t, and 
HETE's are chemotactic for neutrophils and eosinophils239. Ncutrophils are degranulated by 
5- and 12_HETE.599 
Rhinitis: Increased concentrations of LTC4, LTD4 and LTE4 were found in nasal lavages 
of rhinitis patients during allergen-induced early nasal response,m 
As a consequence of their activity, the eicosanoids have been implicated as potential 
candidates in the pathogenesis of rhinitis. 
Platelet activating jactor 
PAF was discovered during experiments designed to study cell-cell interactions following 
antigen challenge of rabbit leukocytes in the presence of IgE-sensitized basophilssl, capable 
of activating platelets. PAF is idelltilied as a phospholipase-A,-(PLA,)-sensitive 
phospholipid and later as a I-alkyl-2(R)-acetyl-sn-glycero-3-phosphorylchloride.1l8 PAF can 
be synthesized by two distinct pathways. The first is a two-stcp pathway which involves 
the production of the biologicitlly inactive intermediate Iyso-PAF by phospholipase A,. 
Lyso-PAF is converted into PAF by acetyl coenzyme A-dependent acetyltransferase 
enzyme. This pathway is only activatcd in response to inflanunatory stimuli,59) The second 
pathway involves cholinephosphotransferase which produces PAF indirectly from ether-
linked phospholipides.59) This pathway may be required to maintain physiological levels of 
PAF for normal cell function, 59) 
There are specific G-protein linked PAF receptors, on inflammatory cells, which activate 
PLA, and PLC. 
Basophils, mast cells, neutrophils, eosinophils, monocytes and macrophages can synthesize 
P AF when stimulated with calcium ionophore or IgE,75 PAF is released by macrophages 
from allergic patients stimulated by allergen. 16 
PAF is a potent ill vitro activator of eosinophil, platelet, neutrophil, monocyte and 
macrophage chemotaxis and superoxide-allion production, and activator of the release of 
arachidonic acid metabolites, such as LTC4, by neutrophils, eosinophils and 
macrophages,S(,75,81,194.275,283,380,48),639,6(j(j,691 PAP has been shown to be a potent mucus 
secretagogue for human airways ill vitro247 and stimulates the secretion of chloride ions 
and, thus, allows the movement of water toward the hUllen,622,678 Basophils arc activated by 
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PAF and, thereafter, releases histamine and L TC4 by a rise in calcium influx. liS 
Intravenous injections of PAF to guinea-pigs leads to a bronchoconstriction and 
hypotension640 as well as bronchial hyperreactivity to serotonin6-H, histamine or 
acetylcholine132,429: In humans PAF induces bronchial hyperreactivity to methacholine in 
non_asthmatics. I04,105,1J8,547,664 This is in contrast with other investigators, who found that 
PAF failed to induce hyperreactivity to methacholine in normal subjeets I03,363,596 and 
astlullatic patients22l,m. 
Rhinitis: Lyso-PAF-acether, but almost no PAF was significantly increased in nasal 
secretions from allergic patients in the immediate reaction to antigen challenge.438,626 
Topical pretreatment with PAF of seasonal allergic rhinitis patients induced only minor 
changes in nasal respiratory peak flow rate and symptom score as compared with placebo. 
However, it induced an increase in responsiveness of the nasal vasculature to allergen 
challenge, measured as increased symptoms and nasal peak flow, but other parameters, 
such as sneezes and secretion remained identical. 1J Nasal challenge with PAF induced 
nasal obstruction, rhinorrhoea and itching in allergic rhinitis patients, but no increase in 
histamine levels were observed in nasal lavages. No changes were seen after challenge 
with lyso-PAF.:m Topical nasal application of PAF induced an increase in eosinophils in 
the nasal lavage fluid and bmshes of allergic rhinitis patients, but did not produce any 
changes in methacholine-induced secretory responsiveness. m 
Thus, PAF may have pathogenetic and clinical relevance in allergic rhinitis. 
Eosinophil-derived granule proteills 
Activation of granulocytes, including eosinophils, can result in the release of granule 
contents, providing the cells with a very potent mechanism of inflammatory action, 
Specific eosinophil granule proteins include MBP, EPO, ECP and EON, Degranulation of 
these cationic proteins has been correlated to several of the symptoms of astluna and 
rhinitis and hyperresponsiveness. MBP is toxic to many mammalian cells, such as human 
lung epitheliull120\ and induces mast cell and basophil histamine release,481 The EPO can 
stimulate mast cell secretion281 , inactivate mediators of immediate hypersensitivHy282, and is 
cytotoxic to various target cells280. ECP can inhibit T-Iymphocyte proliferation in a non 
cytotoxic fashion, but the mechanisms involved are unclear.508 
There appear to be two mechanisms of eosinophil granule release: 1) Selective release. 
Although residing in the same intracellular granule, eosinophils can selectively release 
specific proteins, while retaining others. After anti-IgE stimulation, eosinophils released 
. EPO} but no ECP. IgG-dependent stimulation causes the opposite, while IgE-dependent 
stimulation releases both EPO and ECP,9o Therefore, granular constituents can be 
solubilized within the eosinophil granule and then transported through the cell cytoplasm 
as molecules or, via the endoplasmic reticulum through the cell membrane. 597 2) 
Exocytosis, In contrast, eosinophils stimulated with calcium ionophore result in the fusion 
of granules with each other and with the plasma membrane, suggesting the presence of a 
secondary mechanism of granule release, indicated as exocytosis. 279 
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Eosinophil cationic protein 
ECP is localized in the granules of eosinophils and has a molecular mass of 18-21 kDa.2~6 
Motojima ef ai. found that ECP caused dose-dependent damage to guinea-pig tracheal 
epithelium in vitro.455 However, ECP had no effect on bronchoconstrictor or airway 
hyperresponsiveness of cynomolgus monkeys.262 
Increased serum levels of ECP occur in allergen-provoked asthma. 14D.643 Elevated levels of 
ECP have been found in bronchoalveolar lavage fluid of astlunatics obtained during the 
late phase reaction after allergen-inhalation challenge of asthmatics, as well as in 
unchallenged patients with chronic asthma,445 
Rhinitis: In both allergic and nonallergic rhinitis increased serum levels of ECP are 
observed. 64~ Lavage fluid from allergic rhinitis patients showed marked elevations of ECP 
after segmental bronchial antigen challenge.569 An increased number of eosinophils and 
raised levels of ECP were found on the nasal mucosal surface during natural allergic 
rhinitis patiellts.60J These changes were not accompanied by an increased secretory 
responsiveness of the nasal mucosa to methacholine,J48 In the lavage fluid of the patients 
with a late phase reaction, a significant eosinophilia was found, compared with controls 
and those patients who only demonstrated early responses. This suggested that eosinophils 
and their mediators might be involved in the development of the late phase reaction, 
This suggests that the eosinophil influx and levels of ECP and the hyperresponsiveness 
following an allergen challenge are not necessarily integrally linked, but are possible 
simultaneous expressions of coincedental processes. 
Cylokil1es 
Cytokines function as up~ and down-regulators of immunologic, inflammatory and 
reparative host responses to injury. Cytokines produced by lymphocytes are called 
lymphokines, whereas peptides produced by monocytes or macrophages are called 
monokines. Cytokines generally arc synthesized and secreted peptides which are often 
glycolysed with Illolecular weights ranging frolll 6000 to 60000 Da. Cytokines are 
transmembrane glycoproteins with an extracellular amino-terminal ligand binding domain, 
a short hydrophobic transmembrane region and a carboxyl-terminal intracellular domain.493 
Cytokines generally act in a paracrine (i.e. locally near the producing cell) or autocrine 
(Le. directly on the producing cell) rather than in an endocrine manner on distant target 
cells. Cytokines modulate reactions of the host to foreign antigens or injurious agents by 
regulating the growth, mobility and differentiation of leukocytes and other cells, Normal 
resting cells must be stimulated to produce cytokines, and therefore usually no cytokines 
are normally present in serum, Many cytokines arc simultaneously produced by activated 
cells, These cytokines interact with high aftlnity cell surface receptors specific for each 
cytokine. A single purified cytokine can have multiple effects on the growth and 
differentiation of many cell types. Consequently, cytokines may exhibit considerable 
overlap in their biologic effects on target cells. In addition, biologically distinct cytokines 
may have similar effects by initiating the production of a cascade of identical cytokines or 
of one another. 
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Some cytokines have direct histamine-releasing properties, such as IL-3, GM-CSF and 
IL-I from basophils and mast cells.26J ,4oS Cytokines can prime basophils for enhanced 
histamine release in response to other secretagogues, such as anti-IgE and FlvILP. This 
priming effect has been documented for IL_I_3426,449,669, IL_5 53, IL-II, GM_CSF54 and IFN-
y557. Some of these priming cytokines, sllch as IL-5, also uprcgulate adhesion molecules in 
nasal mucosa, including E select in, P selectin, ICAM-I, ICAM-2 and VCAM_1. 360,520.616 
The inducible expression of these molecules on endothelium directs the focal adherence of 
leukocytes to endothelium for extravasation at sites of inflammation. 
Several investigators have suggested that the cytokines, IL-2, IL-3, IL-4 IL-5 and GM-CSF 
may be contributing to the occurrence of degranulation of cells in bronchial mucosa of 
asthmatics. 269,271 
Rhinitis: Durham el al. 163 showed with in situ hybridization messenger ribonuclear acid 
(mRNA) for IL-3, IL-4, IL-5 and GM-CSF in nasal biopsies 24 hours after allergen 
challenge, which is correlated with the number of activated T-cell and eosinophils, In 
addition to the work in nasal mucosal tissue, attempts have been made to quantitate 
cytokines in nasal secretions following antigen challenge.4,27,202 In general, little success has 
been reported in nasal lavages, with some cytokines such as IL-lB, IL-2 and IL-6 being 
detectable in higher levels than preclmllenge fluids only in a subset of allergic subjects. 27 
Increased levels of IL- Wand GM-CSF have been detected by using strips of filter paper 
to collect secretions from the nose. 4 
Of these cytokines, IL-5 is highly important, because IL-5 alone is capable of inducing 
eosinophil degranulation in the absence of a ligand and greatly enhancing ligand-stimulated 
eosinophil degradation.209 
Interleukin-5 
IL-5 has a molecular weight of 18 kDa. It was initially detected and its gene was later 
cloned on the basis of its T-cell-replacing activity and B-cell-growth activity for the BCI-I 
lymphoma line. Today, it is known that fL-5 is produced by mast cells519, eosinophilsl 52 
and mainly TIl2_cells453 . 
IL-5 promotes the proliferation and differentiation of B-cells and promotes the antibody 
production by B-cells, particularly of the IgA isotype, IL-5 has modest mitogenic effects 
on T -cells. In addition, it induces the differentiation of bone marrow precursors into 
eosinophils and support the growth of eosinophilic cell lines and induction of cytotoxic T-
cells. IL-5 enhances eosinophil development and differentiationllJ,594 and prolong survival 
of eosinophils545• IL-5 can alter functional and immunologic properties of eosinophils. Data 
from patients with eosinophil-related disorders suggest that IL-5 produces rlactivatedl1 
eosinophils. 234 It has been observed that IL-5 increases eosinophil, but not neutrophil, 
adherence to vascular endothelium659 and IL-5 is chemotactic for eosinophils66J . 
Eosinophils can be primed by IL-5 for chemotaxis towards PAF.670 
Thus, although the T-Iymphocyte is considered to be a major source of IL-5, eosinophils 
contribute to the production of IL~5 in allergic airway inflammation.58 This raises the 
possibility of an autocrine mechanism whereby stimulated eosinophils may both release 
and respond to cytokines, such as IL-5. Thus, there is the potential for a self-perpetuating 
cycle, with continuous eosinophil infiltration and activation and consequently chronic 
inflammation. 
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In humans, elevated serum IL-5 was noted in symptomatic asthmatics in association with 
activated T -lymphocytes and eosinophilia.127 
Rhinitis: In allergic rhinitis patients, IL-5 levels were elevated 48 hours after antigen 
challenge and found to correlate strongly with eosinophil number, eosinophil granule 
proteins and LTC4 levels. 569 Application of recombinant humanlL-5 onto the nasal mucosa 
of patients allergic to pollen increased the numbers of eosinophils and epithelial cells and 
ECP and IgA in the nasal lavage fluid. Also the number of eosinophils in both the 
epithelium and lamina propria as well as in the lumens of the blood vessels in the nasal 
mucosa were increased. The responsiveness to histamine also enhanced after the 
application.617,618 
Nitric oxide 
Nitric oxide (NO) is generated from oxygen and L-arginine by nitric oxide synthase (NOS) 
in a complex nicotinamide adenine dinucleotide phosphate (NADPH)-dependent 
reaction.457,500 The NO is freely diffusible, highly reactive, and short-lived, In part of its 
reactivity, the actual molecules emanating from cells may include a complex mixture of 
nitrogen oxides, nitrite (N02')' nitrate (N03 '), and the products of nitrosation of a variety 
of molecules. The interaction of NO with superoxide anion leads to the generation of 
hydroxyl radical, as well as peroxynitrite (ONOO'), 526 In the presence of superoxide 
dismutase, the result of this interaction may be nitroxyl anion (NO,).'m Pcroxynitrite and 
nitroxyl anion are very potently cytotoxic. 
NOS present in various cells from different origin exists in two fo1'ms. 444 The first is a 
constitutive, cytosolic calcium dependent enzyme (cNOS), which releases nitric oxide after 
stimulation; this has been found in the vascular endothelium, platelets, neutrophils and 
neural tissue. The second subtype is an inducible, calcium independent enzyme (iNOS), 
which is found after induction with cytokines, in macrophages, vascular smooth muscle 
cells, cardiac myocytes, endothelial cells, fibroblasts, epithelial cells and adenocarcinoma 
cells. 326,328,443,444 
NO is produced by macrophages, neutrophils, mast cells and platelets.57,527 NO has been 
identified as endothelium-derived relaxation factor (EDRF),442 NO generated by intact 
endothelium not only induces smooth-muscle relaxation, but also appears to serve to 
inhibit further adhesion and aggregation of normal platelets, which suggest protective 
effects against inflammation,8,427.645 NO has the ability to suppress leukocyte adherence and 
T-Iymphocyte proliferation and to regulate the mitogen responses.206 NO can modulate the 
release of histamine form mast cells,421 
NO has been shown to be a potent bronchodilator in isolated guinea-pig trachea smooth 
muscle and in humans,48,63I Probably, NO mediates airway smooth muscle relaxation by 
inhibiting the release of acetylcholine from the nerve tenninal.J6 NO also leads to the 
production of cAMP.259 The products of NO are extremely cytotoxic, Because epithelial 
damage is related to the development of bronchial hyperreactivity365, NO may be greatly 
responsible for hyperresponsiveness in asthmatics. This is supported by Golden, who found 
that inhalation of nitrogen dioxide and ozone increases bronchial reactivity in healthy 
iUIlllans2-1l and by Barnes, who suggested that free oxygen radicals from inflammatory cells 
increases the breakdown of NO, thus leading to exaggeration of the cholinergic reflex 
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bronchoconstriction,36 
Rhinitis: Inhalation of ozone of allergic rhinitis patients caused an increase in symptoms 
after allergen challenge, Also an increase in nasal lavage neutrophils, eosinophils, 
mononuclear cells and epithelial cells was observed, The histamine and albumin 
concentrations in lavage fluid increased on the ozone exposure day,41 
These findings suggests that NO could be associated with rhinitis and hyperreactivity. 
2.4 Concluding I'ClllIUks 
Several inflammatory cells, such as mast cel1s, basophils, lymphocytes and eosinophils and 
their mediators released after specific or non~specific stimuli, have been demonstrated 
during the nasal allergic processes, Although some of these mediators, such as histamine, 
prostaglandins and leukotrienes may be biological active in allergic rhinitis, the role of 
others, such as PAF, IL~5 and nitric oxide still needs clarification, The interaction between 
these different cellular components to induce the clinical symptoms of allergic rhinitis 
remains unclear. Also the relationship between the inflammatory infiltration, cellular 
activation and hyperreactivity needs further establishment. \Ve have investigated some of 
these cells and mediators in nasal lavages and brushes of perelUliai allergic rhinitis patients 
during allergen challenge or natural allergen-exposure. \Ve have particularly investigated 
the role of tryptase, as a marker of activated mast cells, ECP, as a marker of activated 
cosinophils, and furthermore histamine, LTC/D/E4, PGD21 PAF, IL-5 and NO, which are 
involved in the immediate and late phase nasal reaction to allergen challenge, in 
hyperreactivity and in therapeutic intervention, 
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Aim of the study 
From chapter I and 2 it can be concluded that despite still poorly defined mechanisms, 
inflanuuation is clearly associated with the pathogenesis of allergic rhinitis. In order to 
investigate the association between nasal hyperreactivity, the late phase response and nasal 
inflammation in patients with perennial allergic rhinitis, several studies during allergen 
challenges or natural exposure, were performed. . 
Hereto, we tried to find an answer to the following questions: 
1. Are nasal hyperreactivity and the immediate and late allergic reactions to allergen 
challenge associated? 
2. Is nasal hyperrcactivity related to the inflammatory response as measured by the 
release of inflammatory mediators in nasal lavage fluid after house dust mite 
challenge? 
3. \Vhat are the effects of therapeutic interventions with a topical corticosteroid 
(fluticasone propionate) and a topical antihistamine (Jevocabastine) on nasal 
hyperreactivity, nasal inflammation, and the immediate and late response to nasal 
allergen challenge? 
4. Is nasal hyperrcactivity during natural allergen exposure associated with the 
ongoing allergic inflammation as determined by the amount of eosinophils 
(obtained by nasal brush) and the levels of inflammatory mediators in nasal lavage 
fluid? 
5. Is nasal hyperreactivity associated with quality of life scores and with daily nasal 
symptoms? 
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Chapter 4 
Nasal responsiveness to allergen and histamine are associated in patients 
with perennial allergic rhinitis 
C. de Graaf-in 't Veld', I.M. Garrelds1,2, A.W. van ToorenenbergenJ, R. Gerth van \Vijk' 
IDepartment of Allergology, University Hospital Rotterdam-Dijkzigt, 20epartment of Phanuaco!ogy, Erasmus 
University Rotterdam, JLaboratory of Allergology (Department of Clinical Chemistry), University Hospital 
Rotterdam-Dijkzigt. 
Submitted for pUblication. 
4.1 Abstl'act 
Background - In the lower airways an association has been found between early phase 
reaction (EAR), late-phase reaction (LAR) and bronchial hyperreactivity. However, this 
association could not be demonstrated for the upper airways, as shown in nasal pollen 
challenge studies. We have studied whether the EAR, LAR and nasal hyperreac(ivity are 
related in perennial allergic rhinitis. 
Methods - Twenty-four rhinitis patients allergic to house dust mite (HDM) were challenged 
with HDM extract. Nasal response was monitored by symptom scores and nasal lavages for 
up to 9.5 hours aner challenge. In lavage fluid albumin, tryptase and Eel' were measured. 
Eleven patients (LAR+) demonstrated elevated symptom scores behveen 3.5 and 9.5 hours 
compared with the baseline score. The other 13 patients (LAR-) showed an isolated EAR 
only. Nasal hyperrcactivity was determined by nasal histamine challenge 24 hours later. 
Results - LAR+ responders showed a significantly higher symptom score, albumin influx 
and tryptase release during the EAR. During the late phase (3.5 -9.5 hrs) albumin influx 
was significantly increased at most time points and Eep release was significantly higher at 
9.5 hours in the LAR+ group. LAR+ responders showed a significantly stronger response 
to all doses of histamine. The AVe of symptom scores during EAR, LAR and Ave of 
histamine dose-response were significantly correlated (EAR-LAR: 1=0.49, p<O.OI; EAR-
histamine: 1=0.75, p<O.OOI; tAR-histamine: 1=0.66, p<O.OOI). 
ConclusioJ1s - In patients with perennial allergic rhinitis the nasal responses to allergen and 
histamine are associated. LAR- and LAR+ responders show a different profile of mediator 
involvement. 
Keywords: perennial allergic rhinitis; early allergic response; late allergic response; 
inflammation; nasal hyperreactivity 
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4.2 Introduction 
In atopic patients, allergen challenge gives rise to increased responsiveness to allergen and 
non-specific stimuli. This phenomenon has been described for the upper as well as for the 
lower airways. 10,1 16,120,261 
In the lower airways, the immediate response to allergen challenge is often foHowed by a 
late-phase response (LAR). This bronchial late-phase reaction is associated with increased 
inflammation and bronchial hyperreactivity.92,115,162,4H In the upper airways late-phase 
responses have also been described.176,505 Several studies have been performed to find out 
whether similar associations could also be shown in allergic rhinitis patients. However, no 
relation was found between nasal hyperreactivity and late nasal response230, between nasal 
hypcrreactivity and activation of eosinophilsJ~6 or between ellhanced responsiveness to 
rechallenge with allergen and late nasal response31O• These shldies were performed in pollen 
sensitive patients tested outside the pollen season. 
In contrast, in a study with rhinitis patients allergic to house dust mite (HDM), we have 
shown an association between nasal responsiveness to allergen and pre-existent nasal 
hyperreactivity229, a finding more in agreement with data from the lower airways. 
In the present shldy, patients with perennial rhinitis were challenged first with hOllse dust 
mite and 24 hours later with histamine. Clinical response, mediators, and nasal 
hyperreactivity of patients with or without a LAR were compared in order to investigate if 
early (EAR), late-phase nasal reaction (LAR), inflammation and nasal hyperreactivity are 
associated in perellllial allergic rhinitis. 
4.3 Matel'ials and methods 
Sul~iecls 
Twenty-foul' patients participated in this study, 11 women and 13 men, mean age 34 yrs 
(range 21 to 50 yrs). All were characterised by a history of perelUlial rhinitis and a 
intradermal skin reaction of at least one plus-sign to 3 BU/ml HDM extract (ALK Benelux, 
Groningen, the Netherlands), according to the standardised plus-sign scoring system 
defined by Nonnan477 . Patients with pollen allergy were tested outside the pollen season. 
Patients pet allergy were only included if they had no contact with pets. 
Symptomatic medication for rhinitis were withdrawn: oral corticosteroids for two months, 
astemizole six weeks, nasal or inhaled corticosteroids, cromoglycate and nedocromil three 
weeks and antihistamines three days before the start of the shldy. Patients with nasal 
polyposis, nasal surgery less than three months before the study, llasal infection during the 
two weeks before the study or immunotherapy in the past were excluded. 
Study design 
Patients were challenged with tluee increasing doses HDM extract. Symptom scores were 
recorded and nasal lavage fluid was obtained for up to 9.5 hours after HDM challenge. 
Allergen-induced nasal hyperreactivity was determined by nasal histamine provocation 24 
hours later. 
During the study patients were not allowed any medication affecting nasal function. The 
study was performed during the period January-August. This period was chosen to 
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minimise natural exposure' to HDM. 
All patients gave their written informed consent and the study was approved by the 
Medical Ethics Committee of the University Hospital. 
Nasal challenge with HDM and hisiamille 
Challenges were performed in accordance with the methods described by Gerth van 
Wijk229,230. Before starting the nasal challenges, the patients waited for 30 minutes in order 
to give the nasal mucosa time to acclimatise. 
Nasal challenges with HDM extract (100, 1000 and 10000 BU/ml, ALK Benelux, 
Groningen, the Netherlands) were performed at ten-minute intervals after challenge with 
phosphate-buffered saline (PBS), containing human serum albumin 0.03% and 
benzalkonium chloride 0.05% (ALK Benelux, Groningen, the Netherlands). The HDM 
extract was sprayed into each nostril by means of a nasal pump spray delivering a fixed 
dose of 0.125 ml solution. The nasal response was measured ten minutes after each 
challenge, 30 minutes after the last challenge (HDM 10000 BU/ml) and hourly for up to 
9.5 hours after the last challenge, Nasal responsiveness was monitored by the number of 
sneezes, the amount of secretion collected according to Borum68 and a symptom score 
according to Lebee73• 
Nasal challenge with histamine phosphate (0.25, 0.50, 1.0, 2.0 and 4 mg/ml) was 
performed at five-minute intervals after challenge with PBS. The amount of secretion, the 
number of sneezes and the symptom score according to Lebel373 were used as nasal-
response indicators. 
Nasal Image 
Nasal lavages were performed as described by Naclerio46s• This protocol comprises four 
pre-challenge lavages with isotonic saline solution to clear the nose from secretions and to 
obtain baseline levels of mediators. In order to prevent nasal congestion due to allergen 
challenge, oxymetazoline 0.1 % (two 0.125 ml puffs) was applied in both nostrils. After 
five minutes the oxymetazoline was washed out just prior to the nasal challenge with PBS. 
A nasal lavage was performed ten minutes after PBS and after each allergen challenge, 
immediately before the subsequent challenge. Subsequently, lavage fluid was obtained 
hourly from 0.5 to 9.5 hours after the last allergen challenge. Nasal lavages were 
performed with 10 ml isotonic saline solution (0.9%) preheated to 3TC. In each nostril 5 
ml saline was instilled with a pipette while the subject gently flexed his/her head 
backwards. After ten seconds, the lavage fluid was expelled and collected in tubes. This 
procedure has shown to produce a mean (SD) recovery of 7.7 (±1.2) ml. 229 
Symptom score 
Symptoms were recorded using a scoring system according to Lebel et 01.373 at the time 
points of lavage. Symptom scores were graded in points (pts): 3-4 sneczes=1 pt, :?:5 
sneezes=3 pts; anterior rhinorrhoea= I pt; posterior rhinorrhoea= I pt; difficult nasal 
breathing~ I pt, one nostril blocked~2 pts, both nostrils blocked~3 pts; pruritus of the 
nose=1 pt; pruritus of palate or em=1 pt and conjullctivitis=l pt (total score ranges from 0 
till 11 pts). In addition, the number of sneezes and the amount of secretion were noted. 
According to their symptom scores, patients were divided into two groups: those with an 
early response only (LAR-) and those with both early and late-phase symptoms (LAR+).229 
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Patients whose symptom scores were above baseline level at two consecutive time points 
(Le. at least one hour) between 3.5 and 9.5 hr, were defined as LAR+ responders. The 
others with symptom scores equal or lower than the baseline score between 3.5 and 9.5 
hours after challenge were assigned to the LAR- responder group. The LAR+ group 
included patients with either a dual response or prolongedipersistent response after 
challenge. The period from 3.5 to 9.5 hours post-challenge was chosen, since other 
investigators found a late-phase nasal response in the same period. 
A1ediafor assays 
Lavage fluid was stored on ice and centrifuged for ten minutes at 400 x g. The supernatant 
was stored at -2D"C. Histamine was measured with an autornated fluorometric assay586. 
Tryptase and ECP were determined by radioinununoassay (RIA), according to the 
manufacturer's instructions (Pharmacia, UppsaJa, Sweden), albumin was determined by 
automatic kinetic nephelometry with use of the Array analyzer (Beckmann, Mijdrecht, the 
Netherlands) according to the manufacturer's instructions. 
4.4 Statistical analysis 
Patients were devided into the LAR- (n~13) or LAR+ group (n~ll) according to their 
symptom scores. Between-group differences of clinical response, mediators in lavage fluid 
and histamine responsiveness were tested with the non parametric Mann-Whitney U test. A 
two-tailed p-value < 0.05 was considered significant. The correlation of AUC of symptom 
scores during EAR (HDM 100, 1000, 10000 BVlml), LAR (3.5 - 9.5 hrs) and Ave of 
histamine dose-response were tested with the Spearman correlation test. 
4.5 Results 
The clinical response to HDM challenge is shown in figure 1. LAR+ responders showed an 
immediate and late nasal response, whHy LAR- responders showed an immediate response 
only. The symptom score of the LAR+ group was significantly higher at most time points 
during both the immediate and late phases as compared with the LAR- group (fig. la). The 
number of sneezes was significantly higher in the LAR+ group at HDM 1000 BU/1111 and 
at 3 time points during the late phase (fig Ib). LAR+ responders showed a significantly 
stronger secretory response at most time points during the late-phase response (fig. Ic). 
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Figul'e 1. 
Nasal clinical response of 
LAR+ and LAR~ patients 
measured for up to 9.5 
hours after HDM 
challenge. Abbreviations: 
b=beforc challenge, c= I 0 
min after PBS, hl~h3=10 
min after challenge with 
100, 1000 and 10000 
8U/ml HDM extract 
respectively. * = two-
sided p~valuesO.05. 
Values are presented as 
illean ± standard error of 
the mean (SEM). 
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Nasal response of LAR+ 
and LAR- patients 
measured for up to 9.5 
hours after HOM 
challenge. Abbreviations: 
b=before challenge, c=IO 
min after PBS, hl-h3=10 
min after challenge with 
100, 1000 and 10000 
BU/ml HDM extract 
respectively. * = two-
sided p-value:S;0.05. 
Values are presented as 
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In the analysis of nasal lavage fluid, albumin influx in the LAR+ group was significantly 
increased at HDM 10000 BV/ml and at most time points during the late phase as compared 
with the LAR- group (fig. 2a). ECP release during the late-phase response was significantly 
higher at 9.5 hour and tends to be higher at 4.5 (p~0.087) and 6.5 hour (p~0.099) in the 
LAR+ group (fig. 2b). Tryptase release was only observed immediately after HDM 
challenge. The high mean and standard error of the mean (SEM) at HDM 100 BUlml are 
largely due to one patient. LAR+ responders showed a significantly higher release at HDM 
10000 BUlml (fig. 2c). 
Allergen~induced nasal hyperreactivity was determined by nasal histamine challenge. 
Comparing the symptom scores, LAR+ responders showed an increased score at all 
histamine concentrations (fig. 3a). Although graphicaJIy the baseline symptom scores are 
different, statistically no significant difference was shown, When we expressed the response 
to histamine in percentage of the baseline, the LAR+ responders still did show significantly 
increased symptom scores to histamine at all doses. The numbers of sneezes of the LAR+ 
responders tended to be higher at 0.5 mg/ml (p~0.064) and 4 mg/ml histamine (p~0.09) 
(fig. 3b). The secretory response tended to be stronger at 0.25 mg/ml (p~0.079) and 1.0 
mg/mi (p=0.079) and was significantly stronger at the two highest histamine concentrations 
(fig. 3c). 
The symptom score and mediator release at HDM 10000 BUlml, during 3.5-9.5 hours and 
nasal hyperreactivity (AVC of histamine dose response) are shown in table 1. LAR+ 
responders showed a significantly stronger response to HDM 10000 BUlml (symptom 
score, tryptase release, albumin influx) and during the LAR (symptom score, albumin 
influx, ECP p=0.099). They also showed a significantly increased nasal hyperreactivity as 
compared with LAR- responders. 
The AVC of symptom scores during EAR and LAR and the AVC of the histamine dose-
response curves were significantly correlated (EAR-LAR: 1=0.49, p<O.Ol; EAR-histamine: 
FO.75, p<O.OOI; LAR-histamine: FO.66, p<O.OOI). 
Table 1. Profile of lar+ and lar- responders 
LAR+ 
symptom score (10000 BVlmL) 7.50 ± 0.69 
albumin (10000 BVlmL) 102.72 ± 42.50 
tryptase (10000 BUlmL) 3.38 ± 0.59 
AVC symptom score (3.5-9.5 hr) 18.00 ± 2.50 
AVC albumin (3.5-9.5 hr) 158.30 ± 68.80 
AVC ECP (3.5-9.5 hI') 248.40 ± 135.90 
Ave histamine dose response 27.27 ± 2.49 
LAR-
5.00 ± 0.026 
25.30 ± 7.89 
1.90 ± 0.64 
2.20 ± 0.82 
27.67 ± 5.06 
35.03 ± 10.87 
13.31 ± 2.71 
p-value 
0.026 
0.022 
0.046 
0.0001 
0.0056 
0.099 
0.0006 
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4.6 Discussion 
Figure 3. Histarnine responsiveness 
Nasal hypcrrcactivity in LAR+ and LAR-
patients. * = two-sided p-value.$:O.05. 
Values are presented as mean ± SEM . 
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Recent study of patients allergic to HDM revealed a relation between pre-existing 
hyperreactivity and LAR229. In view of this finding, we wanted to investigate the relation 
between EAR, LAR, inflammation and nasal hyperreactivity in patients allergic to HDM in 
more detail. Patients were challenged with high doses of HDM extract in order to obtain 
maximal nasal response. 
To define the late-phase reaction in the nose is difficult. Mygind461 could not detect late-
phase reactions by means of symptom scores. In other studies late-phase reactions were 
determined by measurement of nasal obstruction and analysis of nasal lavage fluid. 176,467 
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These studies concerned pollinosis patients. In the present study, patients were divided into 
LAR- or LAR+ responders according to their symptom scores during the late-phase period. 
The same approach has been used in other studies.229,501 
\Vhen comparing the clinical response in both groups, apat1 from the difference in the late 
phase, the immediate response was significantly higher in the LAR+ group. The AUC of 
symptom scores during the EAR and LAR were significantly correlated, which implies that 
a strong immediate response is necessary to induce a late-phase response. Small589 recently 
demonstrated in a pollen challenge study that the amounts of LTC4 and PGD2 during the 
EAR and LAR were correlated, also suggesting a relation between the two phases. 
However, nasal symptoms during the EAR and LAR were not correlated, 
Apart from the clinical response, we also analyzed nasal lavage fluid for albumin, tryptase 
and ECP to monitor the nasal response. Albumin, being the major protein in plasma, can 
be used as a marker of increased vasopenneability.45.60-l Albumin influx showed a pattern 
comparable with the symptom score: a dual response in the LAR+ group and an immediate 
response only in the LAR- group. 
In order to study the inflammatory response we measured tryptase and ECP in lavage fluid, 
Tryptase, a specific marker for mast cell activation560, has proved to be a useful marker of 
the immediate nasal reaction536. The LAR+ responders showed an increased tryptase release 
as compared with the LAR- responders, The late-phase response in the upper and lower 
airways is associated with influx of eosinophils.42,445 In the LAR+ group, ECP release, as a 
marker for activated eosinophiis, could be detected during the late-phase. ECP release from 
3.5-9.5 hours (AUC) tended to be higher in the LAR+ group than in the LAR- group. 
Allergen-induced nasal hyperreactivity was determined 24 hours after HOM challenge. 
\Vhen comparing LAR+ and LAR- responders, the fortner showed a significantly higher 
clinical response at all histamine concentrations. The AUC of symptom scores during EAR, 
LAR and AUC of histamine dose-response were significantly correlated. This association 
between nasal hyperreactivity and EAR Was not found in nasal pollen challenge 
studiesll .230,58S (tested outside the pollen season). The difference might be explained by 
patients allergic to HDM having more hyperreactive upper airways, due to the continuous 
natural allergen exposure. 
The early and late phases might be influenced by the use of oxymetazoline. Svensson605 
showed that oxymetazoline did not influence histamine-induced plasma exudation, but an 
effect on nasal patency appears probable. However, in spite of this bias wc found a clear-
cut relationship between EAR, LAR and nasal hyperreactivity. This systemic error, made in 
all patients, probably did not influence this association. 
In conclusion: In patients with perennial rhinitis due to HDM allergy, LAR+ and LAR-
responders show an different profile of symptom score, mediator involvement and nasal 
hyperreactivity. Just as in the lower airways, the EAR, LAR and hyperreactivity are 
significantly correlated, 
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5.1 Abstmet 
Backgrowui: In perennial allergic rhinitis, patients are exposed almost daily to 
aeroallergens. This ongoing allergic reaction results in increased sensitivity to allergens and 
non-specific stimuli. It is generally known that inflammatory cells and mediators arc 
involved in the pathogenesis of the allergic reaction. 
Objective: To study the relationship between nasal hypcrrcactivity and nasal inflammation 
during natural allergen exposure. 
Alethods: In 48 patients with perelUlial allergic rhinitis and in II volunteers a nasal brush, 
a nasal lavage and a histamine challenge were performed. Nasal inflanunation was 
estimated by the number of eosinophils, levels of albumin, tryptase, prostaglandin D2 
(PGD,), eosinophil cationic protein (ECP) and leukotriene C,ID4IE, (LTC,1D4IE,). 
Results: In contrast to PGD, and tryptase, eosinophils (1.9 vs 0%, p~0.0023), LTCiDiE, 
(17.51 vs 1.43 pg/ml, p<O.OOOI) and albumin (8.61 vs 2.37 mg/ml, p~0.0008) were 
significantly increased in rhinitis patients as compared with controls. Patients also showed 
increased responses to nasal histamine challenge assessed using a composite symptom score 
(21.5 vs 4 pts, p<O.OOOI). The nasal response to histamine was weakly correlated with the 
number of eosinophils in the cytospin (correlation coefficient 1=0.312, p=0.035). 
Conclusion: Nasal hyperreactivity is correlated with the percentage of eosinophils in 
patients with perennial rhinitis. The patients' mediator profile suggest that cosinophils are 
more important than mast cells in the ongoing allergic reaction and nasal hyperreactivity. 
Keywords: perelUlial allergic rhinitis; inflammation; nasal hyperreactivity 
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5.2 Introduction 
Allergic rhinitis is a conunon problem with a prevalence ranging from 2 to 20 per cent l68• 
The pathophysiology has mainly been studied in pollen allergy, and it has been 
demonstrated that inflammatory cells and their products are invoived. 42,188,3J.4,465,642 After 
exposure to the relevant allergen paticnts respond with sneezing, rhinorrhoea and nasal 
stuffiness. Nasal responsiveness to allergen increases after repetitive allergen exposure, 
described by COllllell as nasal priming. 120,261 However, patients become more sensitive not 
only to allergens hut also to non~specific irritants like perfumes and tobacco smoke.1O 
This non-specific nasal hyperreactivity is particularly impOllant in patients with perennial 
allergic rhinitis, who are continuously exposed to allergens. 
Both in the upper and in the lower airways, allergen challenge results in an inunediate 
symptomatic response, often followed by a recurrence of symptoms 4-8 hours later. II5,176,505 
In the lower airways, the late-phase response, inflammation and non-specific 
hyperreactivity me correiated91,162,44S, suggesting that inflammation is involved in the 
pathophysiology of non-specific hyperreactivity. These relationships could not be 
reproduced for the upper airways, as studied in seasonal rhinitis. 230,3I0,346 However, in recent 
nasal challenge studies concerning patients with perennial allergic rhinitis, we did find a 
relationship between nasal hyperreactivity, inflammation and the late-phase response.229,2S3 
In the non-challenged nose Knani el al. 3-19 demonstrated the evidence of higher levels of 
inflammatory mediators and cells in perennial allergic rhinitis as compared with controls. 
The aim of our study was to investigate if in the daily situation (Le. during natural allergen 
exposure) nasal hyperreactivity and inflammation are associated. To this purpose 
consecutive patients with perennial allergic rhinitis visiting our outpatient clinic routinely 
underwent a nasal lavage, a nasal brush and a nasal histamine challenge. Nasal 
inflammation was measured by nasal cytology and indirectly by mediators in nasal lavage 
fluid. 
5.3 Material and Methods 
Study design 
Each adult patient with perennial allergic rhinitis visiting our outpatient clinic for the first 
time participated in this study. At the control visit (about 3 weeks later) they underwent a 
nasal lavage, a nasal brush, and half an hour later a nasal histamine challenge. Eleven non-
atopic nOll-rhinitis volunteers underwent the same procedure. In the control group the 
procedure was performed twice with a one-week interval. 
Subjects . 
Forty-eight patients (23 male, 25 female, aged 30 ± 10 years) with a history of perennial 
rhinitis participated in this study. They had to fulfil the following criteria: perennial rhinitis 
for at least one year; positive intradermal skin test for at least one perennial aeroallergen 
(house dust mites and/or moulds andlor domestic animal danders, ALK Benelux, 
Groningen, the Netherlands) and exposure to the allergen(s) involved. Of the included 
patients, 38 were allergic to house dust mites, 7 were allergic to house dust mites and pets 
(and had a pet at home), 2 were allergic to their pets only, 1 patient was allergic to 
moulds. Patients with a concomitant pollen allergy were included only outside the pollen 
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season. During the study they were not permitted to use any medication affecting nasal 
symptoms, with the exception of Acrivastine 8 mg (as escape medication). Acrivastine had 
to be withdrawn 3 days before the histamine challenge. Patients with a nasal infection were 
excluded. Eleven non~atopic, non~rhinitic volunteers (2 male, 9 female) participated in the 
control group. 
Nasal lavage 
Five tnl isotonic saline solution (0.9%) preheated to 3TC was instilled into each nostril 
with a pipette while the subject gently flexed his/her head backwards. After 10 seconds, the 
lavage fluid was expelled and collected in plastic tubes. 
lvfedialor assays 
Lavage fluid was stored on ice and centrifuged for 10 minutes at 400 x g. The supernatant 
was stored at _20°C. Tryptase and eosinophil cationic protein were determined by 
radioimmunoassay (RIA), according to the manufacturer's instructions (Phannacia, 
Uppsala, Sweden) with sensitivities of 0.5 U/ml and 2 fig/I respectively. Albumin was 
determined by automatic kinetic nephelometry with usc of the Array analyzer (Beckmann, 
Mijdrecht, the Netherlands) according to the manu£.1cturer's instl11ctions (sensitivity 2 
mg/I). L TC/D/E4 and PGD2 levels were measured by BiotrakR and radioimmunoassay 
(RIA) respectively (Amershatn, UK). The limits of sensitivity of the assays were 
approximately 3.1 and 0.75 pg/IOO fli respectively. Cross-reactivity of L TC,tD,IE, assay: 
LTC, (100%), LTD, (100%), LTE, (70%), LTB, (0.4%) and PGD, «0.006%). 
Nasal brush and staining procedure 
In each patient a nasal brush was taken from the lower edge of the inferior turbinate, with 
a cytobrush (CytobrushR Plus, Medscand AB, Sweden); it was stored in phosphate buffered 
saline (PBS) at T C until cytospins (Hettich centrifuge) were made on microscope slides. 
Cytospins were dried, fixed in acetone for 10 min, and rinsed successively in PBS (PH 7.2) 
and in PBS~bovine seHUll albumin 1-2%. The cytospins were incubated for 10 min with 
normal rabbit serum (1: 10) (CLB, Amsterdam, the Netherlands), subsequently incubated for 
60 min with monoelonal antibody RMK13 (Sanbio, Uden, the Netherlands), rinsed twice in 
PBS, incubated for 30 min in Link biotinylated anti~mousc immunoglobulin (l :50) 
(StrAviGen Super Sensitive BioGenex Alkaline Phosphatase concentrated, catIll' 
AZOOOUM), rinsed twice with PBS again, incubated for 30 min in Label streptAP (I :50) 
(StrAviGen Super Sensitive BioGenex Alkaline Phosphatase concentrated, catnr 
AZOOOUM), rinsed successively in PBS and Tris(hydroxymethyl)-aminomethane (TRIS) 
buffer (PH 8.0) respectively and incubated for 30 min with New Fuchsin solution (Chroma, 
Stuttgart, Germany). Finally the cytospins were rinsed with distilled water, counterstained 
with Mayer's haematoxylin, and mounted in glycerin gelatin. 
The number of eosinophils was determined by counting the BMK13 positive cells, 
expressed as a percentage of the number of epithelial cells. 
Nasal histamine challenge 
Challenges were performed according to the methods described by Gerth van \Vijk et 
al. 215 ,228 Patients waited for half an hour prior to the test in order to give the nasal mucosa 
time to acclimatise. Nasal challenge with histamine phosphate (0.25, 0.5, 1.0, 2.0 and 4.0 
mg/ml) was performed at five~minute intervals after challenge with PBS. After each 
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challenge the syrnptom score373 was recorded, sneezes were counted and nasal secretion 
was col1ected in a syringe-equipped fUllllel6s• The areas under the curve (AUCsymp(l)m 5core' 
AUCsneezcs and AUCseeretion) of histamine dose response curves were used in the statistical 
analysis. 
Symptom score 
A composite symptom score according to Lebel et al. m was used: 3M4 sneezes=l pt, ~5 
sneezes=3 pts; anterior rhinorrhoea= 1 pt; posterior rhinorrhoea= 1 pt; difficult nasal 
breathing~ 1 pt, one nostril blocked~2 pts, both nostrils blockcd~3 pts; pruritus of the 
nose=l pt; pruritus of the palate or ear=l pt and conjunctivitis=l pt. Total score ranges 
from 0 till II pts. 
Statistics 
For statistical analysis use was made of the SPSSIPC+ Statistical Package. BctweenMgroup 
differences were tested by the nonparametric Mann-Whitney U test. A twoMtailed p value 
<0.05 was considered significant. 
Correlations were tested with the Spearman correlation test. 
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Figure 1. Nasal response to histamine 
Nasal response to increasing doses of histamine phosphate in 48 patients and II healthy sllbjects. Nasal 
histamine challenge in the control subjects (control I) was repeated one week later (control 2). For each 
histamine dose the data of the three groups were compared. Data are presented as medians. Abbreviations: 
b=baseline, pbs=phosphate buffered saline, *' = p<O.OOl. 
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5.4 Results 
Figure 1 shows the nasal response to histamine assessed with the symptom score, Rhinitis 
patients showed a significantly higher response to all histamine doses than the control 
group. An increased response was also found when nasal hyperreactivity was expressed as 
the AUCs)'mptom mlfe (21.5 vs 4 pts, p<O.OOOl). In the control group, nasal responses to the 
first and second histamine challenges were equal (4 and 3.5 pts respectively). 
For the number of sneezes and the amount of secretion no significant differences were 
found apart from a higher secretory response after challenge with the highest histamine 
dose (data not shown). The AUCswetion was significantly increased in the patient group (0.1 
vs 0 ml, p=O.0319), while the AUCs~eezes was the same in both groups (both 6 sneezes), 
In figure 2 luedian levels of mediators in nasal lavage fluid are demonstrated, Albumin, 
ECP, LTC/D/E, were significantly increased in the patient group (8.61 vs 2.37 mg/ml, 
~0.0008; 1.34 vs 0.74 ng/ml, p~0.043; 17.51 vs 1.43 pg/ml, p<O.OOOI respectively) when 
compared with the first control lavages, However, ECP levels in the second control lavages 
were significantly higher than in the first lavages (1.45 vs 0.66 ng/ml, p~O.O 173) and equal 
to the patient levels. Tryptase levels did not significantly differ between the patient (2.11 
UII) and control group (2.17 UII). POD, levels wcre higher in the control group (27.77 vs 
16.60 pg/ml, p~0.0084). 
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Levels of albumin, ECP, tryptase, L TC/D/E4 and PGD1 in nasal lavage fluid obtained from 48 patients and 
II healthy volunteers, Nasal lavages in the control group were repeated after one week (control I and control 
2). The mediator levels of the three groups were compared. Data are presented as medians, * = p<O.OS. 
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In the cytospins significantly (p~0.0023) more eosinophils could be detected in the patients 
than in the healthy volunteers (medians 1.9% and 0% respectively). 
In the patient group, comparing nasal hyperreactivity with inflammatory mediators, no 
correlations were found. Nasal hyperreactivity (AUCS}lflPt<>m score) correlated with the 
percentage of eosinophils in the cytospin (1~0.312, p~0.035) (fig. 3). When nasal 
hyperreactivity was expressed as AUCsneezes or AUCsenetion no correlations were found. The 
percentage of eosinophils was not correlated with mediator levels. 
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5.5 Discussion 
Nasal hyperreactivity, as determined by nasal histamine challenge, was significantly 
increased in the patient group. From nasal challenge studies it is known that repetitive 
allergen challenges result in increased sensitivity to non~specific stimuli 10. Since patients 
with perennial allergic rhinitis are continuously exposed to perennial aeroallergens this 
increased hyperreactivity is in accordance with our expectations. In previous studies the 
amount of secretion and the number of sneezes proved to be useful tools to measure nasal 
response to histamineys.228 Recently, in some other studies, in addition to these response 
variables, nasal responsiveness to histamine was monitored by the symptom score of 
Lebe1373 • This symptom score turned out to be even morc sensitive than the secretory and 
sneezing responses in detecting treatment effects and in discriminating patients with and 
without a late-phase response by their nasal hyperreactivity in nasal challenge 
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studies. 251 ,253.25-4 Comparing patients with a small control group the composite symptom 
score proved to be a more sensitive tool than the number of sneezes and the amount of 
secretion to measure differences in nasal response to histamine. This is probably due to the 
inclusion of a variety of symptoms such as itchiness and nasal blockage into the symptom 
score. To evaluate the reproducibility of this symptom score, II volunteers ,,,ere challenged 
twice with histamine. The symptom scores of both histamine challenges were highly 
reproducible, even better than the reproducibility of the number of sneezes and the amount 
of secretion. Accordingly, the symptom score of Lebel373 is a useful tool to discriminate 
patients and controls, treatment effects, and patient subgroups, 
Nasal lavages and nasal brushes were performed to evaluate the presence of nasal 
inflammation. In nasal cytospins of patients with perennial allergic rhinitis significantly 
more eosinophils could be detected than in the control group. This might suggest that 
during natural peremlial allergen exposure, the late-phase response plays an important role. 
In nasal HDM challenge studies, a relationship between nasal hyperreactivity, the late-
phase response and inflammation has been found. 22<),253 The present study was performed 
during natural allergen exposure, in non-challenged subjects. A moderate but significant 
correlation was found between nasal response to histamine, expressed as AUCs)'mplom ~C()re and 
the percentage of eosinophils, suggesting that inflammation is involved in the pathogenesis 
of nasal hyperreactivity, The relatively low correlation and the absence of association 
between inflammatory mediators and nasal hyperreactivity are not surprising. Probably, 
non-specific hyperreactivity cannot be explained by activation of one cell or release of one 
specific mediator. 
In lavage fluid several mediators were measured to gain an impression of the mediators 
involved in the ongoing allergic reaction, furthermore, to study the reproducibility of the 
assays, nasal lavages in the control group were performed twice with a one-week interval. 
With the exception of ECP, levels of albnmin, tryptase, LTC,ID,IE, and POD, proved to be 
reproducible, 
Albumin levels were higher in patients, demonstrating increased vasopermeabilily45,60~, 
confirming the presence of nasal inflammation. Tryptase, as a specific marker of activated 
mast cells560, was the same in both groups, Since mast cells are involved in the immediate 
allergic response this might suggest that in the ongoing allergic reaction the late phase is 
more important than the immediate phase. PGD2 is an inflammatory mediator released 
during the immediate allergic response by mast celis,52,619 In the patient group we measured 
lower PGD2 levels than in the control group, In the lungs and liver it has been 
demonstrated that PGD2 is metabolized by a keto-reductase to the vasoactive metabolite 
9o:,11{3-PGF2•571 Possibly, in the nasal mucosa of allergic rhinitis patients an increased 
number of leukocytes, containing keto·reductase, are present, resulting in an increased 
PGD2 metabolism, which may explain the low PGD2 levels in lavage fluid, However, we 
have no explanation for the differences with the results of Knani et alH9 , who measured 
higher levels of PGD2 in nasal lavage fluid of allergic patients than in controls. In lavage 
fluid we also measured LTCiDiE4, arachidonate 5-lipoxygenase metabolites, 
predominantly produced by eosinophils, mast cells and basophilsJ85. In the patients' lavages 
significantly higher levels of LTC,/D,IE, were demonstrated. This LTC4ID,IE, may be 
released by the increased number of eosinophils present in the nasal mucosa. Since in 
rhinitis patients the number of cosinophils was increased, ECP, derived from activated 
eosinophils395, would be expected to be increased also. Initially, comparing patient lavages 
with the first control lavages, slightly but significant higher ECP levels were found for the 
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patient group. However, ECP levels of the second control lavages were as high as in the 
patient group. Measurement of ECP appears to be more variable than determination of the 
other mediators. 
Conclusion: During natural perennial allergen exposure, eosinophils are involved in the 
ongoing allergic inflammation. The number of eosinophils correlated with the nasal 
response to histamine, suggesting that inflammation is involved in the pathogenesis of non~ 
specific hyperreactivity. In addition, nasal responsiveness to histamine assessed with the 
symptom score of Lebel373 proved to be a valid tool in discriminating rhinitic patients and 
healthy controls. 
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Chapter 6 
Glucocorticosteroid intervention 
Glucocorticosteroids, such as cortisone and hydrocortisone (C0l1isol) arc hormones 
synthesized in the adrenal cortex, Synthetic compounds are also available, such as 
prednisolone, beclomethasone dipropionate and dexamethasone. 
The receptor for steroids is an intracellular protein which exists as a soluble constituent of 
the cytosol or nucleus, and is also able to bind with high affinity to nuclear chromatin. The 
basic structure is large monomeric proteins of 400 - 1000 residues, containing a highly 
conserved region of about 60 residues in the middle of the molecule, which is believed to 
constitute the DNA-binding domain of the receptor. It contains two loops of about J 5 
residues each (zinc fingers), and the loops are believed to wrap arollnd the DNA helix. The 
honnone~binding domain lies downstream of this central region. The steroid molecule 
crosses the cell membrane readily, being highly lipid soluble, and binds to the receptor 
which is believed to unfold, thus exposing the normally buried DNA binding domain. 
\Vhen this happens translocation of the receptor from the cytosol to the nucleus may occur. 
The receptor binds to certain well-defined regions of the nuclear DNA. An increase in 
RNA polymerase activity and the production of specific mRNA occurs within a few 
minutes of adding thc steroid, though the physiological response may take hours to 
develop. The different steroid hormones arc able to activate different genes, and thus 
initiate completely different patterns of protein synthesis, and produce different 
physiological effects. 167,447 Glucocorticoids enhance the production of Iipocortin, which may 
account for their anti-inflammatory propeliies by inhibition of the activity and synthesis of 
PLA2 184 and by mechanisms independent of PLA2 activity, 185,248 Whereas, 
mineralocorticoids stimulate the production of various transport proteins that are involved 
in renal tubular function. 167,447 
The anti-inflammatory effects are expressed by two mechanisms: decreased production of 
inflammatory mediators and cells and generation of anti-inflammatory mediators. The 
inflammatory mediators suppressed include histamine from basophils, complemcnt 
components, and cytokines such as IL-t, IL-2, IL-4, IL-6, IL-8 and TNF -a by direct 
inhibition of transcription or interference with intracellular transduction events. 172,424 The 
inhibition of PLA2 activity/synthesis by lipocortin causes a decrease in the production of 
PAF and mediators of arachidonic acid.S19 In addition, glucocorticoids have recently been 
shown to selectively inhibit the expression of COX2• m,m It is known that 
glucocorticosteroids inhibit T-cell proliferation and cytokine production in vitro. os They 
decrease the number of Langerhans cells (in the skin).21 Corticosteroids decrease the 
number of cells expressing IL-4 and IL~5 mRNA in asthmas42 and decrease the number and 
activation of mast cells and eosinophils in bronchial biopsies and lavages of asthmatics. IS7 
Corticosteroids relieve symptoms of asthmatics, however, some patients respond poorly to 
these dl11gs or need such high doses that unwanted sidc~effects become severe while 
symptoms do not fmiher decrease, which is called corticosteroid~resistance,69o 
Rhinitis: Treatment with topical corticosteroids have been associated with a decrease in the 
number of nasal eosinophils, basophils, Langerhans cells and neutrophils of allergic rhinitis 
patients. 293,.11)2,4)J It has been suggested that corticosteroids may act by preventing activation 
of several cells mld subsequent release of inflammatory mediators. 43S The effect of systemic 
steroids, such as prednisolone, reduce symptoms and mediator release in the late phase 
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reaction to allergen, They have little or no effect on the immediate reaction,463,516 In 
contrast, anti-inflammatory therapy with topical corticosteroids have been shown to be 
effective on both the early and late phase reaction after allergen challenge, on nasal 
priming and on nasal hyperreactivity in rhinitis,38,460,515 It is not known whether 
corticosteroid-resistance exists in rhinitis. 
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Effect of intranasal fluticasone propionate on the immediate and late 
allergic nasal reaction and nasal hyperreactivity in patients with a house 
dust mite allergy 
C. de Graaf-in 't Veld l , I.M. Garrelds1•2, A.P,H. Jansen!, A.\V. van Toorenenbergen3, 
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University Rotterdam, 3Laboratory of Allergology (Department of Clinical Chemistry), University Hospital 
Rotterdam-Dijkzigt,4Department of Biostatistics, Erasmus University Rotterdam, SDepartment of ENT, St. 
Franciscus Gasthuis, Rotterdam. 
Based on: Clinical Experimental Allergy, In press 
7.1 Abstract 
Background: Patients with perennial allergic rhinitis develop nasal symptoms not only after 
allergen exposure, but generally also after non-specific stimuli. 
Objective: To cvaluate the effect of two week's treatment with fluticasone propionate 
aqueous nasal spray (FPANS) on the nasal clinical response, inflammatory mediators and 
nasal hyperreactivity. 
Methods: Twenty-four rhinitis patients allergic to house dust mite (HDM), participated in a 
double-blind, placebo-controlled crossover study. After a two week's treatment with 
placebo or 200 J.lg FPANS twice daily, patients were challenged with HDM extract. 
Symptoms were recorded and nasal lavages werc collected for up to 9.5 hoUl's after 
challenge, Nasal hyperreactivity was determined by histamine challenge 24 hours later. 
Results: Because of a carry-over effect for the immediate symptom score, for this variable 
only the data from the first treatment period were used. FPANS treatment resulted in a 
significant decrease of nasal symptoms with 70%, 69% and 63% after 100, 1000 and 
10000 Biological Units (BU)/ml of HDM extract respectively. Active treatment resulted in 
a 76% decrease of the late-phase symptoms. FPANS treatment significantly reduced 
albumin influx after HDM 1000 BV!ml with 62% and tended to reduce tryptase release 
after HDM 1000 BU/ml (p~0.0629). During the late phase FPANS treatment reduced 
albumin influx with 67% and eosinophil cationic protein (ECP) release with 83%. No 
effect of FPANS was seen on histamine levels, FPANS significantly decreased histamine-
induced symptom score with 34%, secretion with 32% and sneezes with 41%. 
Conclusion: FP ANS significantly inhibits the inunediate and late allergic response, and 
nasal hyperreactivity, probably by suppressing mast cells and cosinophils in the nasal 
mucosa, 
Keywords: fluticasone propionate; perennial allergic rhinitis; house dust mite; nasal lavage; 
inflammatory mediators; early allergic response; late allergic response; nasal hyperreactivity 
57 
Chapter 7 
7.2 Introduction 
Allergic rhinitis is a common problem (prevalence ranging from 2 to 20 percent I68), 
characterized by symptoms as sneezing, itching, rhinorrhoea and nasal congestion. The 
pathophysiology is associated with the presence of inflammatory cells such as eosinophils, 
mast cells, T ~cells and Langerhans cells!88,)34,642 in the nasal mucosa. After fe-exposure to 
allergen, mast cells are activated by crosslinking of allergen to mast cell~botlnd specific 
19B. The activated mast cells release vasoactive mediators stich as histamine and 
leukotrienes related to the early nasal symptoms, and chemotactic mediators that attract 
inflammatory cells such as eosinophils associated with the late-phase response. 42 
Connell 120 described in the sixties a phenomenon known as nasal priming: repetitive 
exposure to allergen causes an increased sensitivity to allergens. This effect was confirmed 
by others.28,261 Exposure to allergen also increases nasal responsiveness to non-specific 
stimuli.1O However, the pathophysiology of nasal hyperreactivity and nasal priming is still 
unclear. 
In the lower airways, the late-phase reaction was found to be associated with inflammation 
and bronchial hyperreactivity92,1l5.445, suggesting that inflammation is involved in the 
pathogenesis of hyperreactivity. These associations could not be confirmed in nasal 
chaHenge studies performed in patients with a pollen allergy230,3Io,346, which makes the 
pathogenetic role of inflammation in nasal hyperreactivity less plausible. However, in a 
study with rhinitis patients allergic to HDM, Gerth van Wijk et af29 has shO\vn an 
association between nasal responsiveness to allergen and pre-existent nasal hyperreactivity, 
a finding more in agreement with data from the lower airways. 
Anti-inflammatory therapy with intranasal corticosteroids have extensively been shown to 
be effective in the treatment of seasonal and perelUlial rhinitis.460 It has been shown that 
topical corticosteroids have an effect on both the eady and late~phase reaction after 
allergen challenge, on nasal priming and on nasal hyperreactivity in patients allergic to 
pollen.38.516 In the present study we want to evaluate the anti-inflammatory effects of 
topical corticosteroid therapy on nasal response to HDM challenge, and on allergen-induced 
nasal hyperreactivity. In an attempt to provide further differentiation between the local anti-
inflammatory effects and the unwanted systernic effects of corticosteroids, a new, topically 
active, fluorinated glucocorticosteroid: fluticasone propionate has been developed. It has 
shown to have twice the potency of beclomethasone dipropionate and to have minimal 
systemic effects85,51O, because of extensive firsl~pass metabolism by the liver. 
In 24 rhinitis patients allergic to HDM the effect of two week's treatment with fluticasone 
propionate on nasal response to HDM challenge and nasal hyperreactivity was studied. 
Nasal response to allergen was monitored by symptoms and mediators in nasal lavage fluid 
(histamine, albumin as marker for vasopenneability, tryptase as mast cell marker and ECP 
as marker for activated eosinophils) for up to 9.5 hrs. 
7.3 Matedals and Methods 
Subjects 
Twenty-four rhinitis patients, 11 women and 13 men aged 21 to 50 years (mean 34 yrs) 
participated in this study. They had to fulfil the following criteria: a history of perennial 
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rhinitis; intradermal skin reaction of at least I plus~sign to 3 BU/ml HDM extract, (ALK 
Benelux, Groningen, the Netherlands), according to the standardised plus~sign scoring 
system defined by NOflllan477 ; age between 15 and 65 years. The only patient with a 
concomitant pollen allergy was tested outside the pollen season. Patients with concomitant 
allergy to pets were only included when they had no contact with pets. 
To prevent interference with FPANS, symptomatic medication for rhinitis had to be 
withdrawn. Oral corticosteroids had to he withdrawn 2 months, astemizole 6 weeks, nasal 
or inhaled corticosteroids, cromoglycate and nedocromil 3 weeks and antihistamines 3 days 
before entering the study. Patients with nasal polyposis, nasal surgery less than 3 months 
before the study, nasal infection during 2 weeks before the study or immunotherapy in the 
past were excluded. 
Study design 
In 24 patients with perennial rhinitis a double~blind placebo~controlled crossover study was 
performed. Patients were treated with placebo or 200 fIg FrANS twice daily (Le. twice 
the recommended dosage) for two weeks. At visit I patients received a Basal spray 
containing 50 ~tg fluticasone propionate/actuation 01' placebo. After the first treatment 
period, followed by a wash~out period of 3 weeks, they received the com.plementary nasal 
spray (visit 4). After either treatment period patients were challenged with HDM extract. 
Symptom scores were recorded and nasal lavages were performed for up to 9.5 hours after 
HDM challenge (visit 2 and 5). Allergenainduced nasal hyperreactivity was determined by 
nasal histamine provocation 24 hours after HDM challenge (visit 3 and 6). 
During the study patients were not allowed any medication affecting nasal function other 
than terfenadine 60 mg, which was provided as escape-medication. Terfcnadine had to be 
withdrawn 3 days before the nasal challenges were performed. 
The study was performed during the period January-August, to minimise natural exposure 
to HDM. The study was approved by the Medical Ethical Committee of the University 
Hospital Rotterdam~Dijkzigt and all patients gave written informed consent. 
Nasal challenge with HDM and histamine 
Challenges were performed in accordance with the methods described by Gerth van Wijk et 
al. 229,230 On each occasion the patients waited for half an hour before the test to give the 
nasal mucosa time to acclimatise. 
Nasal challenges with HDM extract (100 BU/ml, 1000 BU/ml, 10000 BU/ml, ALK 
Benelux, Groningen, the Netherlands) were performed at ten~minute intervals after 
challenge with phosphate-buffered saline (PBS), containing human serum albumin 0.03% 
and benzalkonium chloride 0.05% (ALK Benelux, Groningen, the Netherlands). The HDM 
extract was sprayed into each nostril by means of a nasal pump spray delivering a fixed 
dose of 0.125 tnl solution. Nasal response was monitored 10 minutes after each challenge, 
and hourly from 0.5 till 9.5 hours after the last challenge. Nasal responsiveness was 
monitored by the number of sneezes, the am.ount of secretion collected according to 
Bonun6S and a symptolll score according to LcbeI37J• 
Nasal challenge with histamine phosphate (0.25, 0.50, 1.0, 2.0 and 4 mg/Illl) was 
performed at five-minute intervals after challenge with PBS. The alllount of secretion, the 
number of sneezes and the symptom score according to Lebelm were used as nasal-
response indicators. 
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Nasal lavage 
Nasal lavages were performed as described by Naclerio.465 This protocol comprises 4 pre~ 
challenge washings with isotonic saline solution to clear the nose from secretions and to 
obtain baseline levels of mediators. In order to prevent nasal congestion due to allergen 
challenge, oxymetazoline 0.1% (two 0.125 ml puffs) was applied in both nostrils. After 5 
minutes the oxymetazoline was washed out just prior to the nasal challenge with PBS. A 
nasal lavage was performed 10 minutes after PBS and after each allergen challenge, 
inullediately before the subsequent challenge. Subsequently, lavage fluid was obtained 
hourly from 0.5 to 9.5 hours after the last allergen challenge. Nasal lavages were 
performed with 10 ml isotonic saline solution (0.9%) preheated to 37'C. In each nostril 5 
ml saline was instilled with a pipette while the subject gently flexed his/her head 
backwards. After 10 seconds, the lavage fluid was expelled and collected in plastic tubes. 
This procedure has shown to produce a recovery of 7.7 ± 1.21111.229 
Symptom score 
Symptoms were recorded by using a scoring system according to Lebel ef al.)7) at the time 
points of lavage. Symptom scores were graded in points (pts): 3~4 sneezes=l pt, ;:::5 
sneezes=3 pts, anterior rhinorrhoea= 1 pt, posterior rhinorrhoea= 1 pt, difficult nasal 
breathing~ I pt, one nostril blocked~2 pts, both nostrils blocked~3 pts, pruritus of the 
nose= 1 pt, pruritus of palate or eaF I pt and conjunctivitis= 1 pt (total score ranges from 0 
till II pts). In addition, the number of sneezes and the amount of secretion were noted. 
A1ediator assays 
Lavage fluid was stored on ice and centrifuged for 10 minutes at 400 x g. The supernatant 
was stored at ~20·C. Histamine was measured with an automated fluorometric assaySS6 with 
a sensitivity of 0.1 ng/ml. Tryptase and ECP were determined by radioimmunoassay (RIA), 
according to the manufacturer's instructions (Pharmacia, UppsaJa, Sweden), with a 
sensitivity of 0.5 U/I and 2 flg/l respectively. Albumin was determined by automatic kinetic 
nephelometry with use of the Array analyzer (Beckmarl11, Mijdrechl, the Netherlands) 
according to the manufacturer's instructions (sensitivity 2 mgll). 
7.4 Statistical allalysis 
The effecl of FPANS trealment on the immediate (HDM 100, HDM 1000 and HDM 10000 
BU/ml) and lale (area under the curve (AUC) between 3.5 and 9.5 hI'S) nasal reaction and 
on nasal hyperreactivity (AUe of histamine dose response curve) was evaluated. 
Thirteen patients received FPANS during the first treatment period and II during the 
second treatment period. For testing the carry~over effect, within patient totals over the two 
treatment periods were used. \Ve considered there was no significant carry~over effect if 
the means of these within patients totals did not significantly differ between the two 
treatment~order groups. For this test a p~value < 0.1 was considered significant. In case of 
a carry-over effect, only the data of the first treatment period were used for statistical 
analysis. 
For testing the effect of FPANS, within patient differences over the two treatment periods 
were used, provided that there was no carry~over effect. There was an effect of FP ANS if 
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Figure 1. Nasal response of placebo and FPANS treated groups measured for up to 9,5 hours after HDM 
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the means of these within patients differences did differ significantly between the two 
treatmentMorder groups. The nonparametric MannM Whitney U test was used. A twoMtailed PM 
value < 0.05 was considered significant. 
7.5 Results 
Figure 1 shows the results of FPANS treatment on nasal HDM challenge. Because a carry-
over effect was found for the symptom score during the immediate reaction, for this 
variable only the data of the first treatment period were used for statistical analysis. 
FPANS treatment significantly reduced the immediate symptom score with 70% 
(p~0.0104), 69% (p~0.0045) and 63% (p~0.0013) after 100, 1000 and 10000 BU/ml of 
HDM extract respectively and the late-phase symptom score with 76% (AUe from 3.5 till 
9.5 hours, p=0.0003). The amount of secretion was significantly diminished during the 
immediate (HDM 100 BU/ml: 32% decrease, p~0.0105; HDM 1000 BU/ml: 49% decrease, 
p~0.0038; HDM 10000 BU/ml: 17% decrease, p~0.0297) and late response (AUe 3.5-9.5: 
93% decrease, p=0.0464) (data not shown). For the number of sneezes only an effect was 
observed during the early response (HDM 100 BU/ml: 57% decrease, p~0.0477; HDM 
1000 BU/ml: 77% decrease, p~0.0115; HDM 10000 BU/ml: 53% decrease, p~0.0019) 
(data not shown). Analysis of nasal lavage fluid showed a significant reduction of 62% in 
the amount of albumin during the early (HDM 10000 BUlml, p~O.OOII) and of 67% 
during the late phase (AUe 3.5-9.5 hrs, p~0.0019) afier c0l1icosteroid treatment. Tryptase 
release was only observed immediate after HDM challenge; treatment with FPANS tended 
to decrease this release (HDM 1000 BU/ml, p~0.0629). The high mean and standard error 
of the mean (SEM) at HDM 100 BU/ml are mainly caused by one patient. Eel' release in 
the period 3.5-9.5 hours was almost completely inhibited (83% decrease, p~0.0024) by 
FPANS. 
Nasal HDM challenge did not increase histamine levels in nasal lavage fluid. No effect of 
corticosteroid therapy was seen (fig. 2). 
Allergen-induced nasal hyperreactivity was determined as Ave of histamine dose response 
curves. FPANS significantly decreased the symptom score with 34% (p~0.0162), the 
number of sneezes with 41% (p~0.0096) and the amount of secretion with 32% (p~0.0104) 
(fig. 3). 
7.6 Discussion 
Earlier studies mainly focused on seasonal allergic rhinitis. \Ve studied the effect of a 
topical corticosteroid on the immediate and late sequelae after HDM challenge and on nasal 
hyperrcactivity in 24 rhinitis patients allergic to HDM. Patients were challenged with high 
doses of HDM extract in order to obtain maximal nasal response. Since we wanted to 
evaluate the antiMinflammatory effects of FPANS, we were particularly interested in the 
effects 011 the lateMphase response and inflammatory mediators. 
Nasal symptom scores reached their maximum 10 minutes after challenge with HDM 
10000 BVlml and returned to baseline levels at 3.5 hours. Partial recurrence of symptoms 
was shown during 3.5 and 9.5 hours, the period of the late~phase response. 50S 
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Figure 2. 
Histamine in lavage fluid of placebo and 
FPANS treated groups in response to 
HDM challenge. Values are presented as 
mean ± SEM. 
However, in the 110se it is difficult to define the late-phase reaction. Mygind461 could not 
detect a late-phase response, clearly separated from the early response, by means of 
symptom scores and measurement of nasal airway resistance. In other studies late-phase 
reactions were determined by measurement of nasal obstntction and analysis of nasal 
lavage fluid. '76,467 These studies concerned pollinosis patients. 
Albumin, being the quantitative dominant protein in plasma, can be used as a marker of 
increased vasopenneability.45,60-l Assessment of albumin in lavage fluid demonstrated an 
increased influx during the immediate and the late-phase response. 
To monitor the immediate response we assessed histamine and tryptase in lavage fluid. 
Although it is generally accepted that immediate reactions to allergen challenge are mast 
cell-dependent, histamine being the principal mediator, no increased release of histamine 
was found. This corresponds with a recent study by Gerth van \Vijk el at. 229 also in patients 
allergic to HDM. Linder el al. 394 observed a decrease of histamine in nasal secretions 
during the pollen season and after pollen challenge. In contrast, Naclerio and co-workers467 
measured increased histamine release after nasal challenge with ragweed pollen. Davies144 
found an increase in histamine in response to nasal grass pollen challenge, however this 
release was not dose-dependent. Since the histamine levels we measured were above the 
detection limit of 0.1 nglml, our failure to detect an increased histamine release after 
allergen challenge is not due to insensitivity of our assay (automated fluorometric). Our 
failure to detect increased histamine levels may be attributed to our study design, because 
nasal secretion and nasal lavage fluid were collected separately, whereas others mixed 
secretion and lavage fluid. In addition, high levels of histamine have been detected in 
prechallenge lavages without association with the presence of symptoms. 56 Measurement of 
histamine in nasal lavage fluid as marker of the nasal allergic response seems, due to these 
inconsistent observations, not ideal. In contrast, tryptase, a specific marker for mast cell 
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activationS6O, could be detected in measurable amounts during the immediate response. This 
finding is in agreement with the hypothesis that the immediate but not the late-phase 
response to allergen challenge is Illast cell-dependent. A possible explanation for the 
discrepancy in tryptase and histamine release, might be that histamine is metabolized or 
removed more rapidly than tryptase, which has been demonstrated in the circulation567• In 
the present study as well as in a study performed by Rasp et al.536 tryptase seems to be a 
useful marker of the immediate nasal reaction. 
During the late-phase response activated eosinophils are involved42• As an indirect method 
to study the involvement of eosinophils, we measured ECP in lavage fluid. ECP, released 
from activated eosinophils was only detected during the late-phase response, suggesting 
that ECP can be used as a marker to detect the late-phase response. 
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Treatment with FPANS showed a partial but significant decrease of immediate symptoms 
and an almost complete inhibition of late symptoms after allergen challenge. The same was 
true for alburnin influx in nasal lavage fluid. FPANS also reduced nasal inflammation as 
measured by ECP and tryptase. ECP release during the late phase was completely inhibited 
by topical fluticasone. This inhibition of ECP release was also shown by Lozewick402 in 44 
patients allergic to pollen. FPANS tended to decrease tryptase release. The tryptase values 
were widely dispersed. Probably with a larger number of patients the effect on tryptase 
would have reached significance. Juliusson333 demonstrated a significant effect of FPANS 
on tryptase release after pollen challenge in 25 hay fever patients. 
Inhibition of the symptoms during immediate and late~phase response by FPANS is 
assumed to be due to a reduction of the number of mast cells and eosinophils, with as 
consequence decreased levels of mediators. 
In patients with perennial allergic rhinitis, it has been demonstrated that nasal 
hyperreactivity is associated with inflammation.:m In this study two weeks' administration 
of FPANS significantly inhibited nasal response to histamine. This confirms the hypothesis 
that inflammation is involved in nonspecific nasal hyperreactivity. 
Concluding: In patients with perennial allergic rhinitis, an immediate and a late allergic 
response was shown by nasal symptoms as well as by inflammatory mediators in lavage 
fluid. Two~week treatment with FPANS inhibits the immediate and in particular the late 
allergic response as well as allergen~induced nasal hyperreactivity. This may occur as a 
consequence of a reduction of mast cells and eosinophils in the nasal mucosa as indirectly 
measured by tryptase and ECP in lavage fluid. 
7.7 Acknowledgements 
This study was supported by Glaxo B.V., Zeist, the Netherlands and by grant 92.74 of the 
Dutch Asthma Foundation, Leusden, the Netherlands. 
65 

Chapter 8 
Effect of fluticasone propionate aqueous nasal spray treatment on platelet 
activating factor and eicosanoid production by nasal mucosa in patients 
with a house dust mite allergy 
LM. Garrelds"', C. de Graaf-in 't Veld', A.P.H. Jansen', R. Gerth van Wijk' and F.J. 
Zijistra1, 
'Department of Phamlacology, Faculty of Medicine, Erasmus University Rotterdam and 2Department of 
Allergology, University Hospital Rotterdam-Dijkzigt, P.O. Box 1738,3000 DR Rotterdam, The Netherlands. 
Based on: Mediators of Inflammation 1994;3:381-385. 
8.1 Abstract 
Objective: The relationship between the releasc of platelet activating factor [PAF], 
leukotricne C/D41E4 [LTC,1D41E4] and prostaglandin D, [PGD,] from nasal mucosa ill vivo 
was examined in 24 rhinitis patients allergic to the house dust mite (HDM). 
Melhods: During a double blind placebo controlled cross-over study 200 f'g fluticasone 
propionate aqueous nasal spray (FPANS) was administered twice daily for two weeks. 
In response to allergen provocation (100, 1000, 10000 Bu/ml) and during the 9.5 hours 
after this challenge the nasal fluid was obtained by washing the nose with saline and the 
levels of PAF, LTG/D/E4 and POD2, as indicators of rnediator release, were measured at 
the following time-points: baseline (t~-y,), allergen provocation with 10000 Bu/ml (t~0), 
3.5 and 7.5 hours (late phase). 
Results: After allergen provocation the levels of the mediators increased in the nasal fluids 
of placebo treated patients (increase from baseline: PAF: IS-fold; LTC4ID,1E4: 12-fold; 
PGD,: 1.5-fold). In fluids of patients treated with FPANS these levels tended to decrease. 
At the time of provocation the levels of PAF, LTC/D/E4 and PGD2 showed a significant 
correlation. 
Conclusion: The results indicate that these mediators can be used as markers of allergic 
reactions against house dust mites and that fluticasone propionate aqueous nasal spray 
tended to reduce the release of mediators of inflammation correlated with beneficial effects 
on clinical symptoms in this type of allergic reactions. 
KeYl'i'ol'ds: fluticasone propionate aqueous nasal spray; house dust mite; platelet activating 
factor; eicosanoids 
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8.2 Introduction 
In the 1920s house dust allergy was recognized when dust extracts from mattresses and 
vacuum cleaners were found to give relevant positive reactions in skin test on 
asthmatics. J~3,451 Since 1964 it has been known that the majority of house dust sensitive 
patients show positive skin reactions to the mites of the genus Dennatophagoides farinae 
(Df) and D. pteronyssinus (Dp) as a major source in house dust,651 The faeces particles, in 
particular, contain allergenic material in a concentrated form. Practicable control measures, 
such as chemicals, cleaning, ventilation and temperature regulation have only been able to 
reduce the number of mites in houses to some extent but the clinical effect has been 
disappointing.Z78,370,451,651,65J As long as these methods are insufficient other forms of therapy 
are needed, such as immuno-therapy and symptomatic mcdication.77,198.21J.214 
House dust mites are the major cause of perennial rhinitis. The pathophysiology of allergic 
rhinitis, however, has been mainly studied in pollen allergy. Naclerio et al. 465 developed a 
model to explore the role of inflammatory mediators in ragweed pollinosis. As a 
consequence of cross-linking of IgE on mast cells and basophils by antigen mediators, such 
as prostaglandin Dz [PGDzJ, tryptase and histamine are released in the so-called early phase 
of the allergic process. These mediators cause sneezing, rhinorrhoea and nasal congestion, 
which are the main symptoms of allergic rhinitis when they interact with neural elements, 
mucosal gland and blood vessels. After a quiescent period a second phase of the allergic 
process occurs. In this so-called late phase mediators are released again and symptoms 
recur.465,466,463,625 The effect of systemic steroids, such as prednisone, reduce symptoms and 
mediator release in the late phase of the process. They have little or no effect on the early 
phase.46J,m In contrast, topical steroids, such as flunisolide, used in the nose reduce 
symptoms and mediator release in the early phase as well in the late phase of the allergic 
process in a study with patients challenged with pollen antigens.463.516 The corticosteroid, 
fluticasone propionate [FPJ has potent topical anti-inflammatory activity coupled with the 
low systemic activity. It has more than nine times the anti-inflanunatory activity of 
fluocinolone acetonide and twice the activity of beclomethasone dipropionate. 85,510 
The present study uses a nasal challenge model developed by Naclerio el a/. 465 to explore 
the role of PAF and eicosanoids in the early and late phase of the allergic process in 
patients with allergic rhinitis against house dust mites. PAF could be involved in 
respiratory allergies because PAF is a potent eosinophil chemotactic factor. 666 However, to 
the authers'knowledge, there are so far no available data regarding in vivo PAF generation 
by human nasal mucosa of patients allergic to house dust mites. In this report, the effect of 
fluticasone propionate aqueous nasal spray, a new and potent corticosteroid, on the levels 
of platelet activating factor (PAF), lenkotriene C,ID,IE, (LTC,ID,IE,) en prostaglandin D, 
(PGD2) after nasal challenge with house dust mite extract, is also described. 
8.3 Materials and methods 
Patients 
This study was performed in 24 patients. There were 11 women and 13 men aged 21 to 50 
years (mean, 34 years). All were characterized by a history of perennial rhinitis, and by a 
positive skin test to house dust mite extract. All patients showed a skin reaction rated as at 
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least one l1+l1_sign to 0.3 to 3 BU/ml extract, according to the standardized phis-sign 
scoring system defined by Norman. 477 Six of the 24 patients were allergic to grass pollen or 
animal dander as well. The nasal lavage experiments were performed between January and 
August to minimize exposure to house dust mites. The only patient with a concomitant 
pollen allergy was tested outside the pollen season. None of the patients allergic to animals 
had pets in their home. Antihistamines were withdrawn 72 hours before testing. The 
antihistamine astemizole, topical corticosteroids, cromoglycate or nedocromil were not used 
for 3 weeks before the tests were performed. Oral corticosteroids had to be withdrawn 2 
months before the study. Patients who developed a nasal infection during the 2-weeks 
period before entering the study were excluded. None had undergone immunotherapy 
previously. 
The study was approved by the Medical Ethical Committee of the University Hospital 
Rotterdam-Dijkzigt and all patients gave written informed consent. 
Nasal challenge and lavage 
After the positive skin test the subjects entered the double blind placebo-controlled 
crossover phase of the study. Each underwent two allergen challenges, performed after 2 
weeks pretreatment with 200 ~lg tluticasone propionate aqueous nasal spray (FPANS) 
(Glaxo, GRD) or placebo spray twice daily. A 3-weeks washout period separated the two 
challenges. 
Before nasal challenge with house dust mite extract a nasal lavage was performed four 
times to obtain baseline mediator levels and to clear the nose from secretions. To prevent 
nasal congestion caused by the allergen challenges 0.250 ml oxymetazoline (0.1 %) was 
sprayed into each nostril 5 min before the first challenge. Nasal lavage was performed as 
described by Naclerio et al. and Gerth van \Vijk et al.229•23o,465 Both nostrils were washed 
with 5 ml saline, prewarmed to 37°C. Lavage fluid was collected in plastic tubes that were 
kept on ice. These lavage fluids were centrifugated for 10 min at 400 x g and the 
supernatants were stored at _70°C until detection of PAF or eicosanoids. To obtain a 
control challenge, 0.125 fill phosphate buffered saline [PBS] was sprayed in each nostril 
and a nasal lavage was performed. For allergen challenge 0.125 ml allergen extract was 
sprayed in each nostril and 10 min thereafter a nasal lavage was performed. Allergen doses 
of 100, 1000, 10 000 Biological Units [BUj/ml (extract of Dermatophagoides 
pteronyssinus; ALK, Groningen, The Netherlands) \"ere administered. From 30 min up to 
9.5 hours after this challenge the nasal fluid was obtained every hour by washing the nose 
with saline. Allergen-induced secretion collected before nasal lavage was not used for 
analysis. From the series of lavages the levels of P AF, LTC/DiE4 and PGD2, as indicators 
of mediator r~lease. were measured at the following time-points: baseline (t=-~), allergen 
provocation with 10000 BUlml «(~O), 3.5 and 7.5 h. These time-points were chosen based 
on recently described studies229,230, in which it was shown that between 3 and 10 hours after 
antigen challenge the late phase reaction occurred. 
Symptom Score 
Symptoms were scored according to a scoring system described by Lebel et ai, m These 
symptoms were observed in order to study the correlation between these clinical symptoms 
and the inflammatory mediators. The score was compiled before each lavage and after PBS 
and each allergen insufflation. 
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Mediator assays 
The levels of PAF, LTC,ID,IE, and POD, were measured by Scintillation Proximity Assay 
(SPA), BiotrakR and RadioImmunoAssay (RIA) respectively (Amersham, U.K.) The limits 
of sensitivity of the assays were approximately 20, 3.1 and 0.75 pg/l 00 fll respectively. 
Cross-reactivity (50% BlBo displacement) of: PAF-assay: I-Hexadecyl-2-acetyl OPC-
PAF(CI6:0) (100%), I-Octadecyl-2-acetyl OPC-PAF(CIS:O) (40%), rae PAF (29%), 1-
Hexadecyl-2-lyso OPC-Lyso-PAF(CI6:0) «0.01%); LTC41D4IE,-assay: LTC, (100%), 
LTD, (100%), LTE4 (70%), LTB4 (0.4%) and prostaglandins «0.006%); POD,-assay: 
POD, (100%), POJ, (7%), TxB, (0.3%), POF," (0.04%) and other prostaglandins 
«0.02%). 
8.4 Statistical analysis 
Statistical analysis was performed with the Friedman Two~way ANDV A followed by the 
Wilcoxon Matched-pairs Signed-ranks Test. The Kmskal-Wallis rank test was used for 
correlations. For testing equality of the calTy~over effect, withill~patient totals over the two 
treatment periods are used. There is said to he no significant carry~over effect if the means 
of these within~patient totals do not significantly differ between the two treatment~order 
groups. For this test a p-value < 10% is considered significant. 
8.5 Results 
Nasal mediator release 
The levels of the inflammatory mediators, PAF, LTC./D/E4, and PGD2, in nasal washings 
from allergic patients to house dust mites with and without fluticasone propionate aqueous 
nasal spray [FP ANS] are presented in Table I. No significant carry-over effect was 
observed. The baseline-levels of the placebo-group and FPANS-group respectively are: 
PAF: 907 ± 177 [range 147-3172] and 780 ± 316 [range 95-7272] pg/ml; LTC,ID,1E4: 112 
± 10 [range 37-233] and 106 ± 9 [range 10-209] pg/ml and POD,: 94 ± 26 [range 21-592] 
and 92 ± 30 [range 3~ 734] pg/mL Because these baseline-levels are in a large range, the 
levels are recalculated in percent change to baseline. 
Nasal challenge with hOllse dust mite extract caused an inmlediate influx of these 
inflanunatory mediators. After allergen provocation the levels of the mediators increased in 
the nasal fluids of placebo~treated patients (x~fold increase to baseline: PAF: 15; 
LTC41D41E,: 12 and POD,: 1.5). In fluids of patients treated with FPANS these levels 
tended to decrease (x-fold increase to baseline: PAF: 6; LTC/D/E4: 4 and POD,: 1.1). P-
valuc between the placebo and FPANS~group aftcr the primary trigger initiated after 
challenge with 10000 BU/ml house dust mite extract of PAF: 0.2124, LTC4ID,IE,: 0.1618 
and POD,: 0.2227. 
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Table 1: Platelet activating factor (PAF), Leukotricne C41DiE4' (LTC41D4iE4) and Prostaglandin D2 (PGD2) 
production in nasallavagcs at the following time· points: allergen provocation with 10 000 BUlml hOllse dust 
mite (HDM) extract (1=0), 3.5 and 7.S hours (late phase) of allergic paticnts treated with Placebo or with 
fluticasone propionate aqueous spray (FPANS), Because of scattered individual data values are expressed as 
% change of baseline ± S.E,M, Statistical significant decrease to the HDM 10 000 is shown as '" according to 
the Wilcoxon Matched·pairs Signcd·ranks Test (p5;O,OS). 
HDM 10 000 3.5 hOlll'S 7.5 hOlll'S 
BU/ml 
Placebo FPANS Placebo FPANS Placebo FPANS 
PAF 1490±479 554±283 5± 19' 29± 37' 19:120' 1:128' 
LTC,1D41E4 1115±518 355±190 -4± 9' -21 ± 7' -6± 7' -9± 9' 
PGD, 50± 26 8± 16 -42± II' -47± 10' -39± 8' -29± 12 
At 3,5 and 7.5 hour after this challenge a significant decrease of PAP, LTCiDiE4 and 
PGD2 was observed in both groups compared with the value at the time-point of allergen 
provocation with 10000 BU/ml hOllse dust mite extract. The p-values of the placebo-group 
and the FPANS-group at 3.5 hour are respectively: PAF: 0.0004 and 0.0010, 
LTC,ILTD4ILTE4: 0.0003 and 0.0003; PGD,: 0.0126 and 0.0116. At 7.5 hour the p-values 
of the placebo-group and the FPANS-group are respectiVely: PAF: 0.0116 and 0.0184, 
LTC,ILTD,/LTE,: 0.0300 and 0.0025; PGD,: 0.0023 and 0.0936. 
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Figure 1. 
Symptom score at the following time-points: baseline (B), allergen provocation with to 000 BWml house 
dust mite extract (1=0), 3,S and 7.S hours (late phase) of allergic paticnts treated with or without FPANS, 
Values are expressed mean ± S.E,M. Statistical significant difference to the HDM 10000 is shown as >jc 
(p.$;O,05). Statistical significant difference to the baseline is shown as ** (psO,OS), 
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Because a significant carry-over effect was observed, only the results of the first treatment 
period was used. A significant increase is observed immediately after the challenge with 
house dust mite extract in the placebo and FPANS-group. At 3.5 and 7.5 hours after this 
challenge a significant decrease of the symptom score is observed as compared to the level 
at the time-point of the challenge in both groups (p~O.OO I). The symptom score of patients 
treated with FPANS is decreased in comparison to the placebo-group. 
Correlation between i11tlammatOl)1 med;ators and symptom score 
A significant correlation (P';0.05) is found immediately after the challenge with 10000 
BU/ml house dust mite extract between: (I). the release of LTC/D,IE, and PGD, in the 
plaeebo-group (correlation coefficient (c) ~ 0.656) and in the FPANS-group (c~0.776), (2). 
the release of PAF and LTC/D/E4 in the placebo-group (c~0.719) and in the FPANS-
group (c~0.990), (3). the release of PAF and PGD, after the administration of placebo 
(c~0.466) or FPANS (c~0.740), (4). the release of LTC/D4IE, and symptom score in the 
placebo-group (c~0.547) and in the FPANS-group (c~0.545) and (5). the release of PAF 
and symptom score of the FPANS-group (c~0.598). 
8.6 Discussion 
Lavage of the nasal mucosa appears to be a convenient model for measuring inflammatory 
mediator release during an allergic reaction to the hOllse dust mite. 
In agreement with other investigators it was found that within a few minutes of exposure to 
an allergen leukotrienes and prostaglandins can be measured in nasal 
washings. 56.80,465,478.492,682 
This is the first study in which PAF could be measured in nasal lavages in detectable 
amounts seen within a few minutes after nasal provocation with hOllse dust mite extract. 
Other investigators found lyso-PAF but almost no PAF by bioassay in nasal washings after 
nasal challenge of patients with a pollen allergy.435,438 In vitro studies have demonstrated 
that PAF is released by alveolar macrophages l6, eosinophils37S, monocytes and endothelial 
cells87,88 and platelets lO1 • It has now been demonstrated that PAF is present in nasal lavages 
of patients with house dust mite allergy; however, the origin of PAF is uncertain. In the 
early phase of the allergic process IgE crosslinks by antigen challenge on mast ceUs and 
basophils, which release primary mediators. After a quiescent period a late phase allergic 
reaction occurs, in which eosinophils ancl macrophages are involved, releasing secondary 
mediators. 463,465,466,625 It has been shown that PAF is released during the early phase 
reaction as primary mediator and not as a secondary mediator. The present study also 
shows that PGD2 is released only during the early phase of the allergic process as a 
primary mediator. This is in agreement with other investigators, who found that PGD2 is 
produced by mast cells.52.679 Sulphidopeptide-Ieukotrienes are known to be released by 
eosinophils448.575,677 and macrophagcs32,6-t,498, which indicated that LTC/LTD4/LTE4 are 
secondalY mediators. However, these sulphidopeptide-leukotrienes were released during the 
early phase reaction and not during the late phase reaction, which indicated that these 
sulphidopeptide-Ieukotrienes are also primary mediators. The generation of the mediators 
PAF, LTC,ID4IE, and PGD" reached baseline levels after 3.5 hI'S. During the late phase 
reaction symptoms partially recurred, but surprisingly PAP, LTC/D/E4 and PGD2 were not 
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released again. This symptoms should be due to other mediators. Furthermore it was 
elearly demonstrated that the release of PAF, LTC41D/E, and PGD, correlated with each 
other immediately at the time-point of the nasal challenge with house dust mite extract. 
Previous reports of studies with patients allergic to grass-pollen and ragweed described a 
correlation between LTC/D/E4 and POD/13,m 
We also found a significant correlation between the release of LTC/D4IE, and PAF with 
the symptom score at the time-point of challenge, but not between the release of PGD2 and 
the symptom score. However, Lebel et al. m who studied patients with a grass-pollen 
allergy observed that the release of PGD, was well correlated with the symptom score, 
In this study pretreatment of the patients with FPANS for two weeks twice daily greatly 
reduced the development of symptorns. In a study performed with 17 atopic patients, 
during a 2 weeks pretreatment with FPANS 200 J.lg/day the immediate increase in nasal 
airway resistance was not inhibited.619 In another study the dose of ragweed pollen required 
to produce a standardised response was unchanged after 4 weeks of treatment with FPANS 
200 ~lg/day ill 49 patients during the ragweed season,587 However, FPANS improved the 
symptom score after 2 and 4 weeks of treatment in 24 patients with seasonal allergic 
rhinitis after nasal challenge with allergen.295 
It has been suggested that the number of eosinophils and basophilic cells (basophils and 
mast cells) increase following allergen challenge and that this factor is responsible for the 
initiation of the allergic vascular response,JOI.5H Treatment with FPANS 50 to 800 J.lg/day 
administered for 2 weeks to 6 months was associated with a significant decrease in the 
number of nasal eosinophils, basophils and neutrophils compared with placebo patients 
with seasonal allergic rhinitis, ~33 It has been proposed that FPANS may act by preventing 
activation of several cells and subsequent release of inflammatory mediators.435 
The present findings indicate that FPANS reduces not only the allergen-induced symptoms 
(ratio placebo/FPANS: 1.68) but also tended to reduce the release of PAl' (ratio 
placebo/FPANS: 2,69), LTC4ID,IE, (ratio placebo/FPANS: 3,14) and PGD, (ratio 
placebo/FPANS: 6,25) after the primary trigger initiated after challenge with 10000 BU/ml 
house dust mite extract at the time-point of challenge. 
In conclusion, the results indicate that the inflammatory mediators platelet activating factor, 
leukotriene C/D/E4 and prostaglandin D2• can be used as markers of allergic reactions to 
house dust mites and that fluticasone propionate aqueous nasal spray counteracts the release 
of mediators of inflammation. correlated with beneficial effects on clinical symptoms in 
this type o(allergie reaction, 
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Interleukin-5 and eosinophil cationic protein in nasal lavages of rhinitis 
patients 
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Wijk', FJ. Zijlstra'. 
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20epartment of Allergology, University Hospital Rotterdam-Dijkzigt, P,O. Box 1738, 3000 DR Rotterdam, 
The Netherlands and 
lUnite de Pharmacologie Cellulaire, Illstitut Pasteur, 25 Rue du Docteur Roux, 75724 Paris Cedex 15, France. 
Based on: European Journal of Pharmacology 1995;275:295-300 
9.1 Abstract 
Objective: The production of interleukin-5 and eosinophil cationic protein (ECP) in the 
nasal cavity was examined in 24 patients with rhinitis who were allergic to the house dust 
mite. 
Ale/hods: During a double-blind placebo-controlled cross-over study, fluticasone propionate 
aqueous nasal spray (200 J..lg) was administered twice daily for two weeks. After four basal 
nasal lavages provocation with house dust mite extract was performed and nasal lavages 
were collected every hour for 9.5 h, 
Results: Interleukin-S was present in detectable amounts in nasal lavages from patients 
allergic to house dust mite. Nasal challenge with house dust mite extract caused immediate 
nasal symptoms and increased levels of interleukin-S. Between 3,S and 8.S hours after the 
challenge symptoms recurred and interleukin-5 levels increased, reflecting a late phase 
reaction. Eosinophil cationic protein, a marker of activated eosinophils, was released 
between 6.5 and 9.5 hoUl's after challenge. 
Conclusion: Treatment with fluticasone propionate (as an aqueous nasal spray) significantly 
decreased the evoked interleukin-S and ECP levels in the latc phase reaction. This response 
was correlated with an improved symptom score. This could indicate that the number and 
activity of eosinophils are increased during thc latc phase allergic reaction, a response that 
is inhibited by corticosteroids. 
Key,,'ords: intcrlcukin-S; eosinophil cationic protein (ECP); house dust mite; fluticasone 
propionate aqueous nasal spray; rhinitis 
75 
Chapter 9 
9.2 Introduction 
Human allergen-induced responses in the nose are used as a model for allergic 
inflammation.230,465 After provocation with antigen, mediators, such as prostaglandin D2, 
leukotriene E4, tryptase and histamine, are released during the so-called early allergic 
reaction, which causes sneezing, nasal blockage and rhinorrhoea. After a quiescent period, 
a late allergic reaction occurs and symptoms recur.309,465,SOS Studies on human nasal late 
responses have shown an influx of eosinophils and an increase in the content of eosinophil 
cationic protein (ECP) in nasal fluids 3-11 hours after challenge. The presence of 
mononuclear cells in lavage fluid during the late responses has also been recognized.309 
Several studies have suggested a role for cytokines, particularly granulocyte-macrophage 
colony-stimulating factor (GM-CSF), interleukin-3 and interleukin-5, in the initiation of 
allergic inflammation. These cytokines promote the survival and activation of eosinophils 
in vitro, enhance adhesion to microvascular endothelial cells in vitro and induce 
eosinophilia in vivo. Mosmal}.n and colleagues described two classes of T helper 
lymphocytes on the basis of their profile of cytokine release. T HI-cells produce interleukin-
2, interleukin-3, interferon-y and GM-CSF but no interleukin-4 or interleukin-5, whereas 
THl clones produce interleukin-3, interleukin-4, interleukin-5, interleukin-IO and GM-CSF 
but no interleukin-2 or interferon-y.452 However, the exact cells from which GM-CSF, 
interleukin-4 and interleukin-5 are released remain to be determined, because other studies 
have shown that mast cells also produce interleukin-4 and interleukill-5 whereas eosillophils 
may produce GM-CSF and interleukin-5.689 
In our study, the nasal challenge model developed by Naclerio et al. 465 was used to 
correlate clinical symptoms and the release of biochemical markers such as interleukin~5 
and ECP and to establish whether these markers are formed predominantly in the early or 
late phase of the allergic proces..<;; in patients with allergic rhinitis. Furthermore, the effect 
of fluticasone propionate, a new and potent corticosteroid, on the levels of interleukin-5, 
ECP and on symptom scores after nasal challenge with allergen was investigated. 
9.3 Materials and methods 
Patients 
This study was performed with 24 patients. (11 women and 13 men, aged 21 to 50 years, 
mean: 34 years). All patients had a history of perelUlial rhinitis and a skin reaction to 
extract of house dust mite as an inclusion criterion. The skin reaction was rated as at least 
one n+l1~sign in response to 0.3 or 3 biological units (BU)/ml extract, according to the 
standardized plus-sign scoring system. Six of the 24 patients were also allergic to grass 
pollen or animal dander. The nasal lavage experiments were performed in January-August 
to minimize exposure to house dust mite. The patients with a concomitant pollen allergy 
were tested outside the pollen season. None of the patients allergic to animals had pets in 
their home. Anti-histaminic drugs were withdrawn 72 hours before testing. The 
antihistamine astemizole, topical corticosteroids, cromoglycate or nedocromil were not used 
for 3 weeks before the start of the study and oral corticosteroids were withdrawn at least 2 
months before the study. Patients who developed a nasal infection during the 2-week 
period prior to the study were excluded. None of the patients had immunotherapy previously. 
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The study was approved by the Medical Ethics Committee of the University Hospital 
Rotterdam-Dijkzigt and all patients gave written infonned consent. 
Nasal challenge and lavage 
After the positive skin test the subjects entered the double blind placebo-controlled cross-
over phase of the study. Each underwent two allergen challenges, performed after a twice 
daily pretreatment with 200 ~g fluticasone propionate (aqueous nasal spray (Glaxo, U.K.)) 
or placebo spray for 2 weeks. A three-weeks washout period separated the two treatment 
periods. 
Before nasal challenge with house dust mite extract, a nasal lavage was performed 4 times 
to obtain baseline levels and to clear the nose of secretions (b). To prevent nasal 
congestion, 0.25 ml oxymetazoline (0.1 %) was sprayed into each nostrilS min before the 
first challenge (prescribed by the Hospital Ethical Committee). Nasal lavage was performed 
as described before.219.2JO.465 Both nostrils were washed with 5 ml saline, prewarmed to 
37'C. Lavage fluid was collected in plastic tubes and kept on ice. After centrifugation (10 
min, 400 x g) the supernatants of lavage fluids were stored at -20°C until determinations. 
Due to the low number of cells in the lavages we were not able to count the number of 
eosinophils and perform statistical analysis. To obtain a control challenge (c), 0.125 ml 
phosphate-buffered saline (containing 0.03% human serum albumin and 0.05% 
benzalkonium chloride) was sprayed in each nostril and a nasal lavage was performed. For 
allergen chalJenge 0.125 1111 allergen extract was sprayed in each nostril and 10 min 
thereafter a nasal lavage was performed. Allergen doses of 100, 1000, 10 000 (hl-h3) 
BU/ml (extract of D. Pteronyssinus; ALK, Groningen, The Netherlands) were administered. 
From 30 min up to 9.5 hours after the last challenge (given at h3) the nasal washings were 
collected every hour by washing both nostrils with saline (sl-sI0). 
Symptom Score 
Symptoms were scored to assess the correlation between clinical symptoms and interleukin-
S production. The score was compiled before each lavage and after phosphate-buffered 
saline challenge and after each allergen spray. Symptom scores were graded in points: 3-4 
sneezes = 1 point; ;:::':S sneezes = 3 points; rhinorrhoea anterior = 1 point; rhinorrhoea 
posterior = I point; difficult nasal breathing = I point; one nostril blocked = 2 points; both 
nostrils blocked = 3 points; pmritus of the nose = 1 point; pruritus of paiate or ear = 1 
point and conjunctivitis = I point (total score ranged from 0 to II points). 
111terleukin-5 assay 
Malerial 
Tween 20 (Merck, Darmstadt, Germany); bovine serum albumin fraction V (Euromex, 
Schiltigheim, France); horseradish peroxidase-conjugated goat anti-rabbit Immunoglobulin 
G (IgG) F(ab'), (Biosys, Compiegne, France); TMB microwell peroxidase substrate system 
(Kirkcgaard & Perry Lab., Gaithersburg MD, USA); polyclonal rabbit anti-human-
interleukin-S (Oenzyme, Cambridge, MA, USA); anti-human-interleukin-5 monoclonal 
antibody and recombinant human-interleukin-5 were kindly provided by Drs R. Devos, and 
1. Tavernier (Roche, Gent, Belgium). 
77 
Chapter 9 
Method 
ELISA plates (96-well Immuno Plate MaxiSorp, Nunc, Roskilde, Denmark) were coated 
with 100 III of the anti-human-interleukin-5 monoclonal antibody (lllg/mi in phosphate-
buffered saline, pH7.4) at 37°C for 2 h, The wells were washed 5 times with phosphate-
buffered saline containing 0.1 % Tween 20. Then, 100 pi of the sample or recombinant-
human-interleukin-5 standard (0,2-200 ng/mI) in phosphate buffered saline-Tween and 3 % 
bovine serum albumin was added to each well and incubated at 3]DC for 1 h. The wells 
were washed 3 times with phosphate-buffered saline-Tween and incubated with polyclonal 
rabbit anti-human-interleukin-5 (10 ~tg/ml in phosphate-buffered saline-Tween-bovine 
senlln albumin) at 37"C for I h, After the wells were washed 3 times with phosphate-
buffered saline-Tween, horseradish peroxidase-conjugated goat anti-rabbit IgG F(ab')2' at a 
dilution of 114000 in phosphate-buffered saline-Tween-bovine serum albumin, was added 
for I h, Then, 100 III of freshly prepared substrate solution (TMB microwell peroxidase 
substrate) was added to each well. Aftcr a lO-min incubation, the reaction was stopped by 
the addition to each well of 100 fli of a 2 M solution of HC!. Absorbance was read at 450 
Illll. The lower limit of sensitivity of the assay was 0.18 nglrnl. 
Eosinophil Cationic Protein assay 
ECP was determined in the lavages by radioimmunoassay (Kabi Pharmacia Diagnostics, 
Uppsala, Sweden), 
9.4 Statistical analysis 
Statistical analysis was performed with the Friedman two-way analysis of variance 
(ANOY A) followed by the Wilcoxon matched-pairs signed-ranks test. The effect of 
fluticasone propionate nasal spray Oil the early phase reaction (area under the curve (AUe) 
between hi and sI) and the late phase reaction (AVC: between s4 and sIO) was assessed, 
These areas under the curve are based on the outcome of the symptom score. A two-tailed 
P value :0:;; 0.05 was considered significant. 
9,5 Results 
Eleven patients (out of 24) showed both all early alld a late phase reaction to the house 
dust mite extract, as assessed by their symptom scores (Fig. la: Symptom score, Fig. I b: 
interleukin-5 and Fig, I c: ECP), whereas the other 13 patients showed ollly m/ early phase 
reaction (Fig, 2), 
S)1J11ptom score 
The effects of placebo and fluticasone propionate nasal spray on the symptom scores of the 
11 patients who showed both an early- and a late phase reaction to the house dust mite 
with treatment are shown in Fig. 1 a. A significant increase was observed immediately after 
the challenge with house dust luite extract in comparison with baseline levels in the 
placebo group (hI-s3; P<;0,05) and in the fiuticasone group (h2 and h3; P<;0,05), A late 
phase reaction occurred only in the placebo group, when symptoms recurred (s6-s9; 
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P::::;O.05). The symptom score of patients treated with fluticasone propionate nasal spray was 
significantly lower than that of the placebo group in the early phase reaction (AVe hl-sl; 
PsO.05) as well as in the late phase reaction (AVe s4-s10; PsO.05). 
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Figure 1. Effect of placebo and fluticasonc propionate aqueous Ilasal spray 011 the symptom scores, 
illterleukin-5 levels in nasal lavages and eosinophil cationic protein levels in nasal lavages of the II patients 
allergic to house dust mite who showed both all early and a late phase reaction. Values are expressed as 
means ± S.E.M. Significant differences in comparison 10 baseline: *, P.:o:;O,05. b: baseline, c: challenge wilh 
phosphate-buffered saline; hl,h2 and h3, challenge with 100, 1000 and 10000 BUlntl house dust mile extract 
respectively; sl-sIO, lavage perfomled every hour after the challenge with 10000 BUlIllI house dust mite 
extract at h3, 
79 
Chapter 9 
The results of the 13 patients who showed only an early phase reaction are shown in Fig. 
2. A significant increase was observed immediately after the challenge with house dust 
mite extraet in comparison with the baseline levels in the placebo group (hl-sl; P';0.05) 
and in the fluticasone group (pbsws3; P$;0.05). No late phase reaction occurred. The 
symptom score of patients treated with fluticasone propionate nasal spray was significantly 
lower than that of the placebo group in the early phase reaction (AUC hl-sl; P';0.05). 
Nasal inlerleukin-5 release 
The effects of placebo and fluticasone propionate nasal spray on the levels of interleukinw5 
in nasal washings from the 11 patients with both all early and a late phase allergic reaction 
to house dust mite are presented in Fig. lb. Interleukin-5 levels varied between 50 and 100 
pg/ml before provocation, with a tendency towards an increase in comparison with the 
baseline level in the placebo group (h2; P~O.0702), a tendency which was not seen in the 
fluticasone propionate group. During the late phase reaction interleukinw5 was released 
again in the placebo group. Fluticasone propionate nasal spray significantly inhibited the 
release of interleukiuw5 in the late phase reaction in comparison with placebo (AVC s4-s10; 
P';0.05). 
The 13 patients with only an early phase allergic reaction to house dust mite who were 
treated with placebo or fluticasone propionate nasal spray showed neither an immediate nor 
a late phase release of interleukin-5 (Fig. 2). 
Eosinophil Cationic Protein 
The effects of placebo and fluticasone propionate nasal spray on the ECP levels of the II 
patients who showed both an early and a late phase reaction to house dust mite are shown 
in Fig. I c. A significant increase in ECP was observed in comparison with the bascline 
levels during the late phase reaction (s7-slO; P$;0.05). The ECP level in nasal lavages was 
significantly decreased by treatment with fluticasone propionate nasal spray in comparison 
with those of the placebo during the late phase (AUC s4-slO; P';0.05).151 
The 13 patients with only an early phase allergic reaction to house dust mite did not show 
a late phase release of ECP (all levels were below 10 ng/ml; Fig. 2) after placebo or 
fluticasone propionate. 
9.6 Discussion 
This is the first study demonstrating that interleukinw5 is present in detectable amounts in 
nasal lavage obtained from patients allergic to house dust mites who show both an early 
and late phase reaction. Nasal challenge with house dust mite extract immediately caused 
nasal symptoms and tended to increase levels of interleukinw5 in the placebo group in the 
early phase reaction. Nasal challenge with phosphatewbuffered saline also caused an 
immediate increase in the level of interleukin-5 in the placebo group, which may indicate a 
nonspecific reaction due to the human serum alburnin in the phosphate-buffered saline. 
Between 3.5 and 8.5 hours after the challenge with house dust mite extract symptoms 
recurred and interleukin-5 levels increased, reflecting a late phase reaction. 
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Figure 2. Effect of placebo and fluticasone propionate aqueous nasal spray on the symptom scores, and 
interleukin-5 and eosinophil cationic protein levels in nasal lavages of the 13 allergic patients to house dust 
mite who showed ollly all early phase reactiol/, Values are expressed as means ± S.E.M. Significant 
differences in comparison to baseline: "', P.s;O.05. b: baseline, c: challenge with phosphate-buffered saline; 
hl,h2 and h3, challenge with 100, 1000 and 10000 BUlllll house dust mite extract respectively; sl-slO, 
lavages perfomled evelY hour after the challenge with 10000 BUlml house dust mite extract at h3. 
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Interleukin-S was released in the lungs of rhinitis patients allergic to ragweed 24 hours 
after segmental antigen challenge, and this release correlated with eosinophil recruitment, 
degranulation, and lung injury.484 In inferior turbinate biopsies from patients with perennial 
allergic rhinitis interleukin-4 and interleukin-S were localized by immunohistochemical 
staining of mast cells and interleukin-S inununoreactivity was also localized in eosinophils. 
No inununoreactivity for cytokines was found in T_cells.73 In studies with grass pollen-
sensitive patients 24 hours after local provocation with antigen, nasal biopsies showed an 
increase in cells with positive mRNA hybridization signals for interleukin-3, interleukin-4, 
GM-CSF and interleukin-S l63 when allergen-challenged sites were compared with control 
sites. It has bcen recently demonstrated by Terada et al. that interleukin-S is released in 
nasal fluid in the late phase reaction after challenge with Japanese cedar.615 
In this study we demonstrated that ECP was released a few hours latcr (between 6.S and 
9.S h) than interleukin-S (between 3.S and 8.S h), which may indicate that the number of 
eosinophils was increased andlor that the eosinophils present were more activated during 
the late allergic reaction, Due to the low numbers of cells in the lavages we were not able 
to perform statistical analysis of eosinophil numbers. 
Our study showed a significant decrease in interleukin-S and ECP levels during the latc 
phase reaction after treatment with fluticasone propionate nasal spray. This decrease 
correlated with an improved symptom score in the II patients with an early and late phase 
reaction. A decreased relense of ECP may indicate that the number of eosinophils was 
decreased and/or that the eosinophils were less active during the late allergic reaction after 
treatment with fluticasone propionate nasal spray. The protective effects of fluticasone 
propionate nasal spray on interleukin-S were detected in the late phase reaction and failed 
to affect the initial (baseline) release of interleukin-S as well as the early phase response to 
house dust mite provocation. Other factors involved in allergic rhinitis, such as albumin, 
tryptase, leukotriene E4, prostaglandin D2 and platelet activating factor, are also increased 
after house dust mite provocation and are inhibited by fluticasone propionate nasal 
spray.219,251 Pretreatrnent with fluticasone propionate nasal spray improved the symptom 
score of patients with seasonal allergic rhinitis after nasal challenge with allergen and 
decreases the number of nasal eosinophils, basophiJs and neutrophiJs.J3J It has been 
proposed that fluticasone propiOlk1tC nasal spmy may act by preventing the activation of 
these cells and the subsequent release of (chemotactic) inflanunatory mediators and further 
influx of cells. Several in vitro studies have shown that corticosteroids inhibit T-cell 
. proliferation and cytokine production1J5, decrease the number of cells expressing 
interlellkin-4 and interlellkin-S mRNA in vivo 5-12 and decrease the number and activation of 
mast cells and cosinophils in bronchial biopsies and lavages. 157 
In summary, the results of this study show that interleukin-S was found in detectable 
amounts in nasal lavages of patients with a house dust mite allergy before and after 
challenge with house dust mite extract, whieh caused immediately nasal symptoms. 
Between 3.5 and 8.S hours after the last challenge symptoms recurred and interleukin-S 
levels increased, reflecting a late phase reaction. ECP was released between 6.S and 9.S 
hours after challenge. A two-week pretreatment with 200 ~lg fluticasone propionate 
aqueous nasal spray resulted in a significant decrease in interleukin-S and ECP levels in the 
late phase reaction. This decrease was correlated with an improved symptom score. 
Although it is not fully understood how the mechanism of interleukin-5 release is 
modulated, the programmed release of this cytokine would be of interest in other allergic 
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reactions. 
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10.1 Abstmct 
Objective: The role of nitric oxide in the early and latc phase of the allergic process was 
investigated in patients with allergic rhinitis against house dust mite and the effect of 
fluticasone propionate aqueous nasal spray was determined. 
Aiel/wds: Production of nitric oxide (measured as nitrite+l1itrate) ill vivo in nasal mucosa 
Was examined in 24 patients with rhinitis allergic to the house dust mite. In a double blind 
placebo controlled crossover study fluticasone propionate 200 ~tg aqueous nasal spray was 
administered twice daily for two weeks. In response to provocation with house dust mite 
extract (after four basal nasal lavages) nasal lavages were performed every hour for 9.S 
hours by washing the nose with saline. In addition, a similar lavage protocol was 
performed in healthy volunteers with or without challenge with phosphate buffered saline. 
Results: Nitric oxide is present in nasal lavage fluid in detectable amounts (range lOMSO 
~tM), the level gradually increasing with time in both patients and controls after a decrease 
during the four basal lavages. Treatment with fluticasone propionate aqueous nasal spray 
did not affect initial basal production of nitric oxide nor production following provocation 
with house dust mite extract. 
Conclusion: Production of nitric oxide in nasal mucosa determined in sequential nasal 
washings is not affected by therapeutic doses of intranasal steroids. 
Keywords: nitric oxide; house dust mite; fluticasone propionate aqueous nasal spray 
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10.2 Introduction 
House dust mites are the major cause of perennial rhinitis. The pathophysiology of allergic 
rhinitis, however, has been studied mainly in pollen allergy.J43,4SI,6sl To study the role of 
inflammatory mediators in ragweed pollinosis Naclerio el at developed a control mode1,46s 
After provocation with antigen mediators such as prostaglandin D2 (PGD2), leukotriene E4 
(L TE4), tryptase, and histamine are released in the early phase of the allergic process, 
causing sneezing and rhinorrhoea. After a quiescent period a late phase occurs and 
symptoms recur when mediators are again reieased.465,466.463,625 
It has recently been claimed thai nitric oxide (NO) is an important mediator in bronchial 
inflammation.36,145,161,328,387,631 NO synthase (NOS) is the enzyme responsible for the 
generation of nitric oxide from L~arginine, The highly reactive and unstable nitric oxide 
rapidly decomposes to nitrogen oxides sllch as nitrite and nitrate.4B Nitric oxide synthase 
present in various cells from different (emblyological) origin exists in two different 
forl11s444 wlhe constitutive, calcium dependent enzyme (eNOS) which releases nitric oxide 
after stimulation and the inducible, calcium independent enzyme (iNOS) which is found 
after induction with cytokines.326,443,4-14 
The function of nitric oxide in the bronchoalveolar compartment may be either 
brochodilatory (nitric oxide gas retains bronchodilating proporties) or regulatory. Little is 
known of the regulatory function of nitric oxide. 
In patients challenged with pollen antigens topical nasal steroids such as flunisolide reduce 
symptoms and mediator release in both the early and lale phases of the allergic 
process.463,SI6 The corticosteroid lluticasone propionate has potent topical anti-inflammatory 
activity coupled with low systemic activity.85,510 
Our study design is based on the nasal challenge model developed by Naclerio el al465 
which enables us to explore the role of nitric oxide in the early and late phase of the 
allergic process in patients with allergic rhinitis against house dust mites. The effect of 
fluticasone propionate aqueous nasal spray on the levels of nitrite + nitrate after nasal 
challenge with house dust mite extract was investigated and the effect of challenge with 
phosphate buffered saline on normal levels of nitrite + nitrate in healthy volunteers was 
determined. 
10.3 Materials and Methods 
House dust mite experiment 
Patients 
The study was performed in 24 patients (13 Illen) of mean age 34 (range21-50) years with 
a history of perennial rhinitis and skin reaction to house dust mite extract. All patients 
showed a skin reaction rated as at least one plus-sign to 0.3 or 3 biological units (BU)/ml 
extract according to the standardised plus~sign scoring system defined by Nonnan.477 Six of 
the 24 patients were also allergic to grass pollen or animal epithelia. The nasal lavage 
experiments were performed between January and August to minimise exposure to house 
dust mites. The patients with a concomitant pollen allergy were tested outside the pollen 
season. None of the patients allergic to animals had pets in their home. Anti-histamine 
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drugs were withdrawn 72 hours before testing. The antihistamine astemizole, systemic 
corticosteroids, and topical corticosteroids were not used later than three weeks, two 
months, and three weeks respectively before the tests were performed. Patients who 
developed a nasal infection during the two weeks period before the study were excluded. 
None had received inununotherapy. 
The study was approved by the Medical Ethical Committee of the University Hospital 
Rotterdam~Dijkzigt and all patients gave written informed consent. 
Nasal challenge aud lavage 
After the positive skin test the subjects entered the double blind, placebo controlled, 
crossover phase of the study. Each underwent two allergen challenges performed after 
pretreatment with fluticasone propionate aqueous nasal spray (Glaxo,UK), 200 pg twice 
daily for two weeks, or a placebo spray. A three weeks washout period separated the two 
challenges. 
Before nasal challenge with house dust mite extract a nasal lavage was performed four 
times to obtain baseline mediator levels (b l.b4) by the method described by Naclerio ef 
al.465 Both nostrils were washed with 5 ml saline prewanned to 37°C. Lavage fluid was 
collected in plastic tubes and kept on ice. After centrifugation (10 min, 400 g) supernatants 
of lavage fluids were stored at -20°C until assay of NOx. To prevent nasal congestion 0.25 
ml oxymetazoline (0.1%) was sprayed into each nostril five minutes before the first 
challenge. To obtain a control challenge 0.125 ml phosphate buffered saline (PBS) was 
sprayed into each nostril and a nasal lavage was performed. For allergen challcnge 0.125 
ml allergen extract was sprayed into each nostril and a nasal lavage was performed after 10 
minutes. Allergen doses of 100, 1000, 10 000 (hl·h3) Biological Units (BU)/ml (ALK, 
Groningen, The Netherlands) were administered. From 30 minutes up to 9.5 hours after the 
last challenge (time point h3) the nasal washings were performed every houl' by washing 
both nostrils with saline (sl·sIO). 
Symptom Score 
Symptoms were scored to study the correlation between clinical symptoms and production 
of nitric oxide as described by Lebel et al.J73 The score was compiled before each lavage 
and after PBS and each allergen insufflation. 
Control experiments with health}! volunteers 
Two experiments were performed 
Experiment 1: Nasal challenge with PBS and nasal lavage 
This experiment was performed with II healthy volunteers (six men) of mean age 31 
(range 25~40) years. The same protocol as described above for patients was used, but 
instead of nasal challenges with house dust mites extract, challenges with PBS were 
performed. From 30 minutes up to 7.5 hours after the last challenge (timc-point h3) the 
nasal fluid was obtained by washing the nose with saline. 
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Experiment 2: Nasa/lavage without challenge 
This experiment was performed with six healthy volunteers (three men) mean age 29 
(range 25 - 41) years, The same protocol as with healthy volunteers as described in 
experiment 1 was followed but without PBS challenge, 
Nitric oxide assay 
The nitric oxide metabolites nitrate (after reduction to nitrite) + nitrite were assayed 
calorimetrically after the Griess reaction as described by Phizackerly and AI-Dabbagh512 
with the following modifications: 
Colleelioll and deproteinization of samples: 
200 ftl of nasal lavage fluid or standard was deproteinated by adding 20 ~I NaOH (1.0 M, 
4°C; Merck, Germany) and 30 fll ZnSO, (1.3 M, 4°C; Merck, Germany), Samples were 
mixed and allowed to stand on ice for 15 minutes. 
Conversion of nitrate to nitrite: 
After centrifugation (5 min, 4°C, 2600 g) 100 ftl of the supernatant was mixed with 10 fll 
Klebsiella-pneumoniae-suspension (7,5 mg/ml protein), 20 ~I 0,2 M N-tris (hydroxy-
methyl)-methyl-2-amino-ethane sulfonic acid (TES, pH7,0; Sigma, U,S,A,) and 20 ~I 0,5 
M sodium formate (Merck, Germany). After 20 minutes anaerobic incubation at room 
temperature for 20 minutes 1.0 ml water was added to the samples and nitrite was assayed 
in supernatants obtained by centrifugation (5 min, 2600 g). 
Estimatioll of nitrite: 
Deproteinised samples or standard (200 ~t1) were mixed with 20 ~tJ 1 % sulphanilamide 
(Sigma, U,S,A,) in 15% phosphoric acid (Merck, Germany), After 10 minutes 20 fll 0,1 % 
N-(l-naphtyl)ethylenediamine (Sigma, U,S,A,) was added and the absorption at 540 nm 
was determined (595 nm was used as a reference wavelength). 
10.4 Statistical analysis 
The within patient totals over the two treatment periods were used to test equality of the 
carry-over effect. Thirteen of the 24 patients received fluticasone propionate aqueous nasal 
spray during the first treatment period and 11 patients during the second treatment period. 
It was assumed that no significant carry-over effect occurred if the means of these within 
patient totals werc not significantly different in the two treatment groups. For tlus test a p-
valuc < 10% was considered significant. In case of a carry-over effect, only the data of the 
first treatment period were used for statistical analysis. Values are expressed as means 
(SE), 
Statistical analysis was performed with the non-parametric MmUl- \Vitney U test (for 
comparison of placebo and fluticasone treatment) and the \VilCOXOll unpaired Test (for 
comparison between patients and controls). 
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10.5 Results 
House dust mite experiment 
Symptom score 
Symptom scores are shown in the Table 1. Because a significant carry Rover effect was 
observed, only the results of the first treatment period were used. A significant increase 
was observed immediately after the challenge with house dust mites extnict ill both groups. 
A latc phase reaction occurred in both groups} after which symptoms recurred. The 
symptom score of patients treated with fluticasone propionate aqueous nasal spray was 
significantly decreased in comparison with the placebo group at all time points examined. 
Table 1: Mean (SE) symptom scores of patients allergic to house dust miles treated with placebo or with 
fluticasone propionate aqueous nasal spray. b=baseline before challenge; PBS=iavage after challenge with 
phosphate buffered saline; h l,h2 and h3=lavages after challenge with resp. 100, 1000 and, 10 000 biological 
units (BU)/ml house dust mite extract; sl-slO=lavages obtained every hour after the challenge with 10 000 
BUlntl house dust mite extract. 
Placebo FluNcasone 
propionate 
Baseline 0.67 (0.19) 0.29 (0.13) 
PBS 2.25 (0.48) 1.79 (0.49) 
hi 3.50 (0.61) 2.00 (0.46) 
h2 4.38 (0.69) 2.79 (0.47) 
h3 6.17 (0.63) 3.67 (0.51) 
sl 3.58 (0.55) 2.00 (0.41) 
s2 2.13 (0.41) 1.04 (0.28) 
s3 1.54 (0.37) 0.71 (0.19) 
s4 1.00 (0.30) 0.35 (0.14) 
s5 1.04 (0.36) 0.26 (0.14) 
s6 1.58 (0.39) 0.22 (0.13) 
s7 1. 71 (0.44) 0.30 (0.13) 
s8 1.63 (0.47) 0.48 (0.23) 
s9 1. 79 (0.45) 0.48 (0.19) 
slO 0.71 (0.25) 0.22 (0.13) 
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Nasal nitric oxide levels 
The levels of nitric oxide in nasal washings from patients allergic to house dust mite 
treated with fluticasone propionate aqueous nasal spray and with placebo are presented in 
the Figure I (pat1 A). No significant carry-over effect was observed, but because a 
significant carry-over effect was observed for the symptom score only the results of the 
first treatment period were used. The levels of nitric oxide decreased significantly after the 
four basal washings. Nasal provocation with house dust mite extract caused no inunediate 
release of nitric oxide but levels increased during the hours thereafter. No effect of 
fluticasone propionate on production of nitric oxide was observed in comparison with the 
placebo-group, nor was there any effect on the nitric oxide content in the first lavage 
sample (hI). 
COlltrol experiments 
The levels of nitric oxide in nasal washings from healthy volunteers, with and without 
nasal challenge with PBS, (Figure 1, part B) were significantly decreased after the four 
basal washings. Nasal challenge with PBS caused no immediate release of nih-ix oxide but 
levels increased during the subsequent hours in controls both with and without PBS 
challenge. . 
10.6 Dis~ussioll 
Lavage of the nasal mucosa after nasal challenge appears to be a convenient model for the 
determination of inflammatory mediator release during an allergic reaction to house dust 
mite. Exposure to the antigen in the nose triggers the formation of IgE antibodies which 
bind to receptors on several cells in the respiratory epithelium in the nasal cavities. These 
antibodies crosslink to the antigen, and inflammatory mediators such as histamine, tryptase, 
leukotrienc E4, and eosinophil cationic protein are released. It has been suggested that the 
number of eosinophils and basophilic cells (basophils and mast cells) increase following 
allergen challenge and that this factor is responsible for the initiation of the allergic 
vascular response.30I,514 
Our results show that nitric oxide (nitrite + nitrate) is detectable in nasal lavage fluid and 
shows little individual variation. Levels of nitric oxide decreased significantly during the 
first four basal lavages, indicating that nitric oxide present in the nostrils is washed out. 
Nasal challenge with house dust mite extract in patients with a history of perennial rhinitis 
caused no inullediate synthesis of nitric oxide but the levels gradually increased during the 
hours after the challenge. A similar increase was also observed in the lavage fluid of the 
healthy volunteers, with or without challenge or challenge with PBS. Sequential nasal 
washings probably initiate migration of 11l0nocytes from the circulation to the nasal 
compartment or (re)activation of the monocytes present in the nasal mucosa. These 
l1lonocytes may well be responsible for the gradual increase in endogenous nasal producti-
on of nitrix oxide observed. Another possible explanation is plasma exudation of nitric 
oxide. 
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Figure 1. (A) Mean (SE) levels of nitric oxide metabolites in nasal lavage fluid of patients allergic to 
house dust mite treated with placebo or with fluticasonc propionate aqueous nasal spray (FPANS). 
bl-b4=four basal lavages; PDS=iavage after challenge with phosphate buffered saline; hi, h2 and h3=lavages 
after challenge with 100, 1000, and 10 000 BU/1ll1 house dust mite extract respectively; s l-s 1O=lavages 
obtained every hour after the challenge with 10 000 BU/ml house dust mite extract (time-point: 1t3). 
(B) Mean (SE) levels of nitric oxide metabolites in nasal lavage fluid of controls. bt-b4=four basal lavages, 
PBS, hi, h2 and h3=lavage after challenge with (control I) or without (control 2) phosphate buffered saline; 
sl-slO=lavages obtained every hour after time point h3. 
In another study we have measured plasma levels of nitric oxide in healthy volunteers by 
the same method and have fonnd levels of 24.5 (3.4) ftM. 
In contrast, in the same 24, patients levels of albumin, tryptase, leukotriene E4, 
prostaglandin D2, and platelet activating factor increased inunediately after provocation 
with house dust mite allergen (early phase reaction) and during the late phase reaction 
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eosinophilic cationic protein is released. These mediators were inhibited by treatment with 
fluticasone propionate aqueous nasal spray.219,151 
Pretreatment of the patients with fluticasone propionate aqueous nasal spray twice daily 
for two weeks greatly reduces or prevents the major events in the allergic process - the 
development of symptoms and release of inflammatory mediators, In a study performed in 
17 atopic patients the immediate increase in nasal airway resistance was not inhibited by 
two weeks pretreatment with intranasal fluticasone propionate 200 !1g/day.619 In another 
study the dose of ragweed required to produce a standardised response was unchanged after 
four weeks of treatment with intranasal flllticasone propionate 200 ~lg/day in 49 patients 
during the ragweed season,587 However, in 24 patients with seasonal allergic rhinitis the 
symptom score was improved after nasal challenge with allergen after two and four weeks 
of pretreatment with flllticasone propionate,m Longterm treatment with intranasal 
fluticasone propionate was associated with a significant decrease in the nurnbel' of Jlasal 
eosinophils, basophils, and neutrophils compared with placebo patients with seasonal 
allergic rhinitis. It has been proposed that fluticasone propionate may act by preventing 
activation of these cells and the subsequent release of (chemotactic) inflammatory 
mediators and further influx of cells. 619 
Glucocorticoids are able to inhibit the induction of nitric oxide synthase in the lung ill vivo 
after lipopolysaccharide treatmeneS2 and they block the synthesis of nitric oxide in alveolar 
macrophages in vitro.327 Glucocorticoids inhibit induction of nitric oxide synthase in murine 
macrophagcs156 and the anti-inflammatory effects of glucocorticoids could partly result 
from this inhibition. 
In contrast to the above findings, we did not observe any effect of topically applied 
fluticasone propionate on production of nitric oxide in a cross-over study in patients 
allergic to house dust mites, Both in patients and in controls nasal levels of nitric oxide 
gradually increased with time after a decrease during the four basal lavages, 
Systemically applied glucocorticoids may act by preventing activation of 11lonocytes and 
the subsequent production of nitric oxide. 
In conclusion, synthesis of nitric oxide can be monitored in nasal lavage fluid. Although 
intranasally applied fluticasonc propionate aqueous nasal spray successfully reduced the 
allergen-induced symptoms, the production of nitric oxide after challenge with house dust 
mite extract was not affected. 
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The reduction of symptoms to the corticoid fluticasone propionate of 
patients with perennial allergic rhinitis is not associated with 
glucocorticoid receptor binding characteristics of peripheral blood 
mononuclear cells 
I.M. Garrelds1.2, C. de Graaf-in 't Veld', P.O.H. Mulder 3 R. Gerth van Wijk' and F.J. 
Zijlstra l , 
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Allergology, University Hospital Rotterdam-Dijkzigt, JOepartment of Biostatistics, Erasmus University 
Rotterdam, The Netherlands. 
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11.1 Abstract 
Background - The reduction of symptoms due to treatment with corticosteroids varies 
among patients with perennial rhinitis. Most of the patients will respond, however, a few 
patients respond less to these drugs, 
Objective - To investigate the association in reduction of symptoms due to glucocorticoids 
and glucocorticoid receptor characteristics in patients with perennial allergic rhinitis, in 
vitro glucocorticoid receptor binding studies were performed with peripheral blood 
mononuclear cells using dexamethasone and in vitro production of mediators were 
measured. 
Methods - During a double blind placebo-controllcd cross-over study 200 ~g of the 
glucocorticosteroid fluticasone propionate aqueous nasal spray (in the active treatment 
period) and a placebo (in the placebo treatment period) were administered twice daily for 
two weeks to 22 patients allergic to house dust mite. At the end of either treatment period, 
symptoms were scorcd after an allergen provocation (100, 1000, 10000 BU/ml) and during 
the 9.5 hours after this challenge. In patients the symptom scores will differ between the 
active and placebo treatment period. Interest thus is in the partial correlation of the receptor 
characteristics with the symptom score after allergen provocation at the end of the active 
treatment period and adjusted for the symptom score after allergen challenge at the end of 
the placebo treatment period. Binding studies with dexamethasone were performed with 
peripheral blood mononuclear cells. Leukotriene B4 produced by monocytes in vitro and 
soluble interleukin-2 receptor released by lymphocytes in vitro and cortisol levels in plasma 
were determined. 
Results - No significant partial correlations of the number of the peripheral blood 
mononuclear cell glucocorticoid receptors and the affinity for the glucocorticoid receptors 
with the symptom score after active treatment were found. Also no significant partial 
correlations of the levels of leukotriene B4 produced by monocytes in vitro, soluble 
interleukin-2 receptor released by lymphocytes ill vitro and cortisol levels in plasma with 
the symptom score after active treatment were found. 
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Conclusions The reduction of symptom due to the topical corticosteroid fluticasone 
propionate of rhinitis patients allergic to house dust mite is not correlated with the 
characteristics of the glucocorticoid receptor. 
Keywords: glucocorticoid-receptor; fluticasone propionate aqueous nasal spray; perennial 
rhinitis 
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11.2 Introduction 
Perennial rhinitis, which is characterized by chronic nasal symptoms of obstruction, 
rhinorrhoea, sneezing and itching is caused by house dust mite. Treatment with intranasal 
corticosteroids relieves symptoms of rhinitis in the majority of the patients, however, some 
patients respond less to these dmgs. In other diseases, such as asthma and eosinophilic 
gastritis symptoms sometimes do not reduce, which is called corticosteroid-
resistance.J.41"m.686,69o In allergic rhinitis this phenomenon is not known. A group of chronic 
asthmatic patients who were clinically resistant to treatment with prednisolone (40 mg daily 
for two weeks) were described by Carmichael in 1981 and corticosteroid resistance was 
defined as an improvement of less than 15% in the forced expiratory volume in one second 
(FEV,)." 
In addition to our earlier study to explore the effect of fluticasone propionate in the early 
and latc phase of the allergic process218,251, We have investigated whether a relationship 
exists between the reduction in symptoms due to corticosteroid treatment and the 
glucoc011icoid receptor characteristics in these same rhinitis patients. During this double 
blind placebo-controlled cross-over study the glucocorticosteroid fluticasone propionate 
aqueous nasal spray was administered to patients allergic to house dust mite outside the 
season. Symptom scores were measured in response to allergen provocation and during the 
9.5 hours following this challenge.2IS,lSl In addition, we have performed binding studies 
with dexamethasone to determine peripheral blood mononuclear cell glucocorticoid receptor 
Hlimber and binding affinity for dexamethasone to investigate if there is a partial 
correlation between the symptom score concluding the active treatment period and the 
receptor characteristics. Mediator release by peripheral blood mOllocytes and lymphocytes 
were also investigated in vitro to measure the activity of these cells. 
11.3 Materials and methods 
PalienlsllS,W 
This study was performed in 22 patients (10 women and 12 men, aged 21 to 50 years 
(mean: 34 years), with a history of perelUlial allergic rhinitis, and a positive skin test to 
house dust mite extract. All patients showed a skin reaction rated as at least one u+u_sign to 
0.3 or 3 BU/ml extract, according to the standardized plus-sign scoring system defined by 
Nonnan:m Six of the 22 patients were allergic to grass pollen or animal dander as well. 
The experiments were performed in January-August to minimize exposure to house dust 
mite, The only patient with a concomitant pollen allergy was tested outside the pollen 
season. None of the patients allergic to animals had pets in their home. Antihistamines 
were withdrawn 72 hours before testing, The antihistamine astemizoie, topical 
corticosteroids, cromogiycate or nedocromil were not used for 3 weeks before the tests 
were performed. Oral corticosteroids had to be withdrawn 2 months before the study. 
Patients who developed a nasal infection during the 2-weeks period before entering the 
study were excluded. None had undergone inUllunotherapy previously. 
The study was approved by the Medical Ethical Committee of the University Hospital 
Rotterdam-Dijkzigt and all patients gave written informed consent. 
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Nasal challenge and symptom score 
After the positive skin test the subjects entered the double blind placebo-controlled 
crossover phase of the study. Each underwent two allergen challenge-periods, performed 
after 2 weeks pretreatment with 200 ~tg fluticasone propionate aqueous nasal spray (Glaxo, 
U.K.) or placebo spray twice daily. A three weeks washout period separated the two 
challenges. Nasal challenges were performed as described before.219,23D,465 The baseline 
symptoms (b) were scored before nasal challenges and were performed as described by 
Lebel el al.m Symptom scores were graded in points: 3-4 sneezes = 1 point; ~5 sneezes = 
3 points; rhinorrhoea anterior = 1 point; rhinorrhoea posterior = 1 point; difficult nasal 
breathing = 1 point; one nostril blocked = 2 points; both nostrils blocked = 3 points; 
pruritus of the nose = 1 point; pnuitus of palate or ear = 1 point and conjunctivitis = 1 
point (total score ranges from 0 till II points). To prevent the most severe nasal congestion 
caused by the allergen challenges 0.250 ml oxymetazoline (0.1%) was sprayed into cach 
nostril 5 min before the first challenge. To obtain a control challenge, 0.125 1111 phosphate 
buffered saline (PBS, containing 0.03% human bovine serum and 0.05% 
bezalkoniumchloride; ALK, Groningen, The Netherlands) was sprayed in each nostril and 
the symptoms were scored. For allergen challenge, 0.125 1111 allergen extract was sprayed 
in each nostril and 10 min thereafter the symptoms were scored. Allergen doses of 100, 
1000, 10000 Biological Units (BU)/ml (extract of Dermatophagoides pteronyssinus; ALK, 
Groningcn, The Netherlands) were administered (h1-h3). From 30 min up to 9.5 hours 
aller this challenge the symptoms were scored every hour (sl-sIO). 
Blood dOl/ors 
At the time point of blood-collecting none of the patients had used pharmaceutical 
compounds as described before, which could have interfered with the herewith described in 
vitro studies. 
In total 64 1111 venous blood was collected into Iithitllll-heparin~coated tubes (5 x IOml, 
heparinized-blood; VacutainerR, Becton-Dickinson, France) and Ethylenediamine tetra-
acetic acid (EDTA KJ)-coated tubes (2 x 7ml, EDTA-blood; Vacutainer'\ Jlecton-
Dickinson, France) from each patient. An aliquot (I tnt) of the heparinized-blood was 
centrifugated at 4000 rpm for 10 min at 20 'c and the plasma was stored at -80 'C until 
measurement of cortisol levels. 
Peripheral blood mononuclear cell (PBMC) isolation and glucocorticoid receptor 
characteristics 
The method used was described before. 126,J67,J68 Heparinized-blood (50 ml) was mixed with 
an equal volume of PBS. Aliquots (20 ml) were layered onto 10 ml Ficoll-Paque 
(Pharmacia Biotech., Uppsala, Sweden) in 50 ml sterile polypropylene tubes. After 
centrifugation at 1000 x g for 15 min at 20 'C peripheral blood mononuclear cells (PBMC) 
were removed from the plasmaiFicoll interphase using gentle suction, transferred to sterile 
50 ml polypropylene tubes, and washed twice with 15 ml DMEM (Dulbecco's modified 
Eagles medium containing 25 mM HEPES (GIBCa, Life Technologies, The Netherlands), 
supplemented with 2% Penicillin-Streptomycin (leN Biochemicals, Inc) and 10% Foetal 
Calf SenUll (GIBCa, Life technologies, The Netherlands). Total PBMC isolated (approx. 
5-10 x 107 cells) were resuspended in 151111 DMEM and incubated for 30 min in a shaking 
waterbath at 37°C to remove endogenous bound glucocorticoid. 133 After centrifugation (5 
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min at 400 x g) the cells were resuspended in 15 ml DMEM and incubated again for 30 
min under the same conditions in a water bath. This was repeated once. After centrifugation 
PBMC were resuspended in DMEM at IxlO'cells/ml. 
Stock solution of 3H-dexamethasone (specific activity 89 Ci/mmol; total concentration 1.0 
mCi in I ml ethanol; Amersham, The Netherlands) was further diluted in DMEM to final 
concentrations of 64, 32, 16, 8, 4, 2, I and 0.5 nM. Non-labelled, ncold ll dexamethasone 
(Sigma, U.S.A.) was diluted in DMEM to final concentrations of 6.4, 3.2, 1.6, 0.8, 0.4, 
0.2, 0.1 and 0.05 ~tM. For measurements of non-saturable binding (in duplicate), aliquots 
(100 fll) of PBMC suspensions were mixed with 50 fll aliquots of the 3H-dexamethasone 
dilutions and also 50 pi aliquots of the "cold" dexamethasone. For measurements of the 
total binding (in threefold), aliquots (100 fll) of PBMC suspensions were mixed with 50 f" 
aliquots of the 'H-dexamethasone dilutions and also 50 fll aliquots of DMEM. After 
incubation for I hoUl' at 30°C in a shaking waterbath the reaction was stopped by adding 2 
ml ice-cold PBS. The cells were harvested onto glass microfibre filters using a cell 
harvester apparatus (Millipore Corporation, U.S.A.) and washed twice with 4 ml ice-cold 
PBS. These glass fibre filters were added to 7 ml Emulsificr-scintillator-plusR liquid 
(Packard, U.S.A.), incubated over night and the incorporated radiolabel counted using a 
betacounter (Packard, U.S.A.). To measure the amount of added tritiated dexamethasone, 
aliquots of 50 fll were added to 7 ml scintillation liquid and counted. 
Data analysis was performed by construction of a Scatchard plot after subtraction of 
nonspecific dexamethasone binding calculated from the tubes containing the cold 
dexamethasone, assuming that nonspecific binding was nonsaturable and linearly related to 
the concentration of free glucocorticoid in the supernatants. 
PBMe isolation and culiure for leukotriene B, (LTB) and soluble interieukin-2 receptor 
(IL-2 SR) measurements 
EDTA-blood (14 ml) was mixed with an cqual volumc of PBS. Aliquots (14 ml) were 
layered onto 7 ml Ficoll-Paque (Pharmacia Biotech., Uppsala, Sweden) in 50 ml sterile 
polypropylene tubes. After centrifugation at 1000 x g for 15 min at 20°C, PBMC were 
removed from the plasmafFicoll interphase llsing gentle suction, transferred to sterile 15 ml 
polypropylene tubes, and washed twice with 14 ml DMEM, (containing 25 mM HEPES, 
2% Penicillin-Streptomycin and 10% Foetal Calf Serum). PBMC isolated were resllspended 
in DMEM at IxlO'cells/ml. Aliquots (2ml) of this cell suspension were added together 
with 8 ml DMEM in sterile flatbottom culture flasks (75 cm2; Costar) and were incubated 
for I hour at 37°C, 7.5% CO,. After this hour a) the supernatant (containing primarily the 
lymphocytes) was collected and b) to the adherent mononuclear cells consisted primarily of 
monocytes, 5 ml DMEM with or without I f-lM Calcium-ionophore (A23 187, Sigma 
U.S.A.) was added. After 15 min incubation at 37°C, 5% CO, the supernatant of the 
monocytes-suspension was collected and stored at ~80°C until measurements of L TB4, as a 
.. narker of the activity of monocytes. The lymphocytes-suspension was centrifugated at 400 
x g for 5 min at 20°C and aliquots (Iml) of this supernatant were stored at -80°C (t~O) 
until measurements of IL-2 SR. The cells were resuspended in DMEM at a concentration 
of 2x 10' cells/ml and aliquots with and without Phytohemagglutinin (PHA, 20 flg/ml; 
Difco Laboratories, U.S.A.) were transferred to flatbottom 24 wells cell-dishes (Costar, 
U.S.A.). Culture plates were incubated for 48 hours at 37°C, 7.5% CO" whereafter the 
supernatants were collected and stored at -80°C until determination of IL-2 SR, as a 
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marker of the activity of lymphocytes. 
Assays of LTB,. 1L-2 SR and corliso/ 
The levels of LTB" IL-2 SR and cortisol were measured by respectively 
RadioImmunoAssay (RIA; 3H-LTB4: Amersham, U.K.; antibody: Advanced Magnetics Inc., 
U.S.A.), Enzyme-Linked InllllunoSorbent Assay (ELISA; soluble IL-2 receptor; 
Eurogenetics, The Netherlands) and RIA (Coat-a-count cortisol; Diagnostic Products 
Corporation (DPC), The Netherlands). The limits of sensitivity of the assays were 
respectively 7.5 pg/ml, 20 Ulml and 5.5 pmollml. Cross-reactivity (50% BlBo 
displacement) of the LTB4 assay: Lcukotrienes «1.00%) and Prostaglandins «1.00%) and 
of the cortisol assay: Prednisolon (76%), II-Deoxycortisol (11.4%) and Prednisone (2.3%). 
11.4 Statistical analysis 
Statistical analysis was performed with the Friedman two-way analysis of variance 
(ANOV A) followed by the Wilcoxon matched-pairs signed-ranks test for the symptom 
score and the Students T-test for the mediators and other parameters. Values are expressed 
as mean (standard deviation: SD). 
The mean of the symptom score during the early phase reaction (EAR: hI to sl) is 
calculated for each patient in the placebo and fluticasone treatment period as a marker of 
responsiveness. Interest thus is in the partial correlation of the receptor characteristics with 
the symptom score after allergen provocation at the end of the active treatment period and 
adjusted for the symptom score after allergen challenge at the end of the placebo treatment 
period. The partial correlation coefficient (R) is estimated and tested, after logarithmic 
transformation of the Kd• number of receptor sites, cortisol levels and L TB4 levels, because 
of their positive skewness; the levels of 11-2 is not transformed. 
A p-value of :::;0.05 was considered significant. 
11.5 Results 
Symptom score 
The means (SD) of the symptom score of the patients are shown in Figure 1. A significant 
increase of the symptom score was observed immediately after the challenge with house 
dust mite extract in the placebo and fluticasone propionate-group (EAR) and also a late 
phase reaction was seen (LAR). The means (SD) of the meall~symptom scores during the 
EAR of the placebo and ilutieasone treatment period were 4.3 (2.45) pts [range 0.75 -
8.75; median: 4.4] and 2.4 (1.55) [range 0 - 5.8; median: 2.3] respectively. 
Glucocorticoid receptor characteristics 
The Scatchard plot was linear and the mean (SD) of Kd for dexamethasone was calculated 
16.5 (13.51) nmolll [range 2.28 - 51.4; median: 1l.3]. Furthermore, the mean (SD) of 
receptor numbers were 6821 (5669) binding sites per cell [range 397 - 21468; median: 
6010]. 
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Figure 1. Means (SO) of symptom scores of the patients allergic to house dust mite at the end of the 
placebo treatment period and the fluticasone propionate treatment period. b: baseline score, pbs: score after 
challenge with phosphate buffered saline, hI, h2, and h3: score after allergen provocation with 100, 1000 and 
10000 8WIllI house dust mite extract respectively, sl·slO: scores obtained every hour after time point h3. 
Measurements of LTB,. IL-2 SR and cortisol 
Mean (SD) L TB.; production as a marker of the activity of monocytes in vitro after 
addition of 1.0 flM A23187 for 15 min was 45.6 (105.3) [range 2.49 - 457.4; median: 
13.1] ng/lO' monocytes. L TB4 levels without stimulation with A23187 for 15 min were not 
detectable. Mean (SD) IL-2 SR levels as a marker of the activity of lymphocytes in vitro 
after stimulation with 20 pg/ml PHA for 48 hours were 734 (237) [range 342 - 1245; 
median: 689) ngll 0' lymphocytes. IL-2 SR levels at t~O and without stimulation with PHA 
for 48 hours were not detectable. Mean (SD) cortisol levels in plasma were 571 (236) 
[range 248 - 1186; median: 541]ng/ml. 
Associations 
No significant partial correlations of the number of receptor sites (R~-0.2518; p~0.2984) 
and K, (R~-0.3412; p~0.1528) with the symptom score concluding the active treatment 
period were found. Also no significant partial correlations of LTB, (R~-0.0812; p~0.7412), 
IL-2 SR (R~-0.0892; p~0.7165) and cortisol levels (R~0.0047; p~0.9849) with the 
synlptom score after active treatment were found. 
Only a significant correlation was found between the means of the symptom score during 
EAR of the placebo treatment period and the means of the symptom score during EAR of 
the fluticasone treatment period (R~0.5590; 1'=0.007). 
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11.6 Discussion 
In this study treatment of rhinitis patients allergic to house dust mite with fluticasone 
propionate for two weeks twice daily in general reduces the development of symptoms due 
to a provocation test. Response to treatment with the corticosteroid varies among these 
patients. Most patients responded, however, a few patients responded less to this drug. 
Thomas and coworkers performed a study with 17 atopic patients in which the immediate 
increase in nasal airway resistance tended to decrease after a 2 weeks pretreatrnent with 
fluticasone propionate 200 ~lg/day (p=0.089).619 However, the symptom score was 
decreased in 24 patients with seasonal allergic rhinitis after nasal challenge with allergen 
and 2~4 wks pretreatment with fluticasone propionate. 294 
One possible mechanism for the failure of cells not to respond to glucocorticoids could be 
an abnormality in the affinity (l/Kd) or a lower number of glucocorticoid receptors. In 
order to assess whether an association exists between glucocorticoid receptor affinity and 
number and the reduction of symptoms due to glucocorticoid in rhinitis patients, we have 
determined the Kd and number of receptor sites per cell of the glucocorticoid receptor of 
PBMC in perennial rhinitis patients. There was no significant partial correlation of the Kd 
or number of receptor sites with the symptom score concluding the active treatment period 
with fluticasone propionate, while adjustment had been made for the symptom score 
concluding the placebo treatment period. The Kd in PBMC from rhinitis patients was 
higher than those reported previously for monocytes and total mononuclear cells from 
normal individuals (2-8 nmolll), but the number of receptor sites per cell (I -9 x 10') was 
similar [17~ 19].102,391.681 Previous studies in ollr laboratory showed that normal individuals 
(n~9) have a Kd for dexamethasone of 11.0 ± 1.30 nmolll and 4430 ± 340 receptor sites 
per cell of PBMC4I2, from which it was concluded that no significant difference exists 
between rhinitis patients and normal individuals. These results suggest that the 
glucocorticoid receptors are not associated with responsiveness of rhinitis patients to the 
corticosteroid, which is supported by the finding that there is no significant partial 
correlation found of plasma levels of cortisol and responsiveness to fluticasone propionate. 
In asthmatic patients other investigators were unable to demonstrate any significant 
difference in either glucocorticoid receptor density or binding affinity to dexamethasone in 
PBMC between corticosteroidasensitive and aresistant patients, suggesting that the 
molecular defect was not due to abnormal receptor number or function. J68 This is in 
contrast with Corrigan el al., who did not observe a difference in dexamethasone receptor 
density, but found that glucocorticoid receptors from PBMe in c011icosteroidal'esistant 
asthmatics had a significantly lower binding affinity for dexamethasone than that in 
corticosteroid-sensitive patients. 126 Lcung eJ al. performed a study with asthmatics and 
found prior to prednisone therapy a significant greater number of bronchoalveolar cells 
expressing IL-2 mRNA and IL-4 mRNA in resistant astlunatics compared with sensitive 
patients. After one week treatment with prednisone the sensitive patients had a significant 
decrease in the number of cells expressing rnRNA for IL-4 and IL-5 and a rise in the 
numbers of Interferon-gamma mRNA expressing cells. The resistant asthmatics had no 
significant change. This indicated that steroid~resistant astIuna is associated with a 
dysregulation of the expression of the genes encoding for cytokines.382 This is sliPP0l1ed by 
the findings of Sher eJ ai, who found that 15 of the 17 resistant asthmatics demonstrated a 
significant reduced glucocorticoid receptors binding affinity as compared with sensitive 
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patients. This defect was localized to T -cells, which reverted to normal in culture media. 
However, incubation with a combination of IL-2 and IL-4 sustained this abnormality. The 
other two resistant patients had an abnormally low glucocol1icoid receptor number with 
normal binding affinity that was not limited to T -cells, which failed to normalize after 
incubation in media alone or IL-2 and IL-4. Sher suggested that corticosteroid resistant-
asthma may be due to more than one abnormality, the majority related to a reversible 
cytokine-induced reduction in glucoc0l1icoid receptor binding affinity and the second 
related to an irreversible reduction in glucocorticoid receptor number.577 
Recent studies in our laboratory showed that corticosteroid-resistant ulcerative colitis 
patients had a significant lower number of glucocorticoid receptors from PBMC.412 
\Ve also performed an in vitro study with PBMC of the rhinitis patients to investigate if 
there is an association between the activity of monocytes and lymphocytes and 
. responsiveness to the corticoid. L TB4 production in monocytes after stimulation with 
A23l87 and IL-2 soluble receptor release in the lymphocytes after stimulation with PHA 
were not significantly partial correlated with the reduction of symptoms after allergen 
challenge. Lane et al., who found that the generation of cytokines, such as TNF-a, IL-IB 
and OM-eSF, from monocytes was not affected by treatment with hydrocortisone in either 
corticosteroid-sensitive or -resistant asthmatic patients.369 It is known that corticosteroids 
decrease T-lymphocyte proliferation and activation, which is mediated by the inhibition of 
IL-2 production. Induction of lipocortin synthesis, an inunullomodulatory protein which is 
capable of suppressing phospholipase A2, by corticosteroids inhibits the formation of 
arachidonic acid-derived metabolites.139.219 
In conclusion, The reduction of symptoms due to treatment with fluticasone propionate of 
rhinitis patients allergic to house dust mite is not correlated with the characteristics of the 
glucocorticoid receptors of their PBMC. 
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Antihistaminic intervention 
Histamine produces its action by an effect on specific histamine receptors, which are of 
three main types, HI, H2 and HJJ distinguished by means of selective antagonists, HI 
receptors are found in human and guineaRpig bronchial muscle, and in guinea-pig ileum; 
stimulation causes contraction of the muscle. HI receptors afC linked to transduction 
systems which increase intracellular Ca2+. Occupancy of HI receptors results in the 
stimulation of phosphatidyl inositol turnover and the subsequent production of the second 
messengers inositol 1,4,5-triphosphate (IP ,) and 1,2-diaeylglyeerol (DAG), whieh results in 
an increase in intracellular caicium.2S6,440 
In asthma patients they have a mild, dose-related bronchodilator effect, and they protect 
against bronchoconstriction by stimuli stich as exercise, hyperventilation, inhalation of cold 
air, histamine or antigen,155,528,628 
Rhinitis: The second-generation histamine HI receptor antagonists are now widely used for 
the prevention and relief of sneezing, itching and rhinorrhoea in patients with allergic 
rhinoconjunctivitis and rhinitisI99,342,434, but they did not improve nasal obstruction,35-4 In 
addition to their HI-blocking activities, some of the second-generation compounds have 
antiallergic properties as shown by a reduction in the release of mediators of inflammation, 
such as histamine, PGD2 and LTC4 from mast cells and basophils,99,398,462,464,621 They also 
inhibit recruitment of inflammatory cells such as eosinophils, neutrophils and basophils to 
the site of the allergic reaction, suppressing both the em'ly and late phase response to 
allergen,99,17o,439 Levocabastine inhibited the allergen-induced nasal reactivity to histamine 
and the cellular influx in patients with perelUliai rhinitis503, which suggest that levocabastine 
could also have anti-inflanullutory propel1ies. 
103 

Chapter 13 
Effect of topical levocabastine on nasal response to allergen challenge 
and nasal hyperreactivity in perennial rhinitis 
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13.1 Abstmet 
Background: It has been demonstrated that some oral antihistamines reduce non-specific 
nasal reactivity and that topical levocabastine reduces cellular influx after nasal allergen -
challenge. This suggests that antihistamines possess other properties besides the classical 
histamine HI receptor antagonism. 
Olijeclive: To evaluate the effect of one week's treatment with topical levocabastine on the 
nasal clinical response, inflammatory mediators and nasal hyperreactivity . 
.A1etllOds: In a double-blind, placebo-controlled, two-period, two-treatment, crossover study, 
21 rhinitis patients allergic to house dust mite participated. After each treatment period 
paticnts were challenged with house dust mite extract. Symptom scores and nasal lavages 
were collected for 9.5 hours aftcr challenge. 
Allergen-induced nasal hyperreactivity was determined by nasal methacholine challenge 24 
hours after alllergen challenge. A nasal histamine challenge was performed as well. 
Results: Patients showed only an immediate nasal response. Levocabastine significantly 
reduced the symptom score after 100 (p~0.0063), 1000 (p~0.0035) and 10,000 biological 
units (BU)/ml (p=O.OOI3) of house dust mite extract. Albumin influx and tryptase release 
were not significantly reduced by levocabastine. No release of histamine and eosinophil 
cationic protein was seen. Levocabastine did not reduce nasal response to methacholine. 
Active treatment significantly reduced histamine-induced nasal secretion (p=O.0009) and the 
Ilumber of slleezes (p~0.000 I). 
Conclusion: A significant effect of levocabastine was shown on the iIll.mediate clinical 
response to house dust mite and to histamine challenge only. Our findings suggest that 
levocabastine is an effective HI receptor antagonist without anti-inflammatory properties. 
Keywords: levocabastine; perennial allergic rhinitis; nasal hyperreactivity; inflammation 
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13.2 Introduction 
It is generally accepted that histamine, released locally from mast cells, is one of the major 
mediators459 responsible for most symptoms in allergic rhinitis. In the symptomatic 
treatment of allergic rhinitis, oral HI receptor antagonists are widely used.582 Topical 
treatment is preferred however, to prevent systemic side-effects and to obtain locally 
therapeutic drug concentrations. Oral antihistamines administered locally are not very 
effective. so7,5!! In contrast, topical levocabastine, a new selective HI receptor antagolllst2J, 
has proved to be very effective in suppressing sneezing and rhinorrhoea in pollinosis 
patientsm. In a recent study, Pazdrak503 demonstrated an inhibitory effect of levocabastinc 
on allergen-induced nasal reactivity to histamine and cell influx in patients with perennial 
rhinitis. This suggests that levocabastine possesses other properties apart from being a HI 
receptor antagonist. KlementssonJ47 showed that some oral antihistamines inhibit the 
increased response to a non-specific stimulus (methacholine). 
To determine if levocabastine has other properties besides the HI receptor antagonism, we 
studied its effect on the release of inflammatory mediators in lavage fluid in response to 
nasal house dust mite challenge. Allergen-induced nasal hyperreactivity was determined by 
nasal methacholine challenge. 
Nasal histamine challenge was also performed. However, since levocabastille is a HI 
receptor antagonist, nasal histamine challenge cannot be used to study the effect of 
levocabastine on nasal hyperreactivity. 
13.3 Methods 
Subjects 
Twenty-one patients, 13 women and 8 men aged 19 to 54 years (mean 33 yrs), with a 
history of perelUlial rhinitis participated in this study. They all had a positive intradermal 
skin test at 3 BU/ml of house dust mite extract (Dermatophagoides pteronyssinus extract, 
ALK Benelux, Gronillgell, the Netherlands), according to the standardised plus-sign scoring 
system defined by Normatt'H7. If patients had a concomitant allergy, they were only 
included if exposure to the allergen could be avoided. 
Symptomatic medications for rhinitis had to be discontinued: oral corticosteroids 2 nlOnths, 
astemizol 6 weeks, nasal or inhaled corticosteroids, cl'Omoglycate and nedocl'Omil 3 weeks 
and antihistamines 3 days before the start of the study. Patients with nasal polyposis, nasal 
surgery in the 3 months preceding the study, nasal infection during the 2 weeks preceding 
the study or immunotherapy in the previous year were excluded. 
Study design 
A double-blind, placebo-controlled, two-period, two-treatment. crossover study comparing 
levocabastine with placebo was performed. Patients used a nasal spray containing either 
levocabastine (0.5 mg/ml solution) or placebo, twice daily for one week. The treatment 
periods were separated by 2 weeks. After either treatment period patients were challenged 
with house dust mite extract. Symptom scores were recorded atld nasal lavages were 
performed lip to 9.5 hours after allergen challenge. Nasal methacholine challenge was 
performed 24 hours after allergen challenge, followed one hour later by nasal histamine 
106 
Effect of topicallevocabastine .. , 
challenge. During the provocation days, patients continued their study medication. 
The study was performed during the period January-August, to minimise natural exposure 
to house dust mites, All patients gave written informed consent. The study protocol was 
approved by the Medical Ethics Committee of the University Hospital. 
Nasal challenge tests 
Challenges Were performed in accordance with the methods described by Gerth van Wijk et 
{{(lJo. On each occasion the patients used their nasal spray and subsequently waited for half 
an hour before the test in order to acclimatise the nasal mucosa. 
Challenge with house dust mite extract 
Challenges with house dust mite extract (100, 1000, and 10,000 BU/ml, ALK Benelux, 
Groningen, the Netherlands) were performed at telHninute intervals after challenge with 
phosphate-buffered saline, containing human serum albumin 0,03% and benzalkonium 
chloride 0.05% (ALK Benelux, Oroningen, the Netherlands). 
House dust mite extract was sprayed into each nostril with a nasal pump spray delivering a 
fixed dose of 0,125 ml solution, Nasal response was monitored 10 minutes after each 
challenge, and hourly from 0.5 till 9,5 hours after the last challenge, Nasal response was 
monitored by the number of sneezes, the volume of secretion collected according to 
BOl'l..1m68, a symptom score according to Lebelm , and mediators in nasal lavage fluid, 
Methacholine challenge 
Methacholine bromide (32 mg/ml) was sprayed in each nostril, 15 minutes after nasal 
challenge with phosphate-buffered saline, Nasal response was measured by the volume of 
secretion68 and albumin influx in Basal lavage fluid, 
HistamiJle challenge 
Nasal challenge with histamine phosphate (0.25, 0.50, 1.0, 2.0 and 4 mg/ml) was 
performed at five-minute intervals after challenge with phosphate-buffered saline. The 
volume of secretion and the number of sneezes were used as indicators of nasal response, 
We assume the histamine challenge is not influenced by the preceding methacholine 
challenge, since Gronborg261 demonstrated that repeated nasal challenges with histamine 
and methacholine do not increase nasal reactivity. 
Nasal lavage 
Nasal lavages were perfonned as described by Naclerio.465 This protocol comprises 4 pre-
challenge lavages to clear the nose of secretions and to obtain baseline levels of mediators. 
To maintain nasal patency after allergen challenge, oxymetazoline 0.1% (two 0.125 mi 
puffs) was sprayed into both nostrils. 
In each nostril 5 ml isotonic saline solution (0.9%) preheated to 3TC was instilled with a 
pipette while the subject gently flexed his/her head backwards. After 10 seconds, the lavage 
fluid was expelled and collected in tubes, The recovelY was 7.8 ± 0.9 ml. 
Symptom score 
Symptoms were recorded using a scoring system according to Lebel et al,m, immediately 
before the corresponding lavage. Symptom scores were 'graded in points (pts): 3-4 
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sneezes=l pt, ~5 sneezes=3 pts; anterior rhinorrhoea=l pt; posterior rhinorrhoea=l pt; 
difficult nasal breathing~ I pt, one nostril blocked~2 pts, both nostrils blocked~3 pts; 
pruritus of the nose= 1 pt; pruritus of palate or ear= I pt and conjunctivitis= 1 pt (total score 
ranges from 0 till II pts). 
Mediator assays 
Lavage fluid was stored on ice and centrifuged for 10 minutes at 400 x g. The supernatant 
was stored at _20°C. Histamine was measmed with an automated fiuoromctric assay. 586 
Tryptase and eosinophil cationic protein were determined by radioinununoassay (RIA), 
according to the manufactmer's instructions (Phannacia, Uppsala, Sweden), albumin was 
determined by automatic kinetic nephelometry with use of the Array analyzer (Beckmann, 
Mijdrecht, the Netherlands) according to the manufacturer's instructions. 
13.4 Statistical analysis 
Ten patients received the levocabastine nasal spray during the first treatment period and 11 
during the second treatment period. There was no carry-over effect between the two 
groups. The effect of levocabastine on the inullediate and late (area under the curve (AUC) 
between 3.5 and 9.5 hI's) nasal reaction, on nasal hyperreactivity (response to methacholine) 
and response to histamine (AUC of histamine dose response curve) was tested by the 
nonparametric Mann-\Vhitney U test. A two-tailed p-value < 0.05 was considered 
significant. 
13.5 Results 
Nasal allergen challenge resulted in an inullediate clinical response only. Levocabastine 
significantly reduced the symptom score after I 00 (p~0.0063), 1000 (p~0.0035) and 10,000 
BU/ml (p~O.0013) of house dust mite extract (fig. la). The secretory response was 
significantly reduced after 1000 (1.0±0.28 vs 0.83±0.24, p~0.0206) and 10,000 BUlml 
(1.91±0.33 vs 1.45±0.38, p~0.0376), the same was true of the number of sneezes 
(2.52±0.83 vs 1.57±0.58, p~0.0185; 8.14±1.l7 vs 3.1±0.9, p~0.0007). Albumin influx was 
seen after nasal challenge with the highest allergen dose; Levacobastine did not reduce this 
influx (fig. Ib). Patients showed increased histamine levels after phosphate-buffered saline, 
but not after allergen challenge. There was no significant treatment effect (fig. Ie). No 
significant release of eosinophil cationic protein in response to allergen challenge was 
detected; no effect of levocabastine on it was seen (fig. Id). 
Since in a previous study, tryptase release could not be detected during the late-phase 
response250, we measured tryptase during the immediate response only. Tryptase release 
was observed after the highest allergen dose; treatment with levocabastine did not decrease 
this release (fig. 2). 
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Figul'e 1. Nasal response to HDM challenge 
Figure la: symptom scores; b: albumin; c: histamine; d: eosinophil cationic protein. Nasal response to 
allergen challenge in placebo and levocabastine treated groups measured for 9.5 hours after allergen 
challenge. Values are presented as mean ± standard eITor of the mean (SEM). Abbreviations; b; baseline 
symptom score, bl-b4: four pre-lavages, c; 10 min after challenge with phosphate-buffered saline, hl-h3: 10 
min after challenge with 100, 1000 and 10,000 BU/ml house dust mile extract respectively, * = two-sided p-
valuesO.OS. 
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In figure 3 the results of methacholine provocation are demonstrated. Patients showed a 
secretory response (fig. 3a) and a slight albumin influx (fig. 3b) after phosphate-buffered 
saline; methacholine did not further increase this response. Levocabastine did not reduce 
the amount of secretion or the albumin influx. 
In figure 4 histamine dose response curves are shown. One week on levocabastine 
significantly decreased the Ave of the number of sneezes (p~O.OOOI) (fig. 4a) and the 
amount of secretion (p~0.0009) (fig. 4b). 
13.6 Discussion 
Nasal response to allergen challenge was monitored by a nasal symptom score up to 9.5 
Ius. Sypmtoms reached a maximum to minutes after the highest allergen dose and returned 
to baseline levels at 3.5 hours. No recurrence of sym.ptoms was observed during 3.5 and 
9.5 hours, the period of the late-phase response. 505 The allergic response was also 
monitored by assessment of mediators in nasal lavage fluid. Albumin influx, as a marker of 
increased vasopenneabilitlS,60.', could be detected only during the immediate response. 
To study if levocabastine has any anti-inflammatory effects, we paid particular attention to 
the mediators histamine, tryptase and eosinophil cationic protein. It is generally accepted 
that mast cell derived histamine is the principal mediator causing most of the symptoms 
during the immediate allergic reaction. However, we observed an increase of histamine in 
response to phosphate-buffered saline only; no increase of histamine was seen after allergen 
chalJenge. Results concerning histamine release in lavage fluid are not consistent: some 
studies did not show histamine release either229,39\ while others showed an significant 
histarnine release14~,467 after allergen chalJenge. Assessment of histamine in nasal lavage 
fluid therefor appears unsuitable for monitoring the allergic response. Tryptase, as a 
specific marker for mast cell activation560, was only measured during the immediate 
response. In other studies5J6.625, tryptase was also found to be a useful marker of the 
immediate nasal reaction. Eosinophil cationic protein, released from activated eosinophils, 
can be used to measure the latc-phase response.42 However, in this study no significant 
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Figure 3. Secretory response (Figure 3a) and albumin influx (Figure 3b) after Ilasal challenge with 
methacholine, Response to methacholine was not significantly increased as compared with response to 
phosphate-buffered saline, Levocabastine treatment did not significantly reduce the secretory response or the 
albumin influx, Abbreviations: bl-b4: four pre-lavages, Values are presented as mean ± SEM. 
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levocabastine treated groups. Values are presented as Illeau ± SEM. The Aues of the two treatments groups 
are compared. 
release was measured during 3.5 and 9,5 Ius, corresponding to the absence of albumin 
influx and recurrence of symptoms during the late-phase period. 
\Ve monitored the allergic response for 9,5 Ius, because in case of a late-phase response an 
increase of inflammatory cells and mediators is expected, Therefore, this period is suitable 
to study anti-inflammatory effects of drugs. In contrast to previous studies2so,46s, this study 
revealed no increased nasal symptoms, eosinophil cationic protein release or albumin influx 
during this period, Since the patients also showed a milder immediate response than in 
previous studies229,46s, the threshold for developing a late-phase response may not have been 
reached. 
During the inmlediate response the influx of albumin and the release of tryptase after the 
highest allergen dose were not inhibited by levocabastine, Schwartz et al. sM recently 
developed a new, more sensitive immunoassay for tryptase. Using more sensitive assays, a 
treatment effect might be more easily detectable, Levocabastine significantly inhibited the 
clinical response after allergen challenge, Since no release of histamine and eosinophil 
cationic protein was measured in lavage fluid, an effect of levocabastine could not be 
evaluated. Accordingly, in this study levocabastine appeared to have no effect on nasal 
inflammation (Le, on tryptase during the inunediate response). This in contradiction to 
Pazdrak503, who described an inhibitory effect of levocabastinc on influx of inflammatory 
cells 2 hours after house dust mite challenge. However, since Pazdrak did not study 
inflanunatory mediators or activation of cells the results of our studies are difficult to 
compare. Furthermore, since we lIsed half the dose Pazdrak used, our dose of levocabastinc 
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may not have been sufficient to affect the inflammatory markers. 
Allergen-induced nasal hyperreactivity was determined by nasal challenge with 
methacholine. Patients already showed a clear secretory response to the preceding 
phosphate-buffered saline (0.89 ± 0.24 ml) without additional increase after the metha-
choline challenge (0.92 ± 0.15 ml). The same was true of albumin influx in lavage fluid. 
This increased response to phosphate-buffered saline suggests that the nasal mucosa is 
reactive to the challenge (by nasal pump spray) itself. This may reflect a form of nasal 
hyperreactivity, perhaps an increased responsiveness to mechanical stimulation. When we 
compare this response with the other phosphate-buffered saline challenges in this study, 
preceding the house dust mite and the histamine challenge, nasal secretory responses were 
only 0.32 ± 0.16 ml and 0.17 ± 0.08 ml, respectively. Probably the nasal mucosa had 
become so reactive due to the combination of the preceding allergen challenge and the 4 
prewashings immediate prior to the phosphate-buffered saline challenge. Levocabastine did 
not prevent this nasal reactivity. 
Provocation with histamine was performed I hour after the methacholine challenge. 
Secretion and number of sneezes were both significantly decreased by levocabastine 
treatment, which clearly demonstrates the HI receptor antagonist effect. 
In conclusion: Levocabastine significantly decreased the clinical nasal response to house 
dust mite and histamine challenge, as expected by histamine inhibition, but it did not 
decrease albumin, tryptase and nasal hyperreactivity as measured by methacholine 
challenge. 
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14.1 Abstract 
Background: Levocabastine is a potent histamine HI receptor antagonist which is used 
topically in the treatment of patients with allergic rhinitis. It has been suggested that 
antihistamines also have anti-inflammatory properties. 
Objective: The present study was performed to investigate whether levocabastine, in 
addition to the anti-HI receptor activity, has anti-inflammatory properties and thus is able 
to modulate the release of histamine and cytokines, such as interleukin-5 from human 
leukocytes and isolated tissues. 
Methods: Leukocyte suspensions were prepared by dextran sedimentation of peripheral 
venous blood drawn from allergic and healthy volunteers. Leukocytes obtained from 
allergic volunteers were preincubated for 30 min with levocabastine (doses 10-g M to 10-6 
M) and thereafter incubated with allergen. Leukocytes obtained from healthy volunteers 
were incubated for 0 to 3 hours with levocabastine (doses 10-14 M to 10-3 M). Histamine 
release was measured by an automated fluorometric method. Interleukin-S release was 
measured by Enzyme Linked Immuno Assay. Contractile responses to histamine on guinea-
pig trachea and lung parenchyma as well as the release of histamine and interleukin-5 by 
the tissues were investigated in the absence or presence of levocabastine and/or the 
histamine H2 receptor antagonist, cimetidine. 
Results: Levocabastine did not influence the allergen-induced histamine release from 
leukocytes obtained from allergic volunteers. However, high concentrations (10-4 and 10-3 
!vi) of levocabastine caused release of histamine from leukocytes obtained from healthy 
volunteers as well as guinea-pig airways. Pretreatment with levocabastine dose-dependently 
decreased the contractile response to histamine, showing an irreversible competitive 
mechanism. Interleukin-5 release from human leukocytes and guinea-pig airways was not 
detectable. 
Conclusions: These findings indicate that the HI receptor blocker, levocabastine, has 
probably no anti-inflammatOly properties, as indicated by its inability to inhibit the 
allergen-induced histarnille release, and that the histamine release from both human 
leukocytes and guinea'-pig trachea and lung parenchyma only is significantly increased by 
the drug at high concentrations. 
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14.2 Introduction 
Levocabastine is a selective histamine HI receptor antagonist.601 There are several reports in 
literature showing the effectiveness of levocabastine in allergic processes. 148,583 Allergic 
rhinitis is characterized by symptoms such as sneezing, itching, rhinorrhoea and congestion. 
It is well accepted that histamine released locally in the early phase of the allergic reaction 
from mast cells and in the late phase from basophils is one of the major mediators 
responsible for most of these symptoms.459,468,637 Topically applied levocabastine has been 
demonstrated to protect pollinosis patients against allergen-induced rhinorrhoea and 
sneezing; however, levocabastine failed to influence nasal obstmction,354 The inhibitory 
effect of levocabastine on allergen-induced nasal reactivity to histamine and cell influx in 
patients with perennial rhinitis was investigated by Pazdrak et al., who suggested that 
levocabastine possesses properties other than HI receptor biockade.503 In an earlier study we 
demonstrated that while treatment with levocabastine significantly decreased the symptoms 
after nasal challenge with house dust mite extract in allergic rhinitis patients, the release of 
inflammatory mediators in nasal lavage fluid was not affected,254 
Basophils and mast cells are important cells which are involved in the allergic reactions, 
since they express high affinity IgE receptors on their membranes and release potent 
inflanunatory mediators, such as histamine, interleukin-5 and leukotrienes, following 
membrane IgE cross-linking by antigen,317,SI9,558 Mast cells seem to be important in the 
early antigen-induced reaction2H and basophils are believed to act in the late reaction308. 
Although a number of publications have appeared concerning the clinical efficacy of 
levocabastine, little is known about the mechanism of anti-allergic activity. In order to 
examine whether levocabastine has anti-inflammatory properties besides the classical HI 
receptor antagonism, we studied the effect of levocabastine on the release of histamine and 
interlcukin-5 from human blood leukocytes as well as from guinea-pig trachea and lung 
parenchyma during registration of the contractile function, 
14.3 Matedals and methods 
Malerials 
Levocabastine, methacholine hydrobromide and histamine hydrochloride were provided by 
Janssen Pharmaceutica B. V. (Til burg, The Netherlands) and dissolved in dimethylsulfoxide 
(DMSO; Sigma, Sf. Louis USA). DMSO was used as vehicle control. The final 
concentration of DMSO was <10% in all experiments and did not affect histamine release 
or cell viability. Cimetidine was from BUFA B.V. (Uitgeest, The Netherlands) and 
dissolved in Krebs-Henseleit buffer. The EDTA-vacutainer tubes for collecting blood were 
from Becton Dickinson (Meylan Cedex, France), Dextran was purchased from Pharmacia 
(Upssala, Sweden). Glucose, NaCI, KCI, NaOH, CaCI,'2H,O, MgCI,'6H,o, MgS04• 
KH2P04, NaHC03 and Hemacolor Farbetest were from Merck (Darmstadt, Germany), 
Bovine serum albumin (BSA), EDTA and Trypan Blue solution were from Sigma (St 
Louis, USA). Piperazine-l ,4-bis-2~ethanesulfonicacid (PIPES) was from Janssen Chi mica 
(Geel, Belgium.), Human u interleukin-5 Enzyme-linked Immuno-assay was from Pharmingen 
(San Diego, U.S.A.). This ELISA assay also was used in the organ bath experiments, 
because no guinea-pig-IL-5 assay is available and there could be a cross-reactivity with the 
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human~IL-5. 
Blood sample collection and preparation of leukocyte suspension 
Peripheral venous blood was obtained from four allergic volunteers (two were allergic 
against house dust mite, one against grass pollen and one against dog-dander; mean age 45 
years) and from six healthy volunteers (mean age 31 years) in EDTA-vacutainer tubes (7 
ml) with approbation of the local Medical Ethics Conunittee. Leukocyte suspensions were 
prepared by dextran sedimentation of peripheral blood as described by Lichtenstein and 
Osier39D and by Siraganian and Hooks86• Leukocytes were finally resuspended at a 
concentration of 2x106 ce1ls/ml. The viability of all leukocyte suspensions, assessed by 
trypan blue exclusion was greater than 95%. Cells were stained by Hemacolor to examine 
viability of basophils, which was greater than 95%. 
Effect of levocabastine on the release of histamine and interleukin-5 by leukocytes obtained 
ji'om allergic volunteers 
In the experiments the histamine release was determined after incubation of the leukocyte 
suspension with vehicle control (DMSO) or with three concentrations of levocabastine (10.8 
to 10-6 M) for 30 min and thereafter incubation with allergen (10-7, 10-5 , 10-3 and 10-1 
mglml) at 37°C as described by Siraganian and Hook.586 Histamine concentrations in the 
supernatants were measured by an automated fluorometric method,S86 Jnterleukin~5 
concentrations in the supernatants were measured by ELISA. 
E.ffect of levocabastine on the release of histamine and interlellkill~5 by leukocytes obtained 
fi'om healthy volllnteers 
Two series of experiments were performed. In the first series of experiments the histamine 
release was determined after incubation of the leukocyte suspension with DMSO or with 
different concentrations of levocabastine (10·\4 to to-3 M) for I min or 1 hour at 37°C, In 
the second series of experiments the histamine release was determined after incubation of 
the leukocyte suspension with DMSO or with three concentrations of levocabastine (10-5 to 
10-' M) for different time-intervals (0 to 3 hours) at 3TC. These relatively high 
concentrations of levocabastine were used because a) we found in the first series of 
experiments a release of histamine after incubation with high concentrations of 
levocabastine and b) it has also been reported that antihistamines have a dual action on 
cells: at high concentrations they enhance histamine release from mast cells while at low 
concentrations they inhibit the secretion of histamine.674,371,172,454 Histamine concentrations 
in the supernatants were measured by an automated fluol"Ometric method.s86 Interleukin~5 
concentrations in the supernatants were measured by ELISA. Levocabastine or DMSO, at 
the concentrations used, neither interfered with the fluorometric determination of histamine 
nor interleukin~5 ELISA nor modified cell viability, as assessed by trypan blue exclusion, 
Effict of levocabastine on the contractile response to histamine on guinea~pig trachea and 
hmg parenchyma 
After cervical dislocation (with approbation of the local Animal Ethics Conunittee) of the 
guinea-pigs (malc and female, 400-600 g; CPB-TNO, Zeist, The Netherlands), the trachea 
and lungs were taken out and washed in Krebs~Henseleit buffer (composition in 111M: NaCl 
118, KCI 4.7, CaCI, 2.5, MgSO, 1.2, KH,PO, 1.2, NaHCO,25, glucose 5.5) which was 
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aerated with 95% 02' 5% CO2, Two series of experiments were performed using four 
guinea-pigs each. In the first series of experiments, three trachea strips (four cartilage-rings 
for each strip) and three lung parenchyma strips of approximately 20 mm length were 
prepared. In the second series of experiments, four lung parenchyma strips of 
approximately 20 mm length from each guinea-pig were prepared. The tissue preparations 
were mounted in 10 ml double-jacketed organ baths containing aerated buffer at 37"C. 
They were allowed to equilibrate under an isotonic tension of 500 mg which resulted in 
optimal contractility, using Harvard model 386 heart-smooth muscle transducers. 324 All 
strips were primed by adding methacholine (10" to 104 M) in 10-fold concentration steps 
followed by washout, because this ensured a stable function for the rest of the day. The 
response to methacholine (10- 05 M) was used as a reference for the histamine curve. After 
return to baseline, a cumulative concentration response curve (CCRC) was made using 
histamine (10.8 to 10.3 M) on each strip. From the histamine-CCRCs the -log EC50 
(concentration producing 50% of the maximal effect) was derived. After washout, in the 
first series of experiments levocabastine (10-6, 10-7 or 10-8 M) was added and preincubated 
for 15 min, whereafter a second histamine-CCRC was generated. In the second series of 
experiments, after washout, cimetidine (H2 receptor antagonist; 10-6 M) was added and 
preincubated for 15 min. Thereafter levocabastine (10", 10"7 or 10.8 M) was added and 
preincubated for 15 min, whereafter a second histamine-CCRC was generated. 
Effect of levocabastine on Ihe release of histamine and il1terleukin-5 by guinea-pig trachea 
and lung parenchyma 
After priming by adding methacholine to the organs and returning to baseline, the organs 
were allowed to equilibrate for 15 min, whereafter samples of 800 pI were taken from the 
bath solution for measurements of histamine and interleukin-5 concentrations. In the series 
of experiments in which cimetidine andlor levocabastine and/or histamine were added and 
preincubated for 15 min, samples were taken for histamine and interleukin-5 measurements. 
To examine whether the endogenolls histamine release after incubation with exogenous 
histamine for 15 min was influenced, samples were taken for histamine measurements. 
Histamine concentration in the bath solutions was measured by an automated fluorometric 
method_ Interleukin-5 concentration were measured by ELISA. Cimetidine, levocabastine, 
DMSO or Krebs-Henseleit buffer, at the concentrations used, did neither interfere with the 
fluol'Ometric determination of histamine nor with the interleukin-5 ELISA. 
14.4 Statistical analysis 
The results were expressed as means ± S.E.M. ANOVA for multiple comparisons followed 
by a Students t-test for paired data was used to analyze the effect of levocabastine on 
histamine release, on interleukin-5 release, on -log EC5o , and on the CCRe's. P-values < 
0.05 were considered significant. 
119 
30 
Ii 
~ 
'0 
~ " 
• 
" 
'" •~ 
• 10 
,e 
E 
~ 
J' 
50 
Ii 
~ 40 
'0 
~ 
• 
30 
" 
" •~ 
" 
• c 
E 10 
'" .~ 
r 
Chapter 14 
14,5 Results 
Effect of levocabastine on the release of hislamine and interleukin-5 by leukocytes obtail/ed 
from allergic volunteers 
Incubation with 10-8 to 10-6 M levocabastine did not influence the release of histamine by 
leukocytes after stimulation with allergen (10'7, 10", 10.3 and 10" mglml) compared with 
the iilCuhation with DMSO. The allergen~induced histamine release from allergic patients 
are shown in Figure I. 
Interleukin~5 release from the leukocytes were not detectable. 
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Figure 1. Effect of preincubation with levocabastine or vehicle control (DMSO) on spontaneous (s) or 
allergen-induced histamine release from human leukocytes obtained from allergic patients for 30 min. Values 
are expressed as % histamine release of the total amount of histamine present in the leukocytes. 
Effect of levocabastine on the release of /t;stamine and interleuldn-5 by leukocytes obtained 
from healthy volunteers 
The results of the histamine release in the first series of experiments (11=6) after incubation 
of the leukocyte suspension with DMSO or with different concentrations of levocabastine 
(10-14 to 10-3 M) for 1 min or I hour at 37°C are shown in Figure 2. Incubation for I hour 
significantly increased the histamine release in comparison with 1 min. Incubation with 10-4 
and to-3 M ievocabastine significantly increased the release of histamine by leukocytes 
compared with the incubation with DMSO. 
120 
Selective effect of levocabastine '" 
The results of the histamine release in the second series of experiments (11=6) after 
incubation of the leukocyte suspension with DMSO or with three concentrations of 
levocabastine (10-', W-' and 10-3 M) for different time intervals (0, 1,2 and 3 hours) at 
37°C are presented in Figure 3, The release of histamine by leukocytes was significantly 
increased by incubation with 10') M levocabastinc for I to 3 hours. 
Intcrleukin~5 release from the leukocytes was not detectable in either the first or the second 
series of experiments. 
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Figure 2. Histamine release by human leukocytes obtained from healthy volunteers aftcr incubation for I 
min or 1 hour with vehicle control (DMSO) or with levocabastine (10-14 to to-) M). Values are expressed as 
means ± S.E.M. * P<O.05 vs histamine release aftcr incubation wilh vehicle control. 
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Figure 3. Histamine release by human leukocytes obtained from healthy volunteers before (0 hour) or after 
incllb~tion for I, 2 or 3 hours with vehicle control (DMSO) or levocabastine. Valucs are expressed as mcans 
± S.E.M. '" P<O.OS vs histamine release at 0 hour. When no error bar is visible, error falls within the limits 
of the symbol. 
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Effect of levocabastine on Ihe contractile response to histamine on guinea-pig trachea and 
lung parenchyma 
The mean CCRCs for histamine with DMSO or with levocabastine for the guinea pig 
trachea and lung parenchyma in the first series of experiments are shO\vn in Figure 4. The 
mean -log ECso (± S,E.M,) of the CCRC of histamine in the trachea and lung parenchyma 
were 5.62 ± 0.25 and 5.75 ± 0.06 (n~4) respectively, which were not significantly 
different. In both preparations, levocabastinc decreased the Emax of histamine dose-
dependently. 
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Figure 4. Effect of levocabastine on the histamine-induced contractions of the guinea-pig isolated trachea 
(upper curve) and lung parenchyma (lower curve). Values are expressed as means ± S,E.M. * P<O.05 vs 
control response. When no error bar is visible. error falls within the limits of the symbol. 
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The mean CCRCs for histamine with DMSO or with preincubation with the H2 antagonist 
cimetidine and with DMSO or with levocabastine for the guinea-pig llmg parenchyma in 
the second series of experiments are shown in Figure 5. The mean -log ECso (± S.E.M.) of 
the CCRC with histamine in the presence of cimetidine on lung parenchyma was 5.53 ± 
0.04 (n=l), which was not significantly different from the mean -log EC" of the 
histamine-CCRC with DMSO. Cimetidine decreased the Em.tx of histamine, which was 
further decreased dose-dependently in the presence of levocabastine. 
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Figure 5. Effect of cimetidine (cim; IO~ M) alone and levocabastine (Ievo) in combination with cimetidine 
(cim; IO~ M) on histamine-induced contraction of the guinea-pig isolated lung parenchyma, Values are 
expressed as means ± S.E.M. '" P<O.05 vs control response and # P<O,05 vs the response in presence of 
cillletidille. When no error bar is visible, error falls within the limits of the symbol. 
Effect of levocabastine on the release of histamine and illtel'leukin-5 by guinea-pig trachea 
and lung parenchyma 
The results of the measurements of histamine concentrations in the organ baths of the first 
series of experiments are shown in Table 1. 
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Table 1: Histamine concentration in guinea-pig organ bath solutions with DMSO and with incubation of 
levocabastille (10-3 to 10-6 M) for 15 min. Values are expressed as means ± S.E.M. 
Levocabastille (M) Histamine (nglml) 
Trachea vehicle control 0.36 ±0.06 
10'8 548 ± 359 
10'7 607 ± 367 
10'6 55.1 ±26.6 
Lung parenchyma vehicle control 0.33 ±0.15 
10'8 38.4 ± 17.2 
10.7 217 ± 79 
10" 139 ± 48 
Table 2: Histamine concentration in guinea-pig lung parenchyma bath solutions with vehicle control and 
with incubation of cimctidinc (10-6 M) for 15 min -and with vehicle control and with levocabastine (10-8 to 
10-6 M) for 15 min. Values are expressed as means ± S.E.M. 
Levocabastille (M) Cimetidine (M) Histamine (ng/ml) 
vehicle control vehicle control < 0.2 
vehicle control 10'6 10.0 ± 2.5 
10'8 10" 21.5 ± 5.1 
10'7 10" 23.8 ± 8.7 
10" 10'6 103 ± 58 
Histamine concentrations in the bath solutions of the second series of experiments are 
shown in Table 2. 
Krebs-Henseleit buffer, DMSO, levocabastine (10", 10'7, 10'6 M) and cimetidine (10'6 M) 
did almost not interfere with the fluOl'omctric determination of histamine; measured 
concentrations were all < 0.2 ng/ml. 
Incubation with levocabastine (10-8 to 10-6 M) increased the histamine release by guinea-pig 
trachea and lung parenchyma. After preincubation with 10-6 M cimetidine and thereafter 
incubation with levocabastine (10-8 to 10-6 M) the histamine release was increased in a 
dose-dependent manner. Incubation with exogenous histamine (l0·8 to 10-) M) did not 
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influence the endogenous histamine release by guinea-pig organs (data not shown). 
Interleukin-5 concentrations in the bath solutions of both the first and the second series of 
experiments were not detectable by the human-intcrleukin-5 ELISA. This assay was used 
because no guinea-pig-interleukin-5 assay is available, but probably no cross-reactivity with 
human-interleukin-5 occurs. 
14.6 Discussion 
It is well accepted that histamine released locally from mast cells and basophils is one of 
the major mediators responsible for most of the symptoms, such as sneezing, itching, 
rhinorrhoea and congestion in allergic rhinitis. Mast cells seem to be important in the early 
antigen-induced reaction244 and basophils seem to be involved mainly in the late 
reaction308,317,558. 
Topical application of levocabastine has been demonstrated to protect pollinosis patientsm 
and patients with house dust mite allergy254 against allergen-induced symptoms. The 
inhibitory effect of levocabastine on allergen-induced nasal reactivity to histamine and cell 
influx in patients with perennial rhinitis was investigated by Pazdrak et al., which 
suggested that levocabastine possesses other properties than being only a selective HI 
receptor antagonist. 503 However, in our earlier studies the release of inflammatory 
mediators, such as histamine and tl'yptase, in nasal lavage fluid of patients allergic to house 
dust mite was not affected by treatment with levocabastine.254 Several investigators have 
found that the most recent generation of antihistamines, such as terfenadine, cetirizine, 
astemizole and loratidine, possesses anti-inflammatory activities in vivo and in vitro, such 
as inhibitory effects on histamine release from mast cells and lor 
basophils. 12,72,J06,\73,425,437,462,464,S04 Tasaka el al found that levocabastine did not inhibit 
histamine release from rat peritoneal mast cells induced by compound 48/80, A23187 or 
concanavalin A. In sensitized rat peritoneal mast cells, however, the drug caused a 
significant inhibition of histamine release, though relatively high concentrations were 
necessary.613 
In the present study, we examined whether levocabastine has anti-inflammatory properties 
besides the classical HI receptor antagonism. \Ve studied the effect of levocabastine on the 
release of histamine from human blood leukocytes and from guinea-pig isolated trachea 
and lung parenchyma. 
Leukocytes from allergic volunleers: Our results showed that the allergen-induced release of 
histamine from leukocytes obtained from allergic volunteers was not influenced by 
levocabastine (10.8 to 10" M). 
Leukocytes fi'olll healthy volullteers: Though lower concentrations (10.14 to 10" M) of 
levocabastine did not affect spontaneous release of histamine from leukocytes obtained 
from healthy volunteers, high concentrations (10.4 and 10') M) of tite drug, not likely to be 
encountered in clinical situations, increased histamine release from these leukocytes. It is 
possible that incubation of leukocytes, obtained from allergic patients, with levocabastine 
(104 and 10-3 M) increase the release of histamine, but such high concentrations were not 
used in these experiments. 
Guinea-pig isolaled airways: Incubation with levocabastine (10-8 to 10-6 M) induced 
histamine release from guinea-pig isolated trachea and lung parenchyma in the organ bath 
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solution with DMSO and with preincubation with the H2 receptor antagonist cimetidine. 
Thus levocabastine stimulated both the histamine release by human peripheral leukocytes 
(basophils) and of mast cells in the guinea-pig organs. It has been suggested that the 
histamine releasing properties of antihistamines are due to direct cytotoxic action and 
consequently cell lysisJ71 ,m,454, but in our experiments levocabastine at the concentrations 
used did not modify cell viability, as assessed by trypan blue exclusion and Hemacolor (see 
Material and Method section), which suggests that the intracellular granules of the mast 
cells or basophils did not release histamine caused by mortality of the cells. Furthermore, it 
has also been reported that antihistamines have a dual action on cells: at high 
concentrations (> 1 OmM) they enhance while at low concentrations they inhibit the release 
of histamine from mast cells.674,371,m,4S4 
We did not study the intracellular mechanism of action of histamine release by 
levocabastine in these experiments. However, inhibitory effects of antiMhistamines on 
intracellular Ca2+ release from the sequestered Ca2f store and Ca2+ influx into the cell have 
been reported.431,~62,612 Other investigators have shown that a relationship exists between 
Ca2t influx into the cell ~Uld histamine release. 196,405 Some antihistamines can inhibit 
histamine release by inducing membrane stabilization.2 The dual action on cells by 
antihistamines could be caused by a biphasic action on Ca2t : low concentrations of 
antihistamines inhibit intracellular Ca2+ release and Cu2+ influx into the celi, while high 
concentrations probably induce intracellular Ca2t release and Ca2f influx. Another 
hypothesis is that the release of histamine by the HI antagonist levocabastine could be due 
to a feedback mechanism regulated by the H2 receptor614• Therefore, we performed the 
experiments with the H2 antagonist eimetidine, but no effect was seen on the histamine 
release from the guineaMpig airways after preincubation with cimetidine. 
Although levocabastine caused a doseMdependent release of histamine of human leukocytes 
and guineaMpig smooth muscle tissues, the clinical relevance is negligible. In a recent study 
we have demonstrated that nasal provocations with high doses of histamine of rhinitis 
patients allergic to the house dust mite have no systemic effects [De GraafMin't Veld, 
personal communication]. 
In this study, we could not show that levocabastine, modulated the release of the cytokine 
interieukiuMS, because interleukin~5 was not detectabled in the supernatant of the leukocyte 
suspensions, In an earlier study, we demonstrated that interieukinM5 plays an important role 
in allergic rhinitis. We found that interleukin-5 was present in detectable amounts in nasal 
lavages of patients with a house dust mite allergy before and after challenge with hOllse 
dust mite extract, which immediately caused nasal symptoms, and in the late phase 
reaction.no It is known that TH2Mcells452, mast cells and eosinophils519 can produce 
interieukinM5. However, Alam and Grant demonstrated that basophils failed to produce 
interleukin~5. 3 The interleukin-S concentrations in the organ baths were not detectable, 
because the organs were from guinea-pigs and the ELISAMkit was based on human-
interleukin-5; there was no crossMreactivity between the two species. 
In this study we showed that the selective HI receptor antagonist levocabastine significantly 
reduced the contractile response of guineaMpig isolated trachea and lung parenchyma caused 
by histamine in an irreversible competitive manner. After preincubation with levocabastine 
higher doses of histamine were necessary to obtain the same contractile responses, and the 
histamine-CCRC with levocabastine did not reach the same Ern.a~ in comparison to the 
histamineMCCRC with DMSO. AileI' washing with Krebsabuffer for 2 hours levocabastine 
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was not diffused from the histamine receptors; furthermore new incubations with histamine 
resulted in the same histamine-CCRC in comparison to preincubation with levocabastine 
for 15 min. Thus, levocabastine reduced the contractile response of the guinea-pig tissues 
in an irreversible manner. Before and at the end of each experiment with levocabastine we 
performed CCRCs with methacholine. The same contractile responses were observed with 
methacholine before and after the experiments with levocabastine, which suggests that 
levocabastine is selective for histamine receptors. High concentrations of histamine caused 
a relaxation of the guinea-pig organs, which is not diminished by preincubation with the H2 
receptor antagonist cimctidine. The Emax of the histamine-CCRC with cimetidine did not 
rcach the same contractile-response as the histamine-CCRC with DMSO, which is probably 
caused by the small HI receptor activity of cimetidinc; KB: HI: 4.5 x 10'4 M, H,: 0.8 x 10.6 
M and H,: 3.3 x 10'5 M.5JO 
In conclusion, in addition to HI receptor blocking activity levocabastine has probably no 
anti-inflammatory properties. Levocabastine significantly reduced the contractile response 
of guinea-pig isolated trachea and lung parenchyma caused by histamine in a irreversible 
competitive manner and the histamine release from both human leukocytes and guinea-pig 
trachea and lung parenchyma only was significantly increased after incubation with 
levocabastine at high concentrations. 
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The relationships between nasal hyperreactivity, quality of life and nasal 
symptoms in perennial allergic rhinitis 
C. de Graaf-in 't Veld', S. Koenders', l.M. Garrelds"', R. Gerth van Wijk'. 
IDepartment of Allergology, University Hospital Rotterdam-Dijkzigt, 2Department of Phamlucology, Erasmus 
University Rotterdam, the Netherlands. 
Based on: Journal of Allergy and Clinical Immunology, In press. 
15.1 Abstract 
Background: It would be useful to have a clinical test that would he able to inform the 
clinician about the severity of the patients nasal symptoms and health-related quality of life 
(QOL). 
Objective: We investigated if in patients with perennial allergic rhinitis nasal challenge 
with histamine may be used to estimate daily symptoms and QOL. 
A1ethods: Forty-eight patients with perennial allergic rhinitis were challenged with 
histamine to determine nasal hyperreactivity, Nasal response was monitored by the number 
of sneezes, the amount of secretion and a symptom score, Daily nasal symptoms were 
recorded during the two preceding weeks, Patients also completed a rhinitis QOL 
questionnaire (according to Juniper), 
Results: Responsiveness to histamine and total daily nasal symptoms were moderately 
correlated (FO.51, p~O.OO I). Comparing total daily nasal symptoms with the overall 
quality of life score showed a moderate correlation (FO.59, p<O.OOI). Nasal response to 
histamine and overall QOL score were also correlated (1=0.43, p=O.002). However, overall 
QOL and daily nasal symptoms could be predicted by wide 95% prediction intervals only 
for each decade of nasal responsiveness to histamine (expressed by a composite symptom 
score). 
Cone/usioll: In patients with perelll1ial allergic rhinitis nasal hyperreactivity as determined 
by histamine challenge, quality of life and daily nasal symptoms are moderately correlated. 
ThereforeJ nasal histamine challenge can be used as a tool to estimate the severity of daily 
nasal symptol11S and QOLJ although it can not predict nasal symptoms and QOL very 
accurately, 
Keywords: perennial allergic rhinitis; daily symptoms; quality of life; nasal 
hyperreactivity; histamine challenge 
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15.2 Introduction 
Patients with allergic rhinitis suffer from sneezing, nasal itchyness, rhinorrhoea and nasal 
blockage after exposure to the relevant allergen, After repetitive exposure to allergen, nasal 
responsiveness to allergens increases, This phenomenom, known as nasal priming, was first 
described by Connell '20 and was confinned by others18.261. Exposure to allergen also 
increases nasal responsiveness to non~specific stimuli,lO This non~specific nasal 
hyperreactivily is particularly important in patients with perennial allergic rhinitis, since 
they are continously exposed to allergen, 
Hyperreactivity can be described as a clinical feature characterized by occurence of 
symptoms on exposure to daily~life stimuli as estimated by history (clinical hyperreacti-
vity), Determination of nasal hyperreactivity by nasal provocation tests with pharmaco~ 
logical or physical agents assumes a relationship between this form of nasal hyperreactivity 
and hyperreactivity as estimated by history. Gerth van Wijk ef al.'" demonstrated that the 
amount of secretion and the number of sneezes in response to hist:'lmine challenge were 
associated with the clinical hyperreactivity assessed by a hyperreactivity score, 
The importance of routine histamine challenges in daily practice is not clear. In a previous 
study, we showed that assessment of nasal airway resistance after histamine challenge is 
less appropriate in distinguishing patients from healthy subjccts in terms of reproducibility 
and estimation of clinical hYPclTeactivity compared with assessment of munber of sneezes 
and amount of secretion,m Recently, we demonstrated that reactivity to histarnine 
expressed as area under the curve with a composite symptom score (according to LebeI37J) 
as response variable is a valid method to detect treatment effect.251 In addition the method 
is valid to distinguish between patients with and without a late-phase allergic reaction,227 
Moreover, this method appears to be reproducible.252 
Recently, a correlation between daily symptoms and response to histamine challenge was 
demonstrated in patients suffering from non~allergic nasal hyperreactivity.265 We investiga~ 
ted if in patients with perelUlial allergic rhinitis nasal hyperreactivity (responsiveness to 
histamine) corresponds with daily nasal symptoms, Besides the amount of secretion and 
the number of sneezes, the symptom score of Lebel373 was used to monitor the nasal 
responsiveness to histamine. 
Patients' suffering from nasal symptoms, also interferes with their day-to~day lives. To 
measure the influence of nasal symptoms on day-to-day life, rhinitis quality of life (QOL) 
questionnaires have been developed.71 •335,336 Juniper et al. demonstrated that QOL 
deteriorated after allergen exposure (pollen season) and increased after symptomatic 
treatment.335.336 
We studied the questions if in patients with perennial allergic rhinitis the daily nasal 
symptoms arc correlated with QOL, and also jf nasal hyperreactivity, as measured by nasal 
histamine challenge, is correlated with QOL scores and nasal symptoms. Furthermore, we 
studied whether nasal histamine challenges can be llsed as a tool to estimate the severity of 
patients daily nasal symptoms and health~related QOL. 
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15.3 Materials and Methods 
Study design 
Each adult patient with perennial allergic rhinitis visiting our outpatient clinic for the first 
time completed a nasal symptom diary during the two weeks preceding the follow~up visit. 
At this second visit, patients completed a rhinitis QOL questionnaire and underwent a 
nasal histamine challenge. 
Subjects 
Forty-eight patients (23 males, 25 females, aged 30 ± 10 years) with a history of perennial 
rhinitis participated in this study. They had to meet the following criteria: perennial rhinitis 
for at least one year; positive intradermal skin test with at least one perennial allergen 
(hollse dust mites andlor moulds andlor animal dander, ALK Benelux, Groningcn, the 
Netherlands) and exposure to the aUergen(s) involved. Of the patients included, 38 were 
allergic to hOllse dust mites, 7 were allergic to house dust mites and pets (and had a pet at 
home), 2 were allergic to their pets only, 1 patient was allergic to moulds. Patients with a 
concomitant allergy to pollen were only included outside the pollen season. During the 
study they were not permitted to use any medication affecting nasal symptoms, apart from 
Acrivastine 8 mg (as escape medication). Acrivastine had to be withdrawn 3 days before 
the histamine challenge. Patients with a nasal infection were excluded. 
Nasal ,\)Ifllpfom dimy 
Patients recorded their nasal symptoms during two weeks on a modified diary card 
according to the symptom score system of Norman479 • Sneezes/itching nose, nasal 
blockage, and rhinorrhoea were scored according to their daily duration (0 = no symptoms, 
I = symptoms<l hour, 2 = symptoms between I and 4 hours, 3 = symptoms>4 hours). 
The sum of the individual symptoms during the 2 weeks and the total nasal symptom score 
(sneezing + rhinorrhoea + nasal blockage) during these 2 weeks were used for statistical 
analysis. 
Rhinitis quality of life questionnaire 
We translated the rhinitis QOL questionnaire developed by Juniper ef al. 336 Patients had to 
score 25 items subdivided into the following domains: sleep (n=3), nasal symptoms (n=5), 
practical problems (n=3), emotions (n=4), activities (n=3), and nonrhinitis symptoms 
(n=7). They were asked how much they were troubled in each item as a result of their 
nasal symptoms during the previous week. The score of these items ranged from 0 (not 
troubled) to 6 pts (extremely troubled). In case of the items concerning emotions, patients 
were asked how often they were troubled in each of the items as a result of their nasal 
symptoms. The score also ranged from 0 pts (never troubled) to 6 pts (constantly 
troubled). In the analysis the mean score of the items in each domain was used. In 
addition, the total score of the means of the six domains was used to calculate the overall 
QOL score. 
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Nasal histmnille challenge 
Challenges were performed aecording to the methods described by Gerth van Wijk e/ 
al. 225,228 Patients waited for half an hour prior to the test in order to give the nasal mucosa 
time to acclimatise. Nasal challenge with histamine phosphate (0.25, 0.5, 1.0, 2.0 and 4.0 
mg/ml) was performed at fiveMminute intervals after challenge with phosphate-buffered 
saline (PBS). The PBS and the increasing doses of histamine were sprayed into the nostrils 
with a nasal pump spray delivering a fixed dose of 0.125 ml solution. After each challenge 
the symptom score373 was recorded, sneezes were counted and anterior rhinorrhea was 
measured by collecting nasal secretion in a syringeMequipped fUllllel68• The areas under the 
curve of histamine dose response were used in the statistic analysis. 
Symptom score 
The symptom score according to Lebel et al. 373 was used: 3-4 sneezes= 1 pt, ;:::':5 sneezes=3 
pts; anterior rhillorrhoea=1 pt; posterior rhinorrhoea=1 pt; difficult nasal breathing=1 pt, 
one nostril blocked~2 pts, both nostrils blocked~3 pts; pruritus of the nose~ 1 pt; pmritus 
of the palate or ear= I pt and conjunctivitis~ I pt. Total score ranges from 0 till II pts. 
Statistics 
40 patients completed their nasal symptom diary correctly; in comparing nasal symptoms 
with QOL scores and nasal hyperreactivity we used data of these patients only (n~40). 
When testing the correlation between QOL scores and nasal hyperreactivity all data could 
be used (IF48). 
Because not all variables were normal distributed, relationships between the variables were 
tested by Spearman rank correlations. A two-tailed p-value <0.05 was considered 
significant. Furthennore, the mean predicted values and 95% prediction intervals of overall 
QOL and total nasal symptoms for each decade of nasal response to histamine challenge 
were determined by multiple regression analysis (this method could be used since these 
three variables were normal distributed). 
15.4 Results 
Table I shows correlation coefficients of daily nasal symptoms compared with nasal 
response to histamine. Histamine rcsponsiveness is expressed as the AVe of the amount of 
secretion, the number of sneezes and the symptom score of Lebel after nasal histarnine 
challengc. Moderate, but statistical significant correlations were found between histamine 
responsiveness, expressed as symptom score of Lebel3?3 and daily nasal symptoms. The 
secretory response to histamine is moderately correlated with daily secretion only. 
Expressing histamine responsiveness as the number of sneezes no correlations were found. 
Table II shows the correlation coefficients of nasal response to histamine and QOL 
domains. The symptom score of Lebelm correlates moderately with most QOL domains 
with exception of sleep and emotions. However, the correlations with sleep and emotions 
tended to be significant (pO.27, IrO.067 and 1~0.24, p~0.098 respectively). The 1I1Imber 
of sneezes is correlated with the activities and with overall QOL score only. Secretory 
response to histamine is correlated with sleep, nonrhinitis symptoms and the overall QOL 
score. 
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Comparing daily nasal symptoms with the QOL domains, moderate, but statistical 
significant correlations are shown for all domains and the overall QOL score (table III). Of 
the individual symptoms, itchyness/sncezing is correlated with five of the six QOL 
domains and the overall QOL, congestion with three domains and the overall QOL, and 
secretion with two domains and the overall QOL only. 
\Vhen daily Acrivastine intake was added to the total score of the diary, as Norman did479, 
the correlations of total daily symptoms with hyperreactivity were 0.05 (sneezes), 0.26 
(secretion) mld 0.51 (symptom score) compared to 0.10, 0.24 and 0.51 without 
Acrivastine. 
Table I. Nasal hyperreactivity versus daily nasal symptoms (11=40). Associations are presented by 
Speannan rank correlation coeflicients (r). *= p-value< 0,05, 
Nasal hyperreactivity 
Daily uasal Sneezes Secretion Symptom 
symptoms score 
I tchyness/Slleezi ng r=0.00 1~0.22 1""'0.49' 
Secretion r~0.04 r~0.41' r=0.39' 
Congestion t=0.14 1""'0.05 r=0.31' 
Total symptoms t=0.10 1~0.24 t=0.51' 
Table IT. Quality of life versus nasal hyperrcactivity (n=48). Associations are presented by Speamlan rank 
correlation coefficients (r). *= p-value< 0.05. 
Nasal hypel'l'cactivity 
Quality of life Sneezes Secretion Symptom 
score 
Sleep r~0.15 t=0.36' 1""'0.27 
Nonrhinitis symptoms 1~0.28 1~0.34' t=0.29' 
Practical problems 1~0.10 1~0.25 t=0.34' 
Nasal symptoms 1~0.26 1~0.18 1~0.47' 
Activities 1~0.37' 1""'0.21 1~0.32' 
Emotions 1~0.07 r~0.16 1~0.24 
Overall QOL t=0.31' r~0.32' 1~0.43' 
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Correlations of total daily symptoms with QOL domains ranged frolll 0.37 to 0.60 
compared to 0.35 to 0.59 with or without Acrivastine respectively. So Acrivastine intake 
did not change the correlation coefficients 
In figure 1 the association between overall QOL and total daily symptoms is shown 
(1~0.59, p<O.OOI). 
In table IV predicted values and 95% prediction intervals of overall QOL and total nasal 
symptoms for each decade of nasal response to histamine arc demonstrated. Nasal response 
to histamine explained 21 % of the variance of nasal symptoms and 2l % of the variance of 
QOL. 
Tablc III. Quality of life versus daily nasal symptoms (0=40). Associations arc presented by Speannan 
rank correlation coefficients (r). += p-value< 0.05. 
Quality of life Itchynessl 
Sneezing 
Sleep r=0.33' 
Nonrhinitis symptoms FO.37' 
Practical problems 1=0.57' 
Nasal symptoms r=0.61' 
Activities 1=0.46' 
Emotions r=0.29 
Overall QOL 1=0.59' 
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Daily nasal symptoms 
Secretion Congestion Total 
FO.25 1~0.29 1=0.35' 
1=0.19 r=0.29 1=0.36' 
1~0.37' 1=0.39' FO.56' 
r=0.43' FO.23 1=0.54' 
1=0.14 FO.52' FO.45' 
1=0.19 1~0.36' 1=0.36' 
1~0.36' 1=0.47' r=0.59' 
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Figurc 1. Overall quality of life score plotted 
against total daily nasal symptoms recorded 
during two weeks (n=40). 
Total daily nasal symptoms 
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Table IV. Predicted nasal symptoms (n=40) and QOL (n=48) for each decade of the hyperr~activity range 
Predicted nasal symptom score Predicted QOL score 
HypelTcactivity mean 95% prediction mean 95% prediction 
symptom score interval interval 
10 34.98 0.00 - 88.34 1.43 0.00 - 3.44 
20 48.46 0.00 - 100.79 1.89 0.00 - 3.88 
30 61.94 0.31 - 114.57 2.36 0.37 - 4.35 
40 75.42 21.19 - 129.65 2.81 0.79 - 4.85 
50 88.90 31.88 - 145.93 3.29 1.18 - 5.39 
15.5 Discussion 
\Ve investigated if routine nasal histamine challenges in patients with perennial allergic 
rhinitis can be used to give an impression of the severity of patients' daily nasal 
symptoms. Nasal response to histamine, if expressed as the symptom score of Lebel et 
al.37J, correlated 1110derately with sneezes/itchyness, rhinorrhoea, congestion, and total nasal 
symptoms. Secretory response to histamine correlated only weakly with nasal symptoms, 
wheras the number of sneezes to histamine challenge was not correlated with daily nasal 
symptoms at all. This is in contrast with a previous study of Gerth van Wijk et al., who 
demonstrated that histamine-induced sneezes and secretion correlated well with daily nasal 
symtoms. 228 However, the diary he used contained, besides the symptom score system of 
Norman479, also specific questions about nasal hyperreactivity, so the two diaries are not 
completely comparable. This might suggest that routine histamine challenges in daily 
practice, if monitored by the symptom score of Lebel et al.m , give a good impression of 
the severity of patients' daily symptoms. The correlations, however, were only moderate 
and daily nasal symptoms could be predicted by wide 95% prediction intervals only. It can 
not be expected from one clinical test to be able to predict exactly daily nasal symptoms. 
It might be used however, in addition to a carefully taken history, to make a better 
estimation of the severity of patients' symptoms. 
R11initis patients not only suffer from the nasal symptoms themselves, their day-to~day 
lives can also be impaired by their nasal symptoms. We used the rhinitis QOL question-
naire developed by Juniper et al.336 to measure the effect of rhinitis on day~to~day life. 
Juniper has validated this questionnaire and has shown that it is a useful instrument in 
clinical trials to detect within-subject changes over time (treatment effect, allergen 
exposure). We did not study changes in QOL but we investigated if QOL scores are 
correlated with the daily nasal symptoms and nasal response to histamine. 
Malo el af. demonstrated that in patients with asthma, QOL and bronchial hyperreactivity 
were correlated.414 Since the relationship between nasal hyperreactivity and QOL has not 
been studied yet, we investigated if in patients with pereIUlial allergic rhinitis, such a 
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relationship could be demonstrated also. Nasal hyperreactivity was determined by nasal 
response to histamine. Expressing histamine responsiveness by the symptom score a 
significant correlations were found with all QOL domains with exception of emotions and 
sleep. The correlation coefficients found in our rhinitis study were moderately (0.24 < l' < 
0.47), however they were equal or higher than in asthma studies. Correlation coefficients 
between bronchial responsiveness to methacholine found by Malo el al.414 ranged from ~ 
0.1 to -0.24. Marks et al.418 studied the relationship between changes in bronchial 
hyperreactivity and changes in QOL; correlation coefficients ranged from 0.14 to 0.47. 
The number of sneezes and the amount of secretion in response to histamine challenge 
correlated only slightly with some of the QOL domains. So when comparing nasal 
hyperreactivily with QOL, nasal hyperreactivity expressed as the symptom score of 
Lebel373 is a better variable than the number of sneezes and/or the amount of secretion. 
Comparing QOL with nasal symptom diary, QOL scores (all six donlains and the overall 
score) correlated with total nasal symptoms, indicating that in patients with more severe 
rhinitis symptoms, QOL is more impaired. The moderate correlations between nasal 
symptoms and the nasal symptom domain of QOL might be due to the indivudual 
perception of the degree of impairment caused by the nasal symptoms. Some patients 
might be impaired a lot by only a few nasal symptoms, while other might be less impaired 
in spite of more severe nasal symptoms. The correlation coefficients we found (0.35 to 
0.59) are about in the same range as those found by Juniper ef al.m (0.31 to 0.59), 
however the results are not tot,llly comparable, since Juniper compared changes in nasal 
symptoms with changes in QOL. 
Comparing QOL scores with the individual nasal symptoms, a better correlation was seen 
with sneezes/itchyness than with rhinorrhoea and congestion, so that it seems that 
sneezing/itchyness causes the most impairment of day-to-day life. Perhaps patients become 
used to a stuffy nose, and blowing their nose, but sneezing and nasal itchyness are hard to 
ignore and more difficult to accept. Since the Dutch version of the by Juniper developed 
and validated rhinitis QOL questiollnaire correlates well with daily nasal symptoms, it can 
also in the Netherlands be used as a valid tool to measure rhinitis QOL. 
When Acrivastine intake was added to the total nasal symptoms, as Norman did479, the 
correlations between total nasal symptoms and QOL or responsiveness to histamine 
challenge did not change. So it seems to make no difference whether Acravistine intake is 
included or not. Norman also found that by using the symptom diary to interprete the 
clinical effectiveness of immunotherapy it made no difference when the use of 
antihistamines was included or not. 
To conclude: In patients with perennial rhinitis nasal hyperreactivity, QOL and daily nasal 
symptoms are moderately correlated. Therefore, routine histamine challenge can be used as 
tool to obtain an impression of daily nasal symptoms and rhinitis QOL, although it can not 
predict nasal symptoms and QOL very accurately. 
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General discussion 
The investigations described in this thesis were initiated to study the involvement of 
inflammation in nasal hyperreactivity in allergic rhinitis. Several methods can he used to 
investigate the presence of inflammation in the nasal mucosa. Since the study-design was 
to investigate (the dynamics of) nasal inflammation at different time points over a period 
of 9.5 hours after allergen challenge, a non-invasive method was needed, causing as little 
as possible damage to the nasal mucosa and with only little inconvenience for the patients. 
Therefore, the nasal lavage method according to Naclerio el al,46s was used instead of 
methods like nasal biopsies or brushes. However, tlus method has also some disadvantages; 
for example, the levels of inflammatory mediators are diluted by the large lavage volume 
and only small amounts of inflammatory cells can be detected in the nasal lavage fluid. 
Since the mucous secretion could not be dissolved with the lavage fluid to a homogenous 
manner to detect mediators and cells, nasal lavage fluid and nasal secretion were separately 
collected. Because only a few inflammatory cells could be detected in lavage fluid, nasal 
inflammation was estimated by the levels of inflammatory mediators only. Nasal symptoms 
to HDM challenge were recorded according to a scoring system described by Lebel et 
al. 373, which consists of both objective and subjective symptoms. Earlier studies have 
shown that this scoring system is suitable to measure both the early and late phase response 
to allergen challenge.229 This symptom score was used in order to study the correlation 
between the clinical response and the inflammatory mediators and nasal hypcrreactivity. 
Since it is generally known that during the late phase response inflammatory cells 41,642 and 
mediators55 are involved, the first goal was to investigate if nasal hyperreactivity was 
correlated with the immediate and the late allergic response after allergen challenge, which 
might indirectly give evidence for the involvement of inflammation. The second goal was 
to investigate the relationship between nasal hyperreactivity and inflammatory response, as 
measured by inflammatory mediators ill nasal lavage fluid. According to the symptom 
scores patients were divided in two groups. The first group consisted of patients with only 
an early clinical response, the second consisted of patients with both an early and late 
phase clinical response to allergen provocation. The early and late allergic reaction were 
correlated with each other and also with nasal hyperreactivity. Patients with a late phase 
response demonstrated increased levels of tryptase and albumin during the early response 
and higher levels of albumin and ECP during the late phase response in comparison with 
patients with an early response only. Also nasal response to histamine challenge was more 
severe in the group with both an early and late phase response. Our findings suggest that a 
strong early response gives rise to increased amounts of chemotactic mediators with as a 
consequence an increased amount of inflammatory cells a few hours later, during the late 
phase response, and an increased hyperreactivity 24 hours later. The results suggested that 
nasal hyperreactivity could ~e influenced by the degree of nasal inflammation. 
Mechanisms of allergic rhinitis and nasal hyperreactivity can also be studied by therapeutic 
intervention. The third goal was to study the effect of two different drugs on the clinical 
immediate and late phase response to HUM challenge, on the nasal inflanunation and on 
the allergen-induced nasal hyperreactivity in perennial allergic rhinitis patients. 
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First, the effects of intervention with the topical glucocorticoid fluticasone propionate were 
investigated. Both the clinical immediate and late phase response to nasal provocation with 
HDM extract were inhibited by fluticasone propionate. Assessment of albumin in nasal 
lavage fluid demonstrated an increased influx during both the immediate and late phase 
reaction, which indicated an increased vasopermeability.604 Tryptase, a specific marker of 
mast cells560, was only detected during the immediate nasal response, whether ECP as a 
marker of activated eosinophils267 only could be measured during the late nasal response. 
PAP, POD, and LTC4ID,lE4 only were released immediately after allergen challenge. As 
described in chapter 2, mast cells and macrophages are able to release these mediators. 
Basophils, eosinophils and neutrophils are known to produce LTC4 and PAF, whereas 
platelets can release POD, and PAP. Epithelial cells are also able to produce PAP. The 
levels of IL~5 in the nasal lavage fluids was also measured, which was increased during the 
immediate and late phase reaction. It is known that IL~5 is produced by mast celis, 
eosinophils and T H2-cells. Nasal challenge with allergen did neither cause a release of NO 
during the inUllediate nor in the late phase reaction, which suggests that NO plays no 
important role in hyperreactivity in the nose. The release of inflanunatory products in the 
nasal lavage fluid during the inunediate and late phase reaction to HDM challenge indicates 
that inflammation is involved in this allergic process. Fluticasone propionate decreased the 
release of these inflammatory products, which suggested that the nasal inflammation was 
inhibited. Allergen~induced nasal hyperreactivity was investigated by the clinical response 
described by Lebel el al. 373 to histamine provocation, which was decreased by fluticasone 
propionate. These findings suggest that fluticasone propionate may act by preventing 
activation of several cells during the early response and subsequent release of inflammatory 
mediators, which could be chemotactic to other cells and could cause the late phase 
response. The results showed that the late allergic reaction and hyperreactivity are 
associated and prevention of the late reaction resulted in a decreased nasal hyperreactivity. 
So, indirectly, it is demonstrated that inflammation and nasal hyperreactivity are associated: 
In addition, the relationship between the reduction of symptoms due to treatmcnt with the 
glucocorticosteroid mld the glucocorticosteroid receptor characteristics was investigated, 
because a few patients respond less to these drugs. No correlation between the reduction of 
symptoms due to fluticasone propionate and the glucocorticoid receptor characteristics of 
the perennial allergic rhinitis patients was found. This suggests that the extent of reduction 
of symptoms due to cOliicoids is neither dependent on the number nor on the affinity of 
the corticoid receptors, but probably on other (intracellular) pathways. 
Secondly, the effects of intervention with the topical antihistarnine levocabastine were 
investigated. Another study with perennial rhinitis patients was performed to investigate I) 
the association between inflammation and nasal hyperreactivity and 2) whether 
levocabastine has anti~inf1ammatory propeliies. Treatment with the histamine receptor 
antagonist levocabastine decreased the immediate clinical response to allergen challenge 
and histamine provocation, but did not decrease the nasal hyperreactivity (assessed by nasal 
response to methacholine). Because in this study no late nasal response was measured 
(symptom score and release of ECP), no effect of levocabastille on the late allergic 
response was detected. Levocabastine did not decrease the levels of albumin and tryptase in 
the nasal lavage fluids. Tllis study suggested that levocabastine has no anti-inflammatory 
properties, besides its selective histamine HI receptor antagonism. To investigate further 
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whether levocabastine, also has anti-inflammatory properties an in vitro study was 
performed. The results showed that levocabastine, in contrast to other antihistamines I2,m,464, 
did not seem to possess anti-inflammatory properties. The histamine release from human 
leukocytes and guinea-pig trachea and lung-parenchyma was increased by the drug in 
relatively high doses, which are very unlikely to he encountered in clinical situation, 
particularly after topical application. These studies also showed that levocahastine has no 
anti-inflammatory properties and has no effect on nasal hyperreactivity, which also 
indirectly demonstrates an association between inflammation and nasal hyperrcactivity. 
The fourth goal was to study the relation between hyperreactivity and inflammation in the 
non-challenged situation, i.e. during natural HDM exposure. In this study only one lavage 
and one brush to measure inflanunation was performed. Albumin, ECP, tryptase, PGD2 and 
LTC/D/E4 in lavage fluid did not correlate with nasal hyperreactivity. In contrast to nasal 
lavage fluid, sufficient cells in the brushes were detected. Eosillophils were present in 
increased amounts in comparison to healthy volunteers. The percentage of eosinophils 
showed a mild correlation with nasal responsiveness to histamine, indicating that 
eosinophils are involved in hyperreactivity. 
As a final goal, the relationship bctween nasal hyperreactivity in perennial allergic rhinitis 
patients and their quality of life was studied. Mild correlations were found between quality 
of life scores and nasal hyperreactivity, assessed by nasal response to histamine according 
to the symptom score of Lebel el al. )73 Therefore routine nasal histamine challenges can 
probably he used to estimate health related quality of life and daily nasal symptoms. 
The investigations described in tIus thesis demonstrated an association between nasal 
hyperreactivity and inflammation in perennial allergic rhinitis patients. In the lower airways 
the late phase response to allergen challenge was found to be associated with inflanunation 
and bronchial hyperreactivity%,115.162.445, suggesting tluit inflammation is involved in the 
pathogenesis of hypcrreactivity. Patients with seasonal allergic rhinitis showed an increased 
response to histamine and methacholine during the pollen seasonll9, as well as after nasal 
allergen challenge lO,J46,)95. However, no relation was found between nasal hyperreactivity 
and late phase response230, and activation of eosinophilsJ46 respectively and between nasal 
priming and late phase reaction in patients allergic to pollen outside the pollen season. 
Patients with perellllial allergic rhinitis suffer from almost continuous nasal symptoms 
throughout the year, this situation is in agreement with asthmatics. The nasal lavage model 
with perelllliai allergic rhinitis patients is more suitable to study the association between 
nasal hyperreactivity and inflammation than with pollinosis patients. 
Our studies deal with several inflanuuatory cells and their products which play a 
predominant role in the modulation of perelUlial allergic rhinitis. Although sonIC of these 
mediators, such as histamine, prostaglandins and leukotrienes may be biologically active in 
rhinitis, the role of others needed clarification. 
The studies presented in this thesis showed that tryptase, PAF, PGD2, LTC/D/E4 and IL-5 
are released in the nasal lavage fluid immediately after allergen challenge of patients 
allergic to HDM. This indicates that primary cells such as mast cells, antigen-presenting 
cells and epithelial cells and secondary cells such as basophils, eosinophils, neutrophils, T H-
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cells and platelets are important in the early clinical response. The results of this study 
demonstrated that ECP and IL-5 are released several hours after allergen challenge, which 
suggests that eosinophils and T m-cells play an important role during the late phase 
response. However, in the nasal lavage method only low amounts of inflammatory cells 
could he detected in the nasal lavage fluid, therefore, it was not possible to confirm that 
these cells were responsible for the production of the inflammatory mediators. This could 
he due to the fact that the mucous secretions were not dissolved in the lavage fluid, 
whereas others made a miscellaneous mixtme of the secretion and lavage fluid. 
In a biopsy study an increased percentage of mast cells was found at the surface of the 
nasal mucosa after allergen challenge189 during the immediate allergic reaction. During the 
late phase response, an influx of eosinophils42 and basophils44 was demonstrated in the 
nasal lavage fluid and also an increase of Til-cells, eosinophils and neutrophils was found 
in the nasal mucosa642. During the pollen season, more Langerhans cells were demonstrated 
in the nasal mucosa191 and an increased level of blood basophiislOo was found com.pared to 
outside the season. Our results demonstrated that only the amount of eosinophils was 
increased in the nasal brushes of patients during natural HDM exposure compared with 
healthy volunteers, which showed a correlation with nasal responsiveness to histamine. This 
indicated that eosinophils play an important role in perennial rhinitis and hyperreactivity. 
This is in contrast with other investigators, who found no relation between eosinophils and 
hyperreactivity.346 Others demonstrated an increased influx of neutrophils in nasal lavages 
of rhinitis patients during hyperreactivity.255 Also the involvement of mast cells in 
hyperreactivity could be of importance.62o Damage to the epithelial layer contributes to an 
increased bronchial hyperreactivityl4s, because neuroendopeptidase is decreased, which 
resulted in an increased level of substance P (SP), but this is not demonstrated in the 
nose.391 ,M2 
Increased concentrations of histamine have been found in nasal lavages of rhinitis patients 
during the inunediate230 as well as the late phase44,467 responses to allergen challenge. In our 
studies no release of histamine was detected in the nasal lavage fluid during either the early 
or late phase reaction. This difference is probably due to the fact that the mucous 
secretions were not dissolved in the lavage fluid, whereas others made a miscellaneous 
mixture of the secretion and lavage fluid. However, another mast cell product, tryptase, 
was released during the immediate response. A possible explanation might be that 
histamine is metabolized or removed more rapidly than tryptase, which has been 
demonstrated in the circulation.567 Histamine increases the chemotactic response of 
eosinophils lll and neutrophilsS72, controls the histamine release from hasophils632, modulates 
the immunoglobulin production171.392 and suppresses the antibody secretion from plasma 
cells431 . Tryptase is released immediately in nasal lavage fluid after allergen or cold dry air 
challenge of rhinitis patients95.S24, who indicates an important role of mast cells in the early 
clinical response and in hyperreactivity. Tryptase is not released during the late allergic 
response, but still histamine is found by Naclerio et al. 467 , which indicated that basophils 
play an important role in the late allergic response. It is known that tryptase could cleave 
VIP and CGRP, but not SP, NKA and NKn.96,608 Our results showed only an increase in 
PGD2 release during the immediate response to allergen challenge, which is also found by 
other illvestigators,'m Only mast cells are known to produce PGD2 in the nasal llltiCosa559, 
which suggests that mast cells are only of importance during the early phase response. The 
cysteinyl leukotrienes are only found in the nasal lavage fluids during the immediate 
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response to provocation with HDM, which is also found by Georgitis e/ a/.223 In contrast to 
other investigators4J8, our results demonstrated increased levels of PAP during the 
immediate allergic reaction to allergen challenge. Application of PAF in the nose caused an 
increase in eosinophils in the nasal lavage fluid of rhinitis patients. 345 PAF is an activator 
of eosinophil, platelet, neutrophil, monocyte and macrophage chemotaxis283,483,639,666,691 in 
vitro, sliperoxideRanion production27S and activator of the release of eicosanoids81 and 
histamine"8 from several cells. It is not known whether PAF is correlated with 
hyperreactivity, because in humans PAF induced bronchial hyperrespollsiveness to 
methacholine10"", but other investigators found that PAF failed to induce 
hyperreactivHy363,52J. However, prior inhalation of the PAF antagonist BN52021 inhibited 
the bronchoconstriction induced by PAF and allergen in asthmatics. 303 During natural 
allergen exposure increased levels of ECP were found in the nasal mucosa.603 After nasal 
allergen challenge of rhinitis patients increased levels of eosinophilRderived mediators, such 
as ECP, were found in the nasal lavage fluid during the late phase response43,SS, which was 
confirmed by our results. These eosinophil-derived granule proteins can stimulate mast cell 
secretion281 , are cytotoxic to several cells2so and can inhibit T-Iymphocyte proliferation508. 
Increased levels of 11. .. -5 were demonstrated in the nasal lavage fluids during both the 
immediate and late phase response. After allergen challenge IL-3, IL-4 and IL-5 were 
found in nasal biopsies, which was correlated with the number of activated T -cells and 
eosinophilsl63 and eosinophil granule proteins and LTC4 levels
569
. Application of ILa 5 in the 
nose of allergic rhinitis patients increased the numbers of eosinophils and epithelial cells, 
ECP and IgA in nasal lavage fluid as well as the hyperreactivity.591,617 
Our study was confined to inflammatory cells and their products which certainly play a 
. predominant role in the modulation of perennial allergic rhinitis, but it should be kept in 
mind that allergic inflammation and hyperreactivily as mentioned before are not induced by 
the action of one single cell type or one mediator, but by a variety of cells and mediators. 
Concluding remal'ks 
In answer to the aims of the study it is shown that in nasal hyperreactivity the clinical 
immediate and late allergic response and the inflammatory reaction to allergen challenge 
were associated in patients with perennial allergic rhinitis. Anti-inflammatory therapy with 
the glucocorticosteroid fluticasone propionate reduced the nasal hyperreactivity, nasal 
inflammation, and the inunediate and late clinical response to allergen provocation. 
Intervention with the antihistamine levocabastine, which has no anti-inflammatory 
properties, inhibited the immediate nasal response, but had no effect on nasal 
hyperreactivity and nasal inflammation after allergen challenge. During natural allergen 
expOSlll'e, nasal hyperreactivity was associated with nasal inflammation. Nasal 
hyperreactivity was associated with the quality of life and daily nasal symptoms. 
In addition, the symptonls score according to Lebel et al.313 is suitable to monitor the 
clinical immediate and late phase response to allergen challenge and responsiveness to 
histamine provocation; furthermore, it is sensitive to detect h'eatment effects. 
For treatment of perennial allergic rhinitis several unresolved mechanisms, which also 
could playa role, should be investigated, such as the effect of other inflammatory products, 
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Le. neuropeptides, adhesion molecules and second messengers. 
In recent years several studies have examined the role of neural mechanisms in asthma and, 
in a lesser extent, also in rhinitis. The sensory nerves in the airways may be stimulated by 
inhalation of non~specific irritants. 403 The neural control is complex, comprising 
cholinergic, adrenergic and non~adrenergic non~cholinergic (NANC) mechanisms. Many 
neuropeptides, such as VIP, SP and CORP, have been identified in the human airways.521 It 
has been suggested that they are involved in controlling airway tone and secretion. Since 
the NANC system has longer~actillg effects on blood vessels and submucosal glands 
(causing vasodilatation, transudation and secretion) than the cholinergic and adrenergic 
system, the neuropeptides of this system seems to be more important in rhinitis. Neural and 
neuropeptide mechanisms might be affected by inflammation.35 Of the NANC system, the 
neuropeptide SP, a mediator of C fibres, has been examined extensively. After nasal 
allergen challenge in patients allergic to pollen, an inullediate release of SP was found in 
lavage fluid. 474 In allergic patients increased levels of SP were present in lavage fluid, 
which rnight indicate an increased activation of the NANC system.475 Nasal challenge with 
SP resulted in an increased nasal airway resistance, an increased influx of albumin (Le. 
increased vasopenlleability), and an increased influx of neutrophils in nasal lavage fluid. 475 
In several studies the effect of capsaicin, a neurotoxin on sensory nerves has been 
investigated. Capsaicin's site of action is mainly the C fibres. 297 Nasal challenge with 
capsaicin leads to airway sensory nerve activation and induces burning, rhinorrhoea and 
lacrimation.so9 Capsaicin initially stimulates the C fibres, however, after several 
stimulations, this is followed by depletion of these nerve fibres, resulting in desensitisation 
to capsaicin and other sensory stimuli.297 These desensitising properties have been 
demonstrated to reduce nasal symptoms in patients with nonallergic rhinitis.62,361,415 It would 
be interesting to study if capsaicin has also therapeutic effects in allergic rhinitis. 
Nasal epithelial cells represent the first barrier against noxious agents and aIJergens. In 
allergic rhinitis, in contrast to asthma, epithelial cells are not shed, but are activated. Thc 
epithelial cells in allergic patients can be activated by histamine, cytokines and ECP, and 
leads to increased expression of surface markers like HLA-DR and ICAM_1,9,616.649 ICAM-l 
binds with leukocytes, and might, as a consequence, induce migration of inflanunatory cells 
to the epithelial layer in aIJergic rhinitis.9 Endothelial cells also play an important role in 
the migration of inflammatory cells from the intravascular to the extravascular sites. In 
allergic rhinitis, increased expression of adhesion molecules on endothelial cells has been 
found, which are able to bind leukocytes.4-t6 VCAM-l seems to be an important adhesion 
molecule which predominantly binds eosinophils. Its expression can be induced by allergen 
challenge and is accompanied by increased nasal submucosa eosinophilia.3H Allergic 
rhinitis might be treated by preventing migration of inflammatory cells to the site of action 
(Le. the nasal mucosa) by reducing the expression of adhesion molecules on endothelial 
and epithelial cells. 
The cyclic nucleotides, cAMP and cyclic guanosine monophosphate (cGMP) are important 
second messengers and playa key role in the regulation of cell activity. The intracellular 
concentration of these nucleotides is regulated by stimulation of surface receptors and 
intracellular breakdown by phosphodiesterases (PDEs), such as theophylline. In the airways 
these nucleotides regulate the smooth muscle tone, mediator secretion and activation of 
inflmmnatory cells. There is evidence that atopic disease may be associated with abnormal 
expression of PDEs in inflammatory cells resulting in increased breakdown of cyclic 
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nucleotides.25•98 In vitro and animal studies with selective PDE inhibitors have shown anti-
inflammatory effects by inhibition of mast cells, macrophages, eosinophils and CD4+ 
lymphocytes,627 A study in monkeys has demonstrated that PDE inhibitors inhibited 
allergen-induced eosinophilic inflammation and airway hyperresponsiveness.634 \Vhether 
selective PDE inhibitors will prove to be useful new anti-asthma and may be also an anti-
rhinitis compound is not yet certain. Clinical studies with PDE inhibitors have to be 
performed to study both the therapeutic and side effects. 
Furthermore, the treatment of allergic rhinitis with new 5-lipoxygenase inhibitors should be 
investigated. In antigen sensitized guinea-pigs the 5-lipoxygenase inhibitor E6080 inhibited 
bronchospasm, decreased bronchoepithelial damage and inhibited infiltration of 
leukocytes. 63o The leukotriene production and nasal congestion and airway responses after 
allergen challenge in asthmatics were decreased after treatment with the 5-lipoxygenase 
inhibitor Zileuton (A 64077).305.350 Also the treatment with specific receptor antagonists 
could be lIsefull to modify the condition of rhinitis patients, because several studies with 
asthmatics showed an improvement of their symptoms. The novel leukotriene antagonist 
DNO 1078 reduced the severity of bronchial hyperresponsiveness of asthmatics after 
challenge with allergen, histamine or methacholine. 207,607,611 The early airway reaction to 
cumulative bronchial allergen challenge of asthma patients was inhibited by the 
leukotriene-antagonist ICI_204,219.141.180 In asthmatics prior inhalation of the PAF 
antagonist BN52021 inhibited the bronchoconstriction induced by PAF and allergen, but 
not by methacholine.30) This was in contrast with other investigators who found that 
treatment with the PAF-antagonist \VEB 2086 did not attenuate allergen induced early or 
late responses or airway hyperresponsiveness in asthmatics.2oo Treatment with a 
combination of therapeutic drugs, such as receptor antagonists, should be investigated, 
because this may have a synergistic beneficial effect on the inflammatory process. The 
antigen-induced airway microvascular leakage in guinea-pigs was decreased by a 
combination of LTD4 and PAF antagonists, Ro 24-5913 and Ro 24~4736.671 Simpson 
described a study with hay fever patients treated with budesonide and terfenadine, 
separately, and in combination.S84 Budesonide was more effective than terfenadine in 
reduction of the symptoms, such as nasal blockage. Although the symptom scores tended to 
be lower with combined budesonide and terfenadine treatrnent than with either drug alone, 
the global assessments of combination therapy and budesonide alone were very similar. 
Finally, not only treatment of allergic rhinitis should be investigated, also the analysis of 
treatment failure should have our attention. 
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Summary 
In patients with allergic rhinitis nasal symptoms arc elicited by exposure to specific 
antigens and often also by nOllwspecific stimuli. The pathophysiology of this non-specific 
nasal hyperreactivity is still not clear. In the lower airways it has been demonstrated that 
inflanunation is involved in bronchial hyperreactivity. Most rhinitis studies have been 
performed in patients allergic to poBen. In these studies no clear relationship was found 
between nasal hyperreactivity, inflammation and the latc phase response. Since in a study 
performed in patients allergic to house dust mite nasal hyperreactivity was associated with 
nasal response to allergen, a finding more in agreement with the bronchial situation, we 
further investigated the relationship between nasal hyperreactivity, inflammation and the 
late phase response in this patient group. 
Hereto, patients were challenged with house dust mite and 24 hour later with histamine 
and/or methacholine. We investigated (I) if nasal hyperreactivity and the clinical 
inunediate and late allergic response are associated, (2) if nasal hyperreactivity is associated 
with the inflammatory mediators in lavage fluid, (3) if these associations are influenced by 
treatment with a topical corticosteroid and a topical antihistamine. Further, we investigated 
in perennial allergic rhinitis during natural exposure (4) if nasal hyperreactivity is 
associated with inflanunatory mediators and eosinophils and (5) if nasal hyperreactivity is 
associated with daily nasal symptoms and quality of life. 
Part one consists of a general introduction which contains an overview of allergic nasal 
reactions in rhinitis, the role of intlanunatory cells within this process and their 
inflammatory products. 
In chaptcr 1 a short historical review is given about allergy. Also the prevalence and 
clinical and socio-economic aspects of allergic rhinitis are described. Further, nasal respon-
se to allergen challenge and the present ideas about the pathophysiology, in particular the 
involvement of inflanunation, of alJergic rhinitis and allergen-induced non-specific 
hyperreactivitity are discussed. Most of these studies have been performed in patients with 
seasonal rhinitis. 
Chapter 2 focuses on the role and interactions of inflanunatory cells, their typical 
fUllctions and their release of mediators within the process of allergic rhinitis. To 
understand the mechanism of allergic rhinitis, information on the reactivity and the ability 
to respond to stimuli of the involved cells, and the source, secretion, breakdown and site of 
activity of their mediators is essential. Allergic rhinitis is not induced by the action of one 
single cell type or one mediator, but by a variety of ceIJs and mediators. 
Chaptcr 3 sununarizes the aims of the study. 
In part two the relationship between the allergic response and hyperreactivity is studied. 
In chapter 4 twenty-four patients with perelUlial allergic rhinitis are challenged with house 
dust mite and 24 hours later with histamine. Thirteen patients showed an early response 
only (LAR-), II patients an early as well as a late allergic response (LAR+). LAR- and 
LAR+ responders showed a different profile of symptom score, mediator involvement 
(albumin, ECP, tryptase) and nasal hyperreactivity. In analogy with the lower airways, the 
EAR, LAR, and hyperreactivity are significantly correlated. 
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In chapter 5 nasal hyperreactivity and the involvement of inflammation during the ongoing 
allergic reaction is investigated. Hereto, a nasal brush, a nasal lavage and a nasal histamine 
challenge was performed in 48 patients with perennial allergic rhinitis and in 11 healthy 
controls. Nasal hyperreactivity, assessed by a composite symptom score was significantly 
higher in patients. In contrast to PGDz and tryptase, eosinophils, LTC/D/E4 and albumin 
were significantly increased, which suggest that eosinophils are important in the ongoing 
allergic reaction. Nasal hyperreactivity was weakly correlated with the percentage of 
eosinophils. 
Pal't thl'ee describes the effects of therapeutic intervention on the immediate and late phase 
nasal response, nasal inflammation and nasal hyperreactivity to nasal allergen challenge. 
Chaptet' 6 describes the mechanisms of action of glucocorticosteroids in allergic rhinitis. 
In chapter 7 the effects of the topical glucocorticoid fluticasone propionate aqueous nasal 
spray on the immediate and late phase allergic reaction and nasal hyperreactivity was 
investigated. TwenlYMfour rhinitis patients allergic to HDM were treated with fluticasone 
propionate or with placebo for two weeks twice daily. Thereafter, the patients were 
challenged with HDM extract. Symptoms were recorded and nasal lavages were collected 
every hour up to 9.5 hours after challenge. Nasal hyperreactivity was determined by 
histamine challenge 24 hours later. The results of this study showed that fluticasone 
propionate significantly inhibits the immediate and latc allcrgic response and nasal 
hyperreactivity, probably by suppressing mast ceIJs and eosinophils in the nasal mucosa. 
In chapter 8 the relationship between the release of PAF. LTCiD/E4 and PGDz from 
nasal mucosa in rhinitis patients allergic to HDM was investigated in the srune experiment 
as described in chapter 7. After allergen provocation the levels of PAF, LTC/D41E4 and 
PGDz increased in the nasal lavage fluid, which were significantly correlated. This 
indicates that these mediators can be used as markers of allergic reactions against HDM. 
Furthermore, fluticasone propionate tended to reduce the release of these mediators. which 
was correlated with beneficial effects on clinical symptoms. 
Chapter 9 deals with the effect of fluticasone propionate on ILM5 production in the nasal 
cavity of the rhinitis patients allergic to HDM. Nasal challenge with HDM caused 
immediate nasal symptoms and increased levels of ILM5 in the nasal lavages. ILM5 and ECP 
are released during the late phase reaction. Treatment with fluticasone propionate 
significantly decreased the evoked IL-5 and ECP levels in the late phase reaction. This 
could indicate that the number and activity of eosinophils are increased during the late 
allergic reaction, a response that is inhibited by corticosteroids. 
In chaptel' 10 the role of nitric oxide in the early and late phase of the allergic process 
was investigated and the effect of fluticasone propionate was determined. The production 
of nitric oxide metabolites were measured in the nasal lavages of the rhinitis patients 
described in chapter 7 and of healthy volunteers with or without challenge with PBS. This 
study showed that nitric oxide metabolites are present in nasal lavage fluid in detectable 
amounts, the level gradually increasing with time in both patients and controls. Treatment 
with fluticasone propionate did not affect initial basal production of nitric oxide metabolites 
nor production following provocation with HDM extract. 
In Chapter 11 "the association in reduction of symptoms due to treatment with a 
glucocorticoid and the glucocorticoid receptor characteristics in the rhinitis patients allergic 
to HDM was investigated. In vitro glucocorticoid receptor binding studies with 
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dexamethasone were performed with peripheral blood mononuclear cells of these patients. 
LTB.j produced by monocytes ill vitro and ILR2 SR released by lymphocytes in vitro were 
determined. The number of peripheral blood mononuclear cell glucocorticoid receptors and 
the affinity of dexamethasone for the receptors were not significantly partially correlated 
with the reduction of the symptoms after the active treatment period. Also no partial 
correlation was observed of the levels of LTB, or IL-2 SR release by monocytes and 
lymphocytes, respectively, with the reduction of the syrnptoms. These results suggest that 
the extent of reduction of symptoms due to the topical glucocorticosteroid fluticasone 
propionate of the rhinitis patients is not associated with the characteristics of the 
glucocorticoid receptor. 
Chapter 12 describes the mechanisms of action of antihistaminics in allergic rhinitis. 
Chapter 13 reports the results of a study with the topical antihistamine levocabastine (one 
week twice daily) in 21 patients with perennial allergic rhinitis. Patients responded to HDM 
challenge with an early response only. Levocabastine significantly reduced the clinical 
response to HDM and histamine challenge. Since it has been suggested that antihistamines 
possess other properties besides the classical HI receptor antagonism, the effect of 
levocabastine on inflammatory mediators and on nasal hyperreactivity (nasal response to 
methacholine) was investigated. Levocabastine pretreatment did not reduce inflammatory 
mediators or nasal hyperreactivity, suggesting that it is an effective HI receptor antagonist, 
without antiRinflammatory properties. 
In chapter 14 an ill vitro study with levocabastine is described to investigate further, 
whether levocabastine, in addition to the antiRHI receptor activity, has antiRinflammatory 
properties. Peripheral leukocytes of allergic volunteers were preincubated with 
levocabastine and thereafter incubated with specific allergens. Leukocytes of healthy 
volunteers were incubated for different time-intervals with different concentrations of 
levocabastine. Histamine release was measured. The effect of levocabastine on the 
contractile responses to histamine on guineaRpig trachea and lung-parenchyma as well as 
the histamine release were investigated. The results indicate that the HI receptor blocker 
levocabastine has probably no antiRinflanunatory properties, measured as histamine release, 
and that the histamine release from both human leukocytes and guinea-pig isolated tissue is 
significantly increased by the drug in relatively high doses. 
In part four a study to investigate the association between hyperreactivity and the quality 
of life is described. 
In chapter 15 the impOliance of routine histamine challenges in daily practice was 
investigated. Hereto, 48 patients with perennial allergic rhinitis were challenged with 
histamine and completed a nasal syrnptom diary during the 2 preceding weeks. Since it has 
been demonstrated that rhinitis also has an impact on quality of life, the patients were 
asked to complete a rhinitis QOL questionnaire also. Nasal hyperreactivity, quality of life 
and daily nasal symptoms were significantly correlated. Therefore, routine histamine 
challenge is a useful tool to obtain an impression of daily nasal symptoms and rhinitis 
quality of life. 
lSI 
Samenvattillg 
De neusklachten van patienten met allergische rhinitis worden veroorzaakt door 
blootstelling aan specifieke antigenen en vaak oak door blootstelling aan aspecifieke 
prikkeis. De pathofysiologie van deze aspecifieke hyperreactiviteit is nog steeds niet 
duidelijk. In de lagere luchtwegen is het aangetoolld dat ontsteking betrokken is bij 
brollchiale hyperreactiviteit. De meeste onderzoeken betreffende rhinitis zijn uitgevoerd Qij 
paW~nten met cen allergic voor pollen. In deze studies werd geen duidelijke relatie 
gevonden tussen nasale hyperreactiviteit, ontsteking en de latc fase reaktie. In cen eerder 
onderzoek uitgevoerd bij patientcn met cen huisstofmijt allergic bleek dat nasale 
hyperreactiviteit geassocieerd was met de uasale reaktie op allergeell. Deze bevinding is in 
overeenstemming met de bronchiale situatie. We hebben de relatie tussen nasale 
hyperreactiviteit, ontsteking en de late fase reaktie in deze patienten groep nader 
onderzocht. 
Hiervoor werden patienten geprovoceerd met huisstofmijt en 24 um later met histamine 
en/of methacholine. We hebben onderzocht (I) of nasale hyperreactiviteit en de direkte 
klillische en late allergische reaktie geassocieerd Zijll, (2) of nasale hyperreactiviteit 
geassocieerd is met ontstekingsmediatoren in neusspoelvioeistof en (3) of deze relaties 
bernvloedbaar zijn door behandeling met een Iokaal toegediend corticosteroId en een 
antihistaminicum. Verder hebbell we bij patieltten met chronische allergische rhinitis tijdens 
natuurlijke blootstelling onderzocht (4) of nasale hyperreactiviteit gerelateerd is met ontste-
kingsmediatoren en eosinofielen en (5) of nasale hyperreactiviteit geassocieerd is met de 
dagelijkse neusklachten en de kwaliteit van leven. 
Deel een bestaat uit een algemene inieiding, welke een overzicht geeft van de nasale 
reakties in allergische rhinitis, de rol van ontstekingscellen in dit proces en hun ontste-
kingsprodukten. 
In hoofdstuk 1 wordt cen kort historisch overzicht gegeven over allergie. Ook worden het 
voorkomen van en de klinische en sociaal-economische aspekten van allergische rhinitis 
beschreven. De nasale reaktie op allergeen provokatie en de huidige ideeen over de 
pathofysiologie, in het bijzonder de betrokkenheid van ontsteking, van allergische rhinitis 
en allergeen-gernduceerde aspecifieke hyperreactiviteit worden besproken. De mceste 
studies zijn eehter uitgevoerd in patienten met hooikoorts. 
Hoofdstuk 2 richt zich op de rol en illterakties van ontstekingscellen, hun typische funkties 
en het vrijkomen van mediatoren in het proces van allergische rhinitis. Om het mechanisme 
van allergische rhinitis te begrijpen, is cr informatie nodig over de mate van rcaktiviteit en 
de gevoeligheid voor bepaalde stimuli van de bctrokken ceUen. Ook is de herkomst, 
uitscheiding, afbraak en plaats van werking van hun mediatoren van essentieel belang. 
Allergische rhinitis wordt niet gernduceerd door de werking van een enkele eel of 
mediator, maar door een samenspel van meerdere cellen en mediatoren. 
Hoofdstuk 3 vat de doelstellingen van de studie samen. 
In deel twec is de eelatie tussen de allergische reaktie en hyperreactiviteit bestudeerd. 
In hoofdstul< 4 zijn 24 patienten met chronische allergische rhinitis geprovoceerd met 
huisstofmijt en 24 UHf later met histamine. Dertien patienten vertoonden alJeen een vroege 
reaktie (LAR-), 11 patienten vertoonden zowei een vroege ais eell late alJergische reaktie 
152 
Samenvatting 
(LAR+). LAR+ en LAR- responders lieten een verschillend profiel van symptoom score, 
betrokkeil mediatoren (albumine, ECP, tryptase) en nasale hyperreactiviteit zien. In 
overeenstenuning met de lagere luchtwegen, waren de vroege allergische reaktie (EAR), de 
Jate allergische reactie (LAR) en nasale hyperreactiviteit gecorreleerd. 
In hoofdstul< 5 is de nasa Ie hyperreactiviteit en de roJ van ontsteking gedurende de 
chronische allergische reaktie onderzocht. Hiervoor werd een uitstrijkje van de neus, een 
lleusspoeling en een nasale histamine provokatie uitgevoerd bij 48 patienten met chronische 
allergische rhinitis en 11 gezonde vrijwilligers. Nasale hyperreactiviteit, gemeten door 
middel van een samengestelde symptoom score, was hoger bij de patienten. In tegenstelling 
tot PGD2 en tryptase waren de eosinofielen, LTC/D/E4 en albumine verhoogd, wat 
suggereert dat eosinofielen belangrijk zijn in de chronische allergische reaktie. De nasale 
hyperreactiviteit was matig gecorreleerd met het percentage eosillofielen. 
Deel drie beschrijft het effekt van geneesmiddelen op de onmiddellijke en late nasale 
reaktie, ontsteking en uasale hyperreactiviteit ten gevolge van nasale allergeen provokatie. 
In Hoofdstul< 6 wordt het werkingsmechanisme van glucocorticosteroi'den in allergische 
rhinitis weergegeven. 
In hoofdstul< 7 werd het effekt van het lokaal toegediende giucocorticosteroi'd fluticasone 
propionaat op de onmiddellijke en late fase allergische reaktie en nasale hyperreactiviteit 
onderzocht. Vierentwintig rhinitis patienten met een allergie voor huisstofmijt werden 
gedurende 2 weken, 2 maal daags, behandeld met fluticasonc propionaat of placebo. Hierna 
werden deze patienten geprovocecrd met huisstofmijt extrakt. De symptomen werden 
geregistreerd en de neusspoelingen werden elk uur tot 9,5 uur na provokatie uitgevoerd. De 
nasale hyperreactiviteit werd 24 uur later gemeten door middel van provokatie met 
histamine. De resultaten Heten zien dat fluticasone propionaat de onmiddeHijke en late 
allergische reaktie en nasa Ie hyperreactiviteit verminderde, hetgeen waarschijnlijk 
veroorzaakt wordt door het verminderen van het aantal en de activiteit van mest cellen en 
eosinofielen in het neusslijmvlies. 
In hoofdstuk 8 wordt de relatie beschreven tussen het vrijmaken van PAF, LTC,ID,/E, en 
PGD2 uit het neusslijmvlies van rhinitis patienten met een allergie voor huisstofmijt (zie 
oak hoofdstuk 7). Na provokatie met allergeen namen de concentraties van PAF, 
LTC/D./E,; en PGD2 in de neusspoelvloeistof toe en waren gecorreleerd. De resultaten 
tonen aan dat deze mediatoren gebruikt kunnen worden als markers voor de allergische 
reaktie op huisstofmijt. Fluticasone propionaat verlaagde de vrijmaking van deze 
mediatoren, welke gecorreleerd waren met verbeteringen van de klinische symptomen. 
In hoofdstuk 9 wordt het effekt van fluticasone propionaat op de IL-5 produktie in de 
neusholte van chronische allergische rhinitis patienten onderzocht. Neusprovokatie met 
huisstofmijt veroorzaakte ollmiddellijke neusklachten en cen verhoogde concentratie van 
IL-5 in de neusspoelvloeistof. IL-5 en ECP werden vrijgemaakt gedurende de late fase 
reaktie. Behandelillg met fluticasone propionaat venninderde de verhoogde IL-5 en ECP 
concentraties in de late fase reaktie. Deze resultaten zouden aan kunnen tonen dat, 
gcdurende de late fase reaktie het aantal en de aktiviteit van eosinofielen zijn verhoogd, 
welke afnemen door behandeling met een corticosteroi'd. 
In hoofdstuk 10 werd de 1'01 van stikstofmonoxide (NO) tijdens de v1'Oege en late rase 
reaktie in het allcrgische proces bestudeerd. Ook het effekt van fluticasone propionaat is 
heschreven. De produktie van de afbraakprodukten van NO is gemeten in de 
153 
Samellvatting 
neusspoelingen van rhinitis patiCnten (zie hoofdstuk 7) en in neusspoclingen van gezonde 
vrijwilligers, zowel met als zonder provo katie met PBS. De resultaten tonen aan dat er 
afbraakprodukten van NO aanwezig zijn in de spoelvloeistof en dat de concentratie 
toeneemt in de tijd, zowel bij de patienten als bij de con troles. Behandeling met fluticasone 
propionaat had geen enkel effekt op de basale produktie en op de produktie na 
allergeenprovokatie. 
In hoofdstuk 11 wordt de relatie tussen de verlaging van klachten na bchandeling met 
fluticasone propionaat lllet de glucocorticoId receptor karakteristieken van de rhinitis 
patienten met een allergie voor huisstofmijt onderzocht. Op de enkelvoudige-kern cellen uit 
het bloed van deze patienten zijn glucocorticoid receptor binding-studies gedaan met 
dexamethason. De LTB4 produktie door 1l10nocyten en het vrijmaken van de oplosbare IL-2 
receptor (IL-2 SR) door lymfocyten is onderzocht. Het aantal glucocorticoId receptoren op 
de enkelvoudige-kern cellen en de affiniteit voor dexamethason van deze receptoren was 
niet gecorreleerd met de verlagillg in symptomen na behandelillg met fluticasone 
propionaat. Ook de produktie van LTB4 en IL-2 SR door monocyten en Iymfocyten was 
niet gecorreleerd met de vedaging in symptomen na behandeling. Deze resultatell 
suggereren dat de mate van verlaging van de symptomen na het lokaa1 toegediende 
glucocorticoId fluticasone propionaat niet geassocieerd kan worden met karakteristieken van 
de glucocorticoi'd receptor. 
Hoofdstuk 12 beschrijfi in algemene zin de werkingsmechanismen van antihistaminica in 
allergische rhinitis. 
In hoofdstuk 13 worden de resllJtaten besproken van een studie met het 10kaal toegediende 
antihistaminicum levocabastine (gedurende I week, I maal daags) bij 21 rhinitis patienten 
die allergisch waren voor huisstofmijt. De patienten vertoonden na provokatie met 
allergeen aileen een vroege fase reaktie. Levocabastinc verlaagde significant de klinische 
reaktie op huisstofmijt- en histamine provokatie. Het effect van levocabastine is ook 
onderzocht op de ontstekingsmediatoren en op nasale hyperreactiviteit, omdat 
antihistaminica behalve het klassieke HI receptor antagonisme ook andere effekten kunnen 
hebben. Echter, door behandeling met lcvocabastine werden noeh de ontstekingsmediatoren 
noch de nasale hyperreactiviteit verlaagd. Dit suggereert dat levocabastine een effektieve HI 
receptor antagonist is, zonder ontstekings-renullende eigenschappen. 
In hoofdstul{ 14 wordt een in vitro studie met levocabastine beschreven om nader te 
onderzoeken of levocabastine ontstekillgs-rcnuuende eigensehappen bezit. aansluitcnd op de 
HI receptor blokkcnde werking. Leukocyten uit het bloed van aHergische vrijwilligcrs 
werden voorgei'ncubeerd met levocabastine en daarna ge'incubeerd met een allergeen. 
Leukocyten van gezonde vrijwilligers werden VOOI' verschillel1de tijdsintervallen met 
oplopende concentraties levocabastine gei·ncubeerd. De histamine produktie werd gemeten. 
Het cffekt van levocahastine op de contractie van gladde spieren van de cavia luchtpijp en 
longparenchym op histamine werd onderzocht, alsmede de produktie van histamine. De 
resultaten suggereren dat de HI receptor blokker levocabastine waarschijnlijk geen 
ontstekings-remmende eigenschappen heeft, gcmeten in histamine produktie. De histamine 
prodllktic door zowel humane leukoeyten alsmede door gei'soieerd weefsel van cavia's werd 
in rclatief hoge doseringen aan1l1erkelijk verhoogd door het geneesmiddel. 
In deel vier wordt een studie beschreven waal'in de associatie tussen nasale 
hyperreactiviteit en de kwaliteit van leven werd onderzocht. 
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In hoofdstuk 15 is het belang van routinematige histamine provo katie in de dagelijkse 
praktijk onderzocht. Hiervoor werden 48 patienten met eell chronische allergische rhinitis 
geprovoceerd met histamine, Er is aangetoond dat rhinitis een grote invloed op de kwaliteit 
van leven heeft, Daarom is de patienten gevraagd om een vragenlijst over de kwaliteit van 
leven in te vlIllen, Tevens hebben ze gedurende de 2 voorafgaande weken, hun 
neusklachten in een klachtendagboek genoteerd, Nasale hyperreactiviteit, kwaliteit van 
leven en de dageJijkse neusklachten waren significant gecorreleerd, Daarom is de 
routinematige histamine provokatie een doeltreffend middel om een impressie te krijgen 
van de dagelijkse neusklachten en kwaliteit van leven, 
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